0000039368 FULLER H B CO false --11-29 Q3 2025 11,661 11,621 0 0 10,045,900 10,045,900 1.00 1.00 160,000,000 160,000,000 54,043,300 54,657,103 http://fasb.org/us-gaap/2025#AccountsPayableCurrent 33.33 28,922 10 50 54,382 4,395 29,249 54,545 2,169 12,056 307,173 300,000 50,000 http://fasb.org/us-gaap/2025#OtherLiabilitiesNoncurrent http://fasb.org/us-gaap/2025#OtherLiabilitiesNoncurrent 5 3 false false false false Amounts reclassified from accumulated other comprehensive loss into earnings is reported in other income, net. Income taxes are not provided for foreign currency translation relating to indefinite investments in international subsidiaries. Amounts reclassified from accumulated other comprehensive loss into earnings as part of net periodic cost related to pension and other postretirement benefit plans is reported in cost of sales and other income, net. 00000393682024-12-012025-08-30 xbrli:shares 00000393682025-09-19 thunderdome:item iso4217:USD 00000393682025-06-012025-08-30 00000393682024-06-022024-08-31 00000393682023-12-032024-08-01 iso4217:USDxbrli:shares 00000393682023-12-032024-08-31 0000039368us-gaap:InterestRateSwapMember2025-06-012025-08-30 0000039368us-gaap:InterestRateSwapMember2024-06-022024-08-31 0000039368us-gaap:InterestRateSwapMember2024-12-012025-08-30 0000039368us-gaap:InterestRateSwapMember2023-12-032024-08-31 0000039368ful:NetInvestmentHedgesMember2025-06-012025-08-30 0000039368ful:NetInvestmentHedgesMember2024-06-022024-08-31 0000039368ful:NetInvestmentHedgesMember2024-12-012025-08-30 0000039368ful:NetInvestmentHedgesMember2023-12-032024-08-31 00000393682025-08-30 00000393682024-11-30 0000039368us-gaap:CommonStockMember2024-11-30 0000039368us-gaap:AdditionalPaidInCapitalMember2024-11-30 0000039368us-gaap:RetainedEarningsMember2024-11-30 0000039368us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-11-30 0000039368us-gaap:NoncontrollingInterestMember2024-11-30 0000039368us-gaap:CommonStockMember2024-12-012025-03-01 0000039368us-gaap:AdditionalPaidInCapitalMember2024-12-012025-03-01 0000039368us-gaap:RetainedEarningsMember2024-12-012025-03-01 0000039368us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-12-012025-03-01 0000039368us-gaap:NoncontrollingInterestMember2024-12-012025-03-01 00000393682024-12-012025-03-01 0000039368us-gaap:CommonStockMember2025-03-01 0000039368us-gaap:AdditionalPaidInCapitalMember2025-03-01 0000039368us-gaap:RetainedEarningsMember2025-03-01 0000039368us-gaap:AccumulatedOtherComprehensiveIncomeMember2025-03-01 0000039368us-gaap:NoncontrollingInterestMember2025-03-01 00000393682025-03-01 0000039368us-gaap:CommonStockMember2025-03-022025-05-31 0000039368us-gaap:AdditionalPaidInCapitalMember2025-03-022025-05-31 0000039368us-gaap:RetainedEarningsMember2025-03-022025-05-31 0000039368us-gaap:AccumulatedOtherComprehensiveIncomeMember2025-03-022025-05-31 0000039368us-gaap:NoncontrollingInterestMember2025-03-022025-05-31 00000393682025-03-022025-05-31 0000039368us-gaap:CommonStockMember2025-05-31 0000039368us-gaap:AdditionalPaidInCapitalMember2025-05-31 0000039368us-gaap:RetainedEarningsMember2025-05-31 0000039368us-gaap:AccumulatedOtherComprehensiveIncomeMember2025-05-31 0000039368us-gaap:NoncontrollingInterestMember2025-05-31 00000393682025-05-31 0000039368us-gaap:CommonStockMember2025-06-012025-08-30 0000039368us-gaap:AdditionalPaidInCapitalMember2025-06-012025-08-30 0000039368us-gaap:RetainedEarningsMember2025-06-012025-08-30 0000039368us-gaap:AccumulatedOtherComprehensiveIncomeMember2025-06-012025-08-30 0000039368us-gaap:NoncontrollingInterestMember2025-06-012025-08-30 0000039368us-gaap:CommonStockMember2025-08-30 0000039368us-gaap:AdditionalPaidInCapitalMember2025-08-30 0000039368us-gaap:RetainedEarningsMember2025-08-30 0000039368us-gaap:AccumulatedOtherComprehensiveIncomeMember2025-08-30 0000039368us-gaap:NoncontrollingInterestMember2025-08-30 0000039368us-gaap:CommonStockMember2023-12-02 0000039368us-gaap:AdditionalPaidInCapitalMember2023-12-02 0000039368us-gaap:RetainedEarningsMember2023-12-02 0000039368us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-12-02 0000039368us-gaap:NoncontrollingInterestMember2023-12-02 00000393682023-12-02 0000039368us-gaap:CommonStockMember2023-12-032024-03-02 0000039368us-gaap:AdditionalPaidInCapitalMember2023-12-032024-03-02 0000039368us-gaap:RetainedEarningsMember2023-12-032024-03-02 0000039368us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-12-032024-03-02 0000039368us-gaap:NoncontrollingInterestMember2023-12-032024-03-02 00000393682023-12-032024-03-02 0000039368us-gaap:CommonStockMember2024-03-02 0000039368us-gaap:AdditionalPaidInCapitalMember2024-03-02 0000039368us-gaap:RetainedEarningsMember2024-03-02 0000039368us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-03-02 0000039368us-gaap:NoncontrollingInterestMember2024-03-02 00000393682024-03-02 0000039368us-gaap:CommonStockMember2024-03-032024-06-01 0000039368us-gaap:AdditionalPaidInCapitalMember2024-03-032024-06-01 0000039368us-gaap:RetainedEarningsMember2024-03-032024-06-01 0000039368us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-03-032024-06-01 0000039368us-gaap:NoncontrollingInterestMember2024-03-032024-06-01 00000393682024-03-032024-06-01 0000039368us-gaap:CommonStockMember2024-06-01 0000039368us-gaap:AdditionalPaidInCapitalMember2024-06-01 0000039368us-gaap:RetainedEarningsMember2024-06-01 0000039368us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-06-01 0000039368us-gaap:NoncontrollingInterestMember2024-06-01 00000393682024-06-01 0000039368us-gaap:CommonStockMember2024-06-022024-08-31 0000039368us-gaap:AdditionalPaidInCapitalMember2024-06-022024-08-31 0000039368us-gaap:RetainedEarningsMember2024-06-022024-08-31 0000039368us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-06-022024-08-31 0000039368us-gaap:NoncontrollingInterestMember2024-06-022024-08-31 0000039368us-gaap:CommonStockMember2024-08-31 0000039368us-gaap:AdditionalPaidInCapitalMember2024-08-31 0000039368us-gaap:RetainedEarningsMember2024-08-31 0000039368us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-08-31 0000039368us-gaap:NoncontrollingInterestMember2024-08-31 00000393682024-08-31 iso4217:TWD 0000039368ful:NDIndustriesAsiaIncNDIndustriesTaiwanMember2025-02-152025-02-15 0000039368ful:NDIndustriesAsiaIncNDIndustriesTaiwanMember2025-08-30 iso4217:EUR 0000039368ful:GemMember2025-01-152025-01-15 xbrli:pure 0000039368ful:GemMember2025-01-15 0000039368ful:GemMemberful:HoldbackLiabilityMember2025-01-15 0000039368ful:GemMember2025-08-30 iso4217:GBP 0000039368ful:HsButylLimitedMember2024-08-052024-08-05 0000039368ful:HsButylLimitedMember2025-08-30 0000039368ful:NdIndustriesMemberful:EngineeringAdhesivesMember2024-05-202024-05-20 0000039368ful:NdIndustriesMember2024-05-20 0000039368ful:NdIndustriesMemberus-gaap:CustomerRelationshipsMember2024-05-20 0000039368ful:NdIndustriesMemberus-gaap:TrademarksAndTradeNamesMember2024-05-20 0000039368ful:NdIndustriesMemberus-gaap:TechnologyBasedIntangibleAssetsMember2024-05-20 utr:Y 0000039368ful:NdIndustriesMemberful:TechnologyMember2024-05-202024-05-20 0000039368ful:NdIndustriesMemberus-gaap:CustomerRelationshipsMember2024-05-202024-05-20 0000039368ful:NdIndustriesMemberus-gaap:TrademarksAndTradeNamesMember2024-05-202024-05-20 0000039368ful:NdIndustriesMemberful:EngineeringAdhesivesMember2024-05-20 0000039368us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMemberful:NorthAmericaFlooringMember2024-12-022024-12-02 0000039368us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMemberful:NorthAmericaFlooringMember2024-12-02 0000039368us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMemberful:NorthAmericaFlooringMember2024-12-012025-08-30 0000039368us-gaap:EmployeeSeveranceMember2025-08-30 0000039368us-gaap:OtherRestructuringMember2025-08-30 0000039368us-gaap:CostOfSalesMember2025-06-012025-08-30 0000039368us-gaap:CostOfSalesMember2024-06-022024-08-31 0000039368us-gaap:CostOfSalesMember2024-12-012025-08-30 0000039368us-gaap:CostOfSalesMember2023-12-032024-08-31 0000039368us-gaap:SellingGeneralAndAdministrativeExpensesMember2025-06-012025-08-30 0000039368us-gaap:SellingGeneralAndAdministrativeExpensesMember2024-06-022024-08-31 0000039368us-gaap:SellingGeneralAndAdministrativeExpensesMember2024-12-012025-08-30 0000039368us-gaap:SellingGeneralAndAdministrativeExpensesMember2023-12-032024-08-31 0000039368ful:EmployeeRelatedMember2023-12-02 0000039368ful:AssetRelatedMember2023-12-02 0000039368us-gaap:OtherRestructuringMember2023-12-02 0000039368ful:EmployeeRelatedMember2023-12-032024-11-30 0000039368ful:AssetRelatedMember2023-12-032024-11-30 0000039368us-gaap:OtherRestructuringMember2023-12-032024-11-30 00000393682023-12-032024-11-30 0000039368ful:EmployeeRelatedMember2024-11-30 0000039368ful:AssetRelatedMember2024-11-30 0000039368us-gaap:OtherRestructuringMember2024-11-30 0000039368ful:EmployeeRelatedMember2024-12-012025-08-30 0000039368ful:AssetRelatedMember2024-12-012025-08-30 0000039368us-gaap:OtherRestructuringMember2024-12-012025-08-30 0000039368ful:EmployeeRelatedMember2025-08-30 0000039368ful:AssetRelatedMember2025-08-30 0000039368ful:HygieneHealthAndConsumableAdhesivesMember2024-11-30 0000039368ful:EngineeringAdhesivesMember2024-11-30 0000039368ful:BuildingAdhesivesSolutionsMember2024-11-30 0000039368ful:HygieneHealthAndConsumableAdhesivesMember2024-12-012025-08-30 0000039368ful:EngineeringAdhesivesMember2024-12-012025-08-30 0000039368ful:BuildingAdhesivesSolutionsMember2024-12-012025-08-30 0000039368ful:HygieneHealthAndConsumableAdhesivesMember2025-08-30 0000039368ful:EngineeringAdhesivesMember2025-08-30 0000039368ful:BuildingAdhesivesSolutionsMember2025-08-30 0000039368ful:PurchasedTechnologyAndPatentsMember2025-08-30 0000039368us-gaap:CustomerRelationshipsMember2025-08-30 0000039368us-gaap:TradeNamesMember2025-08-30 0000039368us-gaap:OtherIntangibleAssetsMember2025-08-30 0000039368ful:PurchasedTechnologyAndPatentsMember2024-11-30 0000039368us-gaap:CustomerRelationshipsMember2024-11-30 0000039368us-gaap:TradeNamesMember2024-11-30 0000039368us-gaap:OtherIntangibleAssetsMember2024-11-30 0000039368us-gaap:TrademarksAndTradeNamesMember2025-08-30 0000039368us-gaap:TrademarksAndTradeNamesMember2024-11-30 0000039368ful:AmendedTermLoanBMember2025-08-30 0000039368ful:AmendedTermLoanBMember2025-03-062025-03-06 0000039368ful:AmendedTermLoanBMemberus-gaap:SecuredOvernightFinancingRateSofrMember2025-03-062025-03-06 0000039368ful:AmendedTermLoanBMemberus-gaap:PrimeRateMember2025-03-062025-03-06 0000039368ful:AmendedTermLoanBMembersrt:MinimumMember2025-03-062025-03-06 0000039368country:USus-gaap:PensionPlansDefinedBenefitMember2025-06-012025-08-30 0000039368country:USus-gaap:PensionPlansDefinedBenefitMember2024-06-022024-08-31 0000039368us-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMember2025-06-012025-08-30 0000039368us-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMember2024-06-022024-08-31 0000039368us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember2025-06-012025-08-30 0000039368us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember2024-06-022024-08-31 0000039368country:USus-gaap:PensionPlansDefinedBenefitMember2024-12-012025-08-30 0000039368country:USus-gaap:PensionPlansDefinedBenefitMember2023-12-032024-08-31 0000039368us-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMember2024-12-012025-08-30 0000039368us-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMember2023-12-032024-08-31 0000039368us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember2024-12-012025-08-30 0000039368us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember2023-12-032024-08-31 0000039368ful:NetInvestmentHedgeMember2025-06-012025-08-30 0000039368ful:NetInvestmentHedgeMember2024-06-022024-08-31 0000039368ful:NetInvestmentHedgeMember2024-12-012025-08-30 0000039368ful:NetInvestmentHedgeMember2023-12-032024-08-31 0000039368us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember2024-12-012025-08-30 0000039368us-gaap:AccumulatedTranslationAdjustmentMember2024-12-012025-08-30 0000039368us-gaap:AccumulatedForeignCurrencyAdjustmentAttributableToNoncontrollingInterestMember2024-12-012025-08-30 0000039368us-gaap:AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember2024-12-012025-08-30 0000039368us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2024-12-012025-08-30 0000039368us-gaap:AccumulatedDefinedBenefitPlansAdjustmentAttributableToNoncontrollingInterestMember2024-12-012025-08-30 0000039368us-gaap:InterestRateSwapMemberus-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember2024-12-012025-08-30 0000039368us-gaap:InterestRateSwapMemberus-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2024-12-012025-08-30 0000039368us-gaap:InterestRateSwapMemberus-gaap:AccumulatedGainLossNetCashFlowHedgeNoncontrollingInterestMember2024-12-012025-08-30 0000039368ful:NetInvestmentHedgesMemberus-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember2024-12-012025-08-30 0000039368ful:NetInvestmentHedgesMemberus-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2024-12-012025-08-30 0000039368ful:NetInvestmentHedgesMemberus-gaap:AccumulatedGainLossNetCashFlowHedgeNoncontrollingInterestMember2024-12-012025-08-30 0000039368us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember2024-12-012025-08-30 0000039368us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-12-012025-08-30 0000039368us-gaap:AociAttributableToNoncontrollingInterestMember2024-12-012025-08-30 0000039368us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember2025-08-30 0000039368us-gaap:AociAttributableToNoncontrollingInterestMember2025-08-30 0000039368us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember2023-12-032024-11-30 0000039368us-gaap:AccumulatedTranslationAdjustmentMember2023-12-032024-11-30 0000039368us-gaap:AccumulatedForeignCurrencyAdjustmentAttributableToNoncontrollingInterestMember2023-12-032024-11-30 0000039368us-gaap:AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember2023-12-032024-11-30 0000039368us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2023-12-032024-11-30 0000039368us-gaap:AccumulatedDefinedBenefitPlansAdjustmentAttributableToNoncontrollingInterestMember2023-12-032024-11-30 0000039368us-gaap:InterestRateSwapMemberus-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember2023-12-032024-11-30 0000039368us-gaap:InterestRateSwapMemberus-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2023-12-032024-11-30 0000039368us-gaap:InterestRateSwapMemberus-gaap:AccumulatedGainLossNetCashFlowHedgeNoncontrollingInterestMember2023-12-032024-11-30 0000039368ful:NetInvestmentHedgesMemberus-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2023-12-032024-11-30 0000039368ful:NetInvestmentHedgesMemberus-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember2023-12-032024-11-30 0000039368ful:NetInvestmentHedgesMemberus-gaap:AccumulatedGainLossNetCashFlowHedgeNoncontrollingInterestMember2023-12-032024-11-30 0000039368us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember2023-12-032024-11-30 0000039368us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-12-032024-11-30 0000039368us-gaap:AociAttributableToNoncontrollingInterestMember2023-12-032024-11-30 0000039368us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember2024-11-30 0000039368us-gaap:AociAttributableToNoncontrollingInterestMember2024-11-30 0000039368us-gaap:InterestRateSwapMember2023-01-12 0000039368us-gaap:InterestRateSwapMember2023-02-28 0000039368us-gaap:InterestRateSwapMember2025-08-30 0000039368ful:InterestRateSwap2Member2023-03-16 0000039368ful:InterestRateSwap2Member2025-08-30 0000039368ful:InterestRateSwap3Member2023-03-16 0000039368ful:InterestRateSwap3Member2025-08-30 0000039368us-gaap:InterestRateSwapMemberus-gaap:CashFlowHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMember2025-06-012025-08-30 0000039368us-gaap:InterestRateSwapMemberus-gaap:CashFlowHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMember2024-06-022024-08-31 0000039368us-gaap:InterestRateSwapMemberus-gaap:CashFlowHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMember2024-12-012025-08-30 0000039368us-gaap:InterestRateSwapMemberus-gaap:CashFlowHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMember2023-12-032024-08-31 0000039368ful:InterestRateSwapRelatedToPublicNotesMember2021-02-12 0000039368ful:InterestRateSwapRelatedToPublicNotesMemberful:LondonInterbankOfferedRateLibor1Member2021-02-12 0000039368ful:InterestRateSwapRelatedToPublicNotesMemberus-gaap:SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember2023-06-30 0000039368us-gaap:OtherLiabilitiesMemberful:InterestRateSwapRelatedToPublicNotesMember2025-08-30 0000039368ful:PublicNotesMember2024-06-01 0000039368us-gaap:CrossCurrencyInterestRateContractMember2022-10-17 0000039368us-gaap:CrossCurrencyInterestRateContractMember2022-10-20 0000039368ful:CrossCurrencyInterestRateContractMaturingInFebruary2027Member2025-07-18 0000039368us-gaap:CrossCurrencyInterestRateContractMemberus-gaap:SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember2023-06-30 0000039368us-gaap:CrossCurrencyInterestRateContractMemberful:EuroShortTermRateESTROvernightIndexSwapRateMember2023-07-17 0000039368us-gaap:OtherLiabilitiesMemberus-gaap:CrossCurrencyInterestRateContractMember2025-08-30 0000039368us-gaap:CrossCurrencyInterestRateContractMember2024-12-012025-08-30 0000039368us-gaap:CrossCurrencyInterestRateContractMemberus-gaap:NetInvestmentHedgingMember2025-06-012025-08-30 0000039368us-gaap:CrossCurrencyInterestRateContractMemberus-gaap:NetInvestmentHedgingMember2024-12-012025-08-30 0000039368us-gaap:CrossCurrencyInterestRateContractMemberus-gaap:NetInvestmentHedgingMember2025-08-30 0000039368us-gaap:FairValueMeasurementsRecurringMember2025-08-30 0000039368us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2025-08-30 0000039368us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2025-08-30 0000039368us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2025-08-30 0000039368us-gaap:FairValueMeasurementsRecurringMember2024-11-30 0000039368us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2024-11-30 0000039368us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2024-11-30 0000039368us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2024-11-30 00000393682025-01-152025-01-15 0000039368ful:HoldbackLiabilityMember2024-11-30 0000039368ful:HoldbackLiabilityMember2024-12-012025-08-30 0000039368ful:HoldbackLiabilityMember2025-08-30 0000039368ful:FacilityInSimpsonvilleSouthCarolinaMember2025-08-30 0000039368ful:FacilityInSimpsonvilleSouthCarolinaMember2024-11-30 0000039368ful:AsbestosRelatedLawsuitsAndClaimsMember2024-12-012025-08-30 0000039368ful:AsbestosRelatedLawsuitsAndClaimsMember2023-12-032024-08-31 0000039368ful:AsbestosRelatedLawsuitsAndClaimsMember2021-11-282024-11-30 0000039368ful:AsbestosRelatedLawsuitsAndClaimsMember2025-08-30 0000039368ful:AsbestosRelatedLawsuitsAndClaimsMember2024-08-31 0000039368ful:AsbestosRelatedLawsuitsAndClaimsMember2024-11-30 0000039368ful:The2022ShareRepurchaseProgramMember2022-04-22 0000039368ful:The2022ShareRepurchaseProgramMember2022-04-222022-04-22 0000039368ful:The2022ShareRepurchaseProgramMember2025-06-012025-08-30 0000039368ful:The2022ShareRepurchaseProgramMember2024-12-012025-08-30 0000039368ful:The2022ShareRepurchaseProgramMemberus-gaap:CommonStockMember2024-12-012025-08-30 0000039368ful:The2022ShareRepurchaseProgramMemberus-gaap:AdditionalPaidInCapitalMember2024-12-012025-08-30 0000039368ful:The2022ShareRepurchaseProgramMember2024-06-022024-08-31 0000039368ful:The2022ShareRepurchaseProgramMemberus-gaap:CommonStockMember2024-06-022024-08-31 0000039368ful:The2022ShareRepurchaseProgramMemberus-gaap:AdditionalPaidInCapitalMember2024-06-022024-08-31 0000039368ful:The2022ShareRepurchaseProgramMember2023-12-032024-08-31 0000039368ful:The2022ShareRepurchaseProgramMemberus-gaap:CommonStockMember2023-12-032024-08-31 0000039368ful:The2022ShareRepurchaseProgramMemberus-gaap:AdditionalPaidInCapitalMember2023-12-032024-08-31 0000039368us-gaap:OperatingSegmentsMemberful:HygieneHealthAndConsumableAdhesivesMember2025-06-012025-08-30 0000039368us-gaap:OperatingSegmentsMemberful:HygieneHealthAndConsumableAdhesivesMember2024-06-022024-08-31 0000039368us-gaap:OperatingSegmentsMemberful:EngineeringAdhesivesMember2025-06-012025-08-30 0000039368us-gaap:OperatingSegmentsMemberful:EngineeringAdhesivesMember2024-06-022024-08-31 0000039368us-gaap:OperatingSegmentsMemberful:BuildingAdhesivesSolutionsMember2025-06-012025-08-30 0000039368us-gaap:OperatingSegmentsMemberful:BuildingAdhesivesSolutionsMember2024-06-022024-08-31 0000039368us-gaap:OperatingSegmentsMemberful:TotalSegmentMember2025-06-012025-08-30 0000039368us-gaap:OperatingSegmentsMemberful:TotalSegmentMember2024-06-022024-08-31 0000039368us-gaap:CorporateNonSegmentMember2025-06-012025-08-30 0000039368us-gaap:CorporateNonSegmentMember2024-06-022024-08-31 0000039368us-gaap:OperatingSegmentsMemberful:HygieneHealthAndConsumableAdhesivesMember2024-12-012025-08-30 0000039368us-gaap:OperatingSegmentsMemberful:HygieneHealthAndConsumableAdhesivesMember2023-12-032024-08-31 0000039368us-gaap:OperatingSegmentsMemberful:EngineeringAdhesivesMember2024-12-012025-08-30 0000039368us-gaap:OperatingSegmentsMemberful:EngineeringAdhesivesMember2023-12-032024-08-31 0000039368us-gaap:OperatingSegmentsMemberful:BuildingAdhesivesSolutionsMember2024-12-012025-08-30 0000039368us-gaap:OperatingSegmentsMemberful:BuildingAdhesivesSolutionsMember2023-12-032024-08-31 0000039368us-gaap:OperatingSegmentsMemberful:TotalSegmentMember2024-12-012025-08-30 0000039368us-gaap:OperatingSegmentsMemberful:TotalSegmentMember2023-12-032024-08-31 0000039368us-gaap:CorporateNonSegmentMember2024-12-012025-08-30 0000039368us-gaap:CorporateNonSegmentMember2023-12-032024-08-31 0000039368us-gaap:OperatingSegmentsMemberful:HygieneHealthAndConsumableAdhesivesMember2024-11-30 0000039368us-gaap:OperatingSegmentsMemberful:EngineeringAdhesivesMember2024-11-30 0000039368us-gaap:OperatingSegmentsMemberful:BuildingAdhesivesSolutionsMember2024-11-30 0000039368us-gaap:CorporateNonSegmentMember2024-11-30 0000039368us-gaap:OperatingSegmentsMemberful:HygieneHealthAndConsumableAdhesivesMembersrt:AmericasMember2025-06-012025-08-30 0000039368us-gaap:OperatingSegmentsMemberful:EngineeringAdhesivesMembersrt:AmericasMember2025-06-012025-08-30 0000039368us-gaap:OperatingSegmentsMemberful:BuildingAdhesivesSolutionsMembersrt:AmericasMember2025-06-012025-08-30 0000039368us-gaap:CorporateNonSegmentMembersrt:AmericasMember2025-06-012025-08-30 0000039368srt:AmericasMember2025-06-012025-08-30 0000039368us-gaap:OperatingSegmentsMemberful:HygieneHealthAndConsumableAdhesivesMemberful:EIMEAMember2025-06-012025-08-30 0000039368us-gaap:OperatingSegmentsMemberful:EngineeringAdhesivesMemberful:EIMEAMember2025-06-012025-08-30 0000039368us-gaap:OperatingSegmentsMemberful:BuildingAdhesivesSolutionsMemberful:EIMEAMember2025-06-012025-08-30 0000039368us-gaap:CorporateNonSegmentMemberful:EIMEAMember2025-06-012025-08-30 0000039368ful:EIMEAMember2025-06-012025-08-30 0000039368us-gaap:OperatingSegmentsMemberful:HygieneHealthAndConsumableAdhesivesMembersrt:AsiaPacificMember2025-06-012025-08-30 0000039368us-gaap:OperatingSegmentsMemberful:EngineeringAdhesivesMembersrt:AsiaPacificMember2025-06-012025-08-30 0000039368us-gaap:OperatingSegmentsMemberful:BuildingAdhesivesSolutionsMembersrt:AsiaPacificMember2025-06-012025-08-30 0000039368us-gaap:CorporateNonSegmentMembersrt:AsiaPacificMember2025-06-012025-08-30 0000039368srt:AsiaPacificMember2025-06-012025-08-30 0000039368us-gaap:OperatingSegmentsMemberful:HygieneHealthAndConsumableAdhesivesMembersrt:AmericasMember2024-06-022024-08-31 0000039368us-gaap:OperatingSegmentsMemberful:EngineeringAdhesivesMembersrt:AmericasMember2024-06-022024-08-31 0000039368us-gaap:OperatingSegmentsMemberful:BuildingAdhesivesSolutionsMembersrt:AmericasMember2024-06-022024-08-31 0000039368us-gaap:CorporateNonSegmentMembersrt:AmericasMember2024-06-022024-08-31 0000039368srt:AmericasMember2024-06-022024-08-31 0000039368us-gaap:OperatingSegmentsMemberful:HygieneHealthAndConsumableAdhesivesMemberful:EIMEAMember2024-06-022024-08-31 0000039368us-gaap:OperatingSegmentsMemberful:EngineeringAdhesivesMemberful:EIMEAMember2024-06-022024-08-31 0000039368us-gaap:OperatingSegmentsMemberful:BuildingAdhesivesSolutionsMemberful:EIMEAMember2024-06-022024-08-31 0000039368us-gaap:CorporateNonSegmentMemberful:EIMEAMember2024-06-022024-08-31 0000039368ful:EIMEAMember2024-06-022024-08-31 0000039368us-gaap:OperatingSegmentsMemberful:HygieneHealthAndConsumableAdhesivesMembersrt:AsiaPacificMember2024-06-022024-08-31 0000039368us-gaap:OperatingSegmentsMemberful:EngineeringAdhesivesMembersrt:AsiaPacificMember2024-06-022024-08-31 0000039368us-gaap:OperatingSegmentsMemberful:BuildingAdhesivesSolutionsMembersrt:AsiaPacificMember2024-06-022024-08-31 0000039368us-gaap:CorporateNonSegmentMembersrt:AsiaPacificMember2024-06-022024-08-31 0000039368srt:AsiaPacificMember2024-06-022024-08-31 0000039368us-gaap:OperatingSegmentsMemberful:HygieneHealthAndConsumableAdhesivesMembersrt:AmericasMember2024-12-012025-08-30 0000039368us-gaap:OperatingSegmentsMemberful:EngineeringAdhesivesMembersrt:AmericasMember2024-12-012025-08-30 0000039368us-gaap:OperatingSegmentsMemberful:BuildingAdhesivesSolutionsMembersrt:AmericasMember2024-12-012025-08-30 0000039368us-gaap:CorporateNonSegmentMembersrt:AmericasMember2024-12-012025-08-30 0000039368srt:AmericasMember2024-12-012025-08-30 0000039368us-gaap:OperatingSegmentsMemberful:HygieneHealthAndConsumableAdhesivesMemberful:EIMEAMember2024-12-012025-08-30 0000039368us-gaap:OperatingSegmentsMemberful:EngineeringAdhesivesMemberful:EIMEAMember2024-12-012025-08-30 0000039368us-gaap:OperatingSegmentsMemberful:BuildingAdhesivesSolutionsMemberful:EIMEAMember2024-12-012025-08-30 0000039368us-gaap:CorporateNonSegmentMemberful:EIMEAMember2024-12-012025-08-30 0000039368ful:EIMEAMember2024-12-012025-08-30 0000039368us-gaap:OperatingSegmentsMemberful:HygieneHealthAndConsumableAdhesivesMembersrt:AsiaPacificMember2024-12-012025-08-30 0000039368us-gaap:OperatingSegmentsMemberful:EngineeringAdhesivesMembersrt:AsiaPacificMember2024-12-012025-08-30 0000039368us-gaap:OperatingSegmentsMemberful:BuildingAdhesivesSolutionsMembersrt:AsiaPacificMember2024-12-012025-08-30 0000039368us-gaap:CorporateNonSegmentMembersrt:AsiaPacificMember2024-12-012025-08-30 0000039368srt:AsiaPacificMember2024-12-012025-08-30 0000039368us-gaap:OperatingSegmentsMemberful:HygieneHealthAndConsumableAdhesivesMembersrt:AmericasMember2023-12-032024-08-31 0000039368us-gaap:OperatingSegmentsMemberful:EngineeringAdhesivesMembersrt:AmericasMember2023-12-032024-08-31 0000039368us-gaap:OperatingSegmentsMemberful:BuildingAdhesivesSolutionsMembersrt:AmericasMember2023-12-032024-08-31 0000039368us-gaap:CorporateNonSegmentMembersrt:AmericasMember2023-12-032024-08-31 0000039368srt:AmericasMember2023-12-032024-08-31 0000039368us-gaap:OperatingSegmentsMemberful:HygieneHealthAndConsumableAdhesivesMemberful:EIMEAMember2023-12-032024-08-31 0000039368us-gaap:OperatingSegmentsMemberful:EngineeringAdhesivesMemberful:EIMEAMember2023-12-032024-08-31 0000039368us-gaap:OperatingSegmentsMemberful:BuildingAdhesivesSolutionsMemberful:EIMEAMember2023-12-032024-08-31 0000039368us-gaap:CorporateNonSegmentMemberful:EIMEAMember2023-12-032024-08-31 0000039368ful:EIMEAMember2023-12-032024-08-31 0000039368us-gaap:OperatingSegmentsMemberful:HygieneHealthAndConsumableAdhesivesMembersrt:AsiaPacificMember2023-12-032024-08-31 0000039368us-gaap:OperatingSegmentsMemberful:EngineeringAdhesivesMembersrt:AsiaPacificMember2023-12-032024-08-31 0000039368us-gaap:OperatingSegmentsMemberful:BuildingAdhesivesSolutionsMembersrt:AsiaPacificMember2023-12-032024-08-31 0000039368us-gaap:CorporateNonSegmentMembersrt:AsiaPacificMember2023-12-032024-08-31 0000039368srt:AsiaPacificMember2023-12-032024-08-31

0000039368 FULLER H B CO false --11-28 Q1 2026 13,172 11,922 0 0 10,045,900 10,045,900 1.00 1.00 160,000,000 160,000,000 54,475,112 54,475,112 54,174,963 54,174,963 33.33 47,260 4,444 30,650 47,252 4,459 27,529 307,173 300,000 50,000 5 0 3 false Segment expenses and other items for all segments primarily include raw material costs, compensation and benefits, delivery expense, rent and lease expense, professional services, travel and entertainment, repairs and maintenance and other manufacturing overhead. Amounts reclassified from accumulated other comprehensive loss into earnings is reported in other income, net. Interest expense added back for EBITDA is adjusted for amounts already included in adjusted net income attributable to H.B. Fuller. Depreciation and amortization expense added back for EBITDA is adjusted for amounts already included in adjusted net income attributable to H.B. Fuller. Income taxes are not provided for foreign currency translation relating to indefinite investments in international subsidiaries. Amounts reclassified from accumulated other comprehensive loss into earnings as part of net periodic cost related to pension and other postretirement benefit plans is reported in cost of sales and other income, net. 00000393682025-11-302026-02-28 xbrli:shares 00000393682026-03-20 thunderdome:item iso4217:USD 00000393682024-12-012025-03-01 iso4217:USDxbrli:shares 0000039368us-gaap:InterestRateSwapMember2025-11-302026-02-28 0000039368us-gaap:InterestRateSwapMember2024-12-012025-03-01 0000039368ful:NetInvestmentHedgesMember2025-11-302026-02-28 0000039368ful:NetInvestmentHedgesMember2024-12-012025-03-01 00000393682026-02-28 00000393682025-11-29 0000039368us-gaap:CommonStockMember2025-11-29 0000039368us-gaap:AdditionalPaidInCapitalMember2025-11-29 0000039368us-gaap:RetainedEarningsMember2025-11-29 0000039368us-gaap:AccumulatedOtherComprehensiveIncomeMember2025-11-29 0000039368us-gaap:NoncontrollingInterestMember2025-11-29 0000039368us-gaap:CommonStockMember2025-11-302026-02-28 0000039368us-gaap:AdditionalPaidInCapitalMember2025-11-302026-02-28 0000039368us-gaap:RetainedEarningsMember2025-11-302026-02-28 0000039368us-gaap:AccumulatedOtherComprehensiveIncomeMember2025-11-302026-02-28 0000039368us-gaap:NoncontrollingInterestMember2025-11-302026-02-28 0000039368us-gaap:CommonStockMember2026-02-28 0000039368us-gaap:AdditionalPaidInCapitalMember2026-02-28 0000039368us-gaap:RetainedEarningsMember2026-02-28 0000039368us-gaap:AccumulatedOtherComprehensiveIncomeMember2026-02-28 0000039368us-gaap:NoncontrollingInterestMember2026-02-28 0000039368us-gaap:CommonStockMember2024-11-30 0000039368us-gaap:AdditionalPaidInCapitalMember2024-11-30 0000039368us-gaap:RetainedEarningsMember2024-11-30 0000039368us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-11-30 0000039368us-gaap:NoncontrollingInterestMember2024-11-30 00000393682024-11-30 0000039368us-gaap:CommonStockMember2024-12-012025-03-01 0000039368us-gaap:AdditionalPaidInCapitalMember2024-12-012025-03-01 0000039368us-gaap:RetainedEarningsMember2024-12-012025-03-01 0000039368us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-12-012025-03-01 0000039368us-gaap:NoncontrollingInterestMember2024-12-012025-03-01 0000039368us-gaap:CommonStockMember2025-03-01 0000039368us-gaap:AdditionalPaidInCapitalMember2025-03-01 0000039368us-gaap:RetainedEarningsMember2025-03-01 0000039368us-gaap:AccumulatedOtherComprehensiveIncomeMember2025-03-01 0000039368us-gaap:NoncontrollingInterestMember2025-03-01 00000393682025-03-01 utr:Y 0000039368ful:The10YearPublicNotesMember2017-02-142017-02-14 0000039368ful:The10YearPublicNotesMember2017-02-14 xbrli:pure iso4217:TRY 0000039368ful:NdIndustriesTurkeyMember2025-11-172025-11-17 0000039368ful:NdIndustriesTurkeyMember2026-02-28 iso4217:TWD 0000039368ful:NDIndustriesAsiaIncNDIndustriesTaiwanMember2025-02-152025-02-15 0000039368ful:NDIndustriesAsiaIncNDIndustriesTaiwanMember2025-02-15 iso4217:EUR 0000039368ful:GemMember2025-01-152025-01-15 0000039368ful:GemMemberful:HoldbackLiabilityMember2025-01-15 0000039368ful:GemMember2025-01-15 0000039368ful:GemMember2026-02-28 0000039368us-gaap:EmployeeSeveranceMemberful:ThePlanRelatedToOrganizationalChangesAndOtherActionsMember2026-02-28 0000039368us-gaap:OtherRestructuringMemberful:ThePlanRelatedToOrganizationalChangesAndOtherActionsMember2026-02-28 0000039368ful:ThePlanIncludedInCostOfSalesMember2025-11-302026-02-28 0000039368ful:ThePlanIncludedInCostOfSalesMember2024-12-012025-03-01 0000039368ful:ThePlanIncludedInSellingGeneralAndAdministrativeMember2025-11-302026-02-28 0000039368ful:ThePlanIncludedInSellingGeneralAndAdministrativeMember2024-12-012025-03-01 0000039368ful:ThePlanIncludedInOtherExpensesNetMember2025-11-302026-02-28 0000039368ful:ThePlanIncludedInOtherExpensesNetMember2024-12-012025-03-01 0000039368ful:ThePlanRelatedToOrganizationalChangesAndOtherActionsMember2025-11-302026-02-28 0000039368ful:ThePlanRelatedToOrganizationalChangesAndOtherActionsMember2024-12-012025-03-01 0000039368ful:EmployeeRelatedMemberful:ThePlanRelatedToOrganizationalChangesAndOtherActionsMember2024-11-30 0000039368ful:AssetRelatedMemberful:ThePlanRelatedToOrganizationalChangesAndOtherActionsMember2024-11-30 0000039368us-gaap:OtherRestructuringMemberful:ThePlanRelatedToOrganizationalChangesAndOtherActionsMember2024-11-30 0000039368ful:ThePlanRelatedToOrganizationalChangesAndOtherActionsMember2024-11-30 0000039368ful:EmployeeRelatedMemberful:ThePlanRelatedToOrganizationalChangesAndOtherActionsMember2024-12-012025-11-29 0000039368ful:AssetRelatedMemberful:ThePlanRelatedToOrganizationalChangesAndOtherActionsMember2024-12-012025-11-29 0000039368us-gaap:OtherRestructuringMemberful:ThePlanRelatedToOrganizationalChangesAndOtherActionsMember2024-12-012025-11-29 0000039368ful:ThePlanRelatedToOrganizationalChangesAndOtherActionsMember2024-12-012025-11-29 0000039368ful:EmployeeRelatedMemberful:ThePlanRelatedToOrganizationalChangesAndOtherActionsMember2025-11-29 0000039368ful:AssetRelatedMemberful:ThePlanRelatedToOrganizationalChangesAndOtherActionsMember2025-11-29 0000039368us-gaap:OtherRestructuringMemberful:ThePlanRelatedToOrganizationalChangesAndOtherActionsMember2025-11-29 0000039368ful:ThePlanRelatedToOrganizationalChangesAndOtherActionsMember2025-11-29 0000039368ful:EmployeeRelatedMemberful:ThePlanRelatedToOrganizationalChangesAndOtherActionsMember2025-11-302026-02-28 0000039368ful:AssetRelatedMemberful:ThePlanRelatedToOrganizationalChangesAndOtherActionsMember2025-11-302026-02-28 0000039368us-gaap:OtherRestructuringMemberful:ThePlanRelatedToOrganizationalChangesAndOtherActionsMember2025-11-302026-02-28 0000039368ful:EmployeeRelatedMemberful:ThePlanRelatedToOrganizationalChangesAndOtherActionsMember2026-02-28 0000039368ful:AssetRelatedMemberful:ThePlanRelatedToOrganizationalChangesAndOtherActionsMember2026-02-28 0000039368ful:ThePlanRelatedToOrganizationalChangesAndOtherActionsMember2026-02-28 0000039368us-gaap:EmployeeSeveranceMemberful:OtherRestructuringActionsRelatedToGlobalFootprintOptimizationMember2026-02-28 0000039368us-gaap:OtherRestructuringMemberful:OtherRestructuringActionsRelatedToGlobalFootprintOptimizationMember2026-02-28 0000039368ful:OtherRestructuringIncludedInCostOfSalesMember2025-11-302026-02-28 0000039368ful:OtherRestructuringIncludedInCostOfSalesMember2024-12-012025-03-01 0000039368ful:OtherRestructuringIncludedInSellingGeneralAndAdministrativeMember2025-11-302026-02-28 0000039368ful:OtherRestructuringIncludedInSellingGeneralAndAdministrativeMember2024-12-012025-03-01 0000039368ful:OtherRestructuringActionsRelatedToGlobalFootprintOptimizationMember2025-11-302026-02-28 0000039368ful:OtherRestructuringActionsRelatedToGlobalFootprintOptimizationMember2024-12-012025-03-01 0000039368ful:EmployeeRelatedMemberful:OtherRestructuringActionsRelatedToGlobalFootprintOptimizationMember2025-11-302026-02-28 0000039368ful:AssetRelatedMemberful:OtherRestructuringActionsRelatedToGlobalFootprintOptimizationMember2025-11-302026-02-28 0000039368ful:EmployeeRelatedMemberful:OtherRestructuringActionsRelatedToGlobalFootprintOptimizationMember2026-02-28 0000039368ful:AssetRelatedMemberful:OtherRestructuringActionsRelatedToGlobalFootprintOptimizationMember2026-02-28 0000039368ful:OtherRestructuringActionsRelatedToGlobalFootprintOptimizationMember2026-02-28 0000039368ful:HygieneHealthAndConsumableAdhesivesMember2025-11-29 0000039368ful:EngineeringAdhesivesMember2025-11-29 0000039368ful:BuildingAdhesivesSolutionsMember2025-11-29 0000039368ful:HygieneHealthAndConsumableAdhesivesMember2025-11-302026-02-28 0000039368ful:EngineeringAdhesivesMember2025-11-302026-02-28 0000039368ful:BuildingAdhesivesSolutionsMember2025-11-302026-02-28 0000039368ful:HygieneHealthAndConsumableAdhesivesMember2026-02-28 0000039368ful:EngineeringAdhesivesMember2026-02-28 0000039368ful:BuildingAdhesivesSolutionsMember2026-02-28 0000039368ful:PurchasedTechnologyAndPatentsMember2026-02-28 0000039368us-gaap:CustomerRelationshipsMember2026-02-28 0000039368us-gaap:TradeNamesMember2026-02-28 0000039368us-gaap:OtherIntangibleAssetsMember2026-02-28 0000039368ful:PurchasedTechnologyAndPatentsMember2025-11-29 0000039368us-gaap:CustomerRelationshipsMember2025-11-29 0000039368us-gaap:TradeNamesMember2025-11-29 0000039368us-gaap:OtherIntangibleAssetsMember2025-11-29 0000039368country:USus-gaap:PensionPlansDefinedBenefitMember2025-11-302026-02-28 0000039368country:USus-gaap:PensionPlansDefinedBenefitMember2024-12-012025-03-01 0000039368us-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMember2025-11-302026-02-28 0000039368us-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMember2024-12-012025-03-01 0000039368us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember2025-11-302026-02-28 0000039368us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember2024-12-012025-03-01 0000039368ful:NetInvestmentHedgeMember2025-11-302026-02-28 0000039368ful:NetInvestmentHedgeMember2024-12-012025-03-01 0000039368us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember2025-11-302026-02-28 0000039368us-gaap:AccumulatedTranslationAdjustmentMember2025-11-302026-02-28 0000039368us-gaap:AccumulatedForeignCurrencyAdjustmentAttributableToNoncontrollingInterestMember2025-11-302026-02-28 0000039368us-gaap:AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember2025-11-302026-02-28 0000039368us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2025-11-302026-02-28 0000039368us-gaap:AccumulatedDefinedBenefitPlansAdjustmentAttributableToNoncontrollingInterestMember2025-11-302026-02-28 0000039368us-gaap:InterestRateSwapMemberus-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember2025-11-302026-02-28 0000039368us-gaap:InterestRateSwapMemberus-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2025-11-302026-02-28 0000039368us-gaap:InterestRateSwapMemberus-gaap:AccumulatedGainLossNetCashFlowHedgeNoncontrollingInterestMember2025-11-302026-02-28 0000039368ful:NetInvestmentHedgesMemberus-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember2025-11-302026-02-28 0000039368ful:NetInvestmentHedgesMemberus-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2025-11-302026-02-28 0000039368ful:NetInvestmentHedgesMemberus-gaap:AccumulatedGainLossNetCashFlowHedgeNoncontrollingInterestMember2025-11-302026-02-28 0000039368us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember2025-11-302026-02-28 0000039368us-gaap:AociAttributableToNoncontrollingInterestMember2025-11-302026-02-28 0000039368us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember2026-02-28 0000039368us-gaap:AociAttributableToNoncontrollingInterestMember2026-02-28 0000039368us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember2024-12-012025-11-29 0000039368us-gaap:AccumulatedTranslationAdjustmentMember2024-12-012025-11-29 0000039368us-gaap:AccumulatedForeignCurrencyAdjustmentAttributableToNoncontrollingInterestMember2024-12-012025-11-29 0000039368us-gaap:AccumulatedDefinedBenefitPlansAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember2024-12-012025-11-29 0000039368us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2024-12-012025-11-29 0000039368us-gaap:AccumulatedDefinedBenefitPlansAdjustmentAttributableToNoncontrollingInterestMember2024-12-012025-11-29 0000039368us-gaap:InterestRateSwapMemberus-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember2024-12-012025-11-29 0000039368us-gaap:InterestRateSwapMemberus-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2024-12-012025-11-29 0000039368us-gaap:InterestRateSwapMemberus-gaap:AccumulatedGainLossNetCashFlowHedgeNoncontrollingInterestMember2024-12-012025-11-29 0000039368ful:NetInvestmentHedgesMemberus-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2024-12-012025-11-29 0000039368ful:NetInvestmentHedgesMemberus-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember2024-12-012025-11-29 0000039368ful:NetInvestmentHedgesMemberus-gaap:AccumulatedGainLossNetCashFlowHedgeNoncontrollingInterestMember2024-12-012025-11-29 0000039368us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember2024-12-012025-11-29 0000039368us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-12-012025-11-29 0000039368us-gaap:AociAttributableToNoncontrollingInterestMember2024-12-012025-11-29 0000039368us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember2025-11-29 0000039368us-gaap:AociAttributableToNoncontrollingInterestMember2025-11-29 0000039368ful:InterestRateSwap3Member2023-01-13 0000039368ful:InterestRateSwap3Member2023-02-28 0000039368ful:InterestRateSwap3Member2026-02-28 0000039368us-gaap:InterestRateSwapMember2023-03-16 0000039368us-gaap:InterestRateSwapMember2026-02-28 0000039368ful:InterestRateSwap2Member2023-03-16 0000039368ful:InterestRateSwap2Member2026-02-28 0000039368us-gaap:InterestRateSwapMemberus-gaap:CashFlowHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMember2025-11-302026-02-28 0000039368us-gaap:InterestRateSwapMemberus-gaap:CashFlowHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMember2024-12-012025-03-01 0000039368ful:InterestRateSwapRelatedToPublicNotesMember2021-02-12 0000039368ful:InterestRateSwapRelatedToPublicNotesMemberful:LondonInterbankOfferedRateLibor1Member2021-02-12 0000039368ful:InterestRateSwapRelatedToPublicNotesMember2026-02-28 0000039368ful:PublicNotesMember2026-02-28 0000039368us-gaap:CrossCurrencyInterestRateContractMember2022-10-17 0000039368us-gaap:CrossCurrencyInterestRateContractMember2022-10-20 0000039368us-gaap:CrossCurrencyInterestRateContractMemberus-gaap:SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember2023-06-30 0000039368us-gaap:CrossCurrencyInterestRateContractMemberful:EuroShortTermRateESTROvernightIndexSwapRateMember2023-07-17 0000039368us-gaap:CrossCurrencyInterestRateContractMemberful:EuroShortTermRateESTROvernightIndexSwapRateMember2026-02-28 0000039368us-gaap:CrossCurrencyInterestRateContractMember2025-11-302026-02-28 0000039368us-gaap:CrossCurrencyInterestRateContractMemberus-gaap:NetInvestmentHedgingMember2025-11-302026-02-28 0000039368us-gaap:CrossCurrencyInterestRateContractMemberus-gaap:NetInvestmentHedgingMember2026-02-28 0000039368us-gaap:FairValueMeasurementsRecurringMember2026-02-28 0000039368us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2026-02-28 0000039368us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2026-02-28 0000039368us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2026-02-28 0000039368us-gaap:FairValueMeasurementsRecurringMember2025-11-29 0000039368us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2025-11-29 0000039368us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2025-11-29 0000039368us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2025-11-29 00000393682025-01-152026-02-28 0000039368ful:HoldbackLiabilityMember2025-11-29 0000039368ful:HoldbackLiabilityMember2025-11-302026-02-28 0000039368ful:HoldbackLiabilityMember2026-02-28 0000039368ful:AsbestosRelatedLawsuitsAndClaimsMember2025-11-302026-02-28 0000039368ful:AsbestosRelatedLawsuitsAndClaimsMember2024-12-012025-03-01 0000039368ful:AsbestosRelatedLawsuitsAndClaimsMember2022-12-042025-11-29 0000039368ful:AsbestosRelatedLawsuitsAndClaimsMember2026-02-28 0000039368ful:AsbestosRelatedLawsuitsAndClaimsMember2025-03-01 0000039368ful:AsbestosRelatedLawsuitsAndClaimsMember2025-11-29 0000039368ful:RouseEtAlVHbFullerMember2024-02-012024-02-28 0000039368ful:The2022ShareRepurchaseProgramMember2022-04-22 0000039368ful:The2022ShareRepurchaseProgramMember2022-04-222022-04-22 0000039368ful:The2022ShareRepurchaseProgramMember2025-11-302026-02-28 0000039368ful:The2022ShareRepurchaseProgramMember2024-12-012025-03-01 0000039368ful:The2022ShareRepurchaseProgramMemberus-gaap:CommonStockMember2024-12-012025-03-01 0000039368ful:The2022ShareRepurchaseProgramMemberus-gaap:AdditionalPaidInCapitalMember2024-12-012025-03-01 0000039368us-gaap:OperatingSegmentsMemberful:HygieneHealthAndConsumableAdhesivesMember2025-11-302026-02-28 0000039368us-gaap:OperatingSegmentsMemberful:EngineeringAdhesivesMember2025-11-302026-02-28 0000039368us-gaap:OperatingSegmentsMemberful:BuildingAdhesivesSolutionsMember2025-11-302026-02-28 0000039368us-gaap:OperatingSegmentsMember2025-11-302026-02-28 0000039368us-gaap:CorporateNonSegmentMember2025-11-302026-02-28 0000039368us-gaap:OperatingSegmentsMemberful:HygieneHealthAndConsumableAdhesivesMember2024-12-012025-03-01 0000039368us-gaap:OperatingSegmentsMemberful:EngineeringAdhesivesMember2024-12-012025-03-01 0000039368us-gaap:OperatingSegmentsMemberful:BuildingAdhesivesSolutionsMember2024-12-012025-03-01 0000039368us-gaap:OperatingSegmentsMember2024-12-012025-03-01 0000039368us-gaap:CorporateNonSegmentMember2024-12-012025-03-01 0000039368us-gaap:OperatingSegmentsMemberful:HygieneHealthAndConsumableAdhesivesMembersrt:AmericasMember2025-11-302026-02-28 0000039368us-gaap:OperatingSegmentsMemberful:EngineeringAdhesivesMembersrt:AmericasMember2025-11-302026-02-28 0000039368us-gaap:OperatingSegmentsMemberful:ConstructionAdhesivesMembersrt:AmericasMember2025-11-302026-02-28 0000039368us-gaap:CorporateNonSegmentMembersrt:AmericasMember2025-11-302026-02-28 0000039368us-gaap:OperatingSegmentsMemberful:HygieneHealthAndConsumableAdhesivesMemberful:EIMEAMember2025-11-302026-02-28 0000039368us-gaap:OperatingSegmentsMemberful:EngineeringAdhesivesMemberful:EIMEAMember2025-11-302026-02-28 0000039368us-gaap:OperatingSegmentsMemberful:ConstructionAdhesivesMemberful:EIMEAMember2025-11-302026-02-28 0000039368ful:EIMEAMember2025-11-302026-02-28 0000039368us-gaap:OperatingSegmentsMemberful:HygieneHealthAndConsumableAdhesivesMembersrt:AsiaPacificMember2025-11-302026-02-28 0000039368us-gaap:OperatingSegmentsMemberful:EngineeringAdhesivesMembersrt:AsiaPacificMember2025-11-302026-02-28 0000039368us-gaap:OperatingSegmentsMemberful:ConstructionAdhesivesMembersrt:AsiaPacificMember2025-11-302026-02-28 0000039368srt:AsiaPacificMember2025-11-302026-02-28 0000039368us-gaap:OperatingSegmentsMemberful:ConstructionAdhesivesMember2025-11-302026-02-28 0000039368us-gaap:OperatingSegmentsMemberful:HygieneHealthAndConsumableAdhesivesMembersrt:AmericasMember2024-12-012025-03-01 0000039368us-gaap:OperatingSegmentsMemberful:EngineeringAdhesivesMembersrt:AmericasMember2024-12-012025-03-01 0000039368us-gaap:OperatingSegmentsMemberful:ConstructionAdhesivesMembersrt:AmericasMember2024-12-012025-03-01 0000039368us-gaap:CorporateNonSegmentMembersrt:AmericasMember2024-12-012025-03-01 0000039368us-gaap:OperatingSegmentsMemberful:HygieneHealthAndConsumableAdhesivesMemberful:EIMEAMember2024-12-012025-03-01 0000039368us-gaap:OperatingSegmentsMemberful:EngineeringAdhesivesMemberful:EIMEAMember2024-12-012025-03-01 0000039368us-gaap:OperatingSegmentsMemberful:ConstructionAdhesivesMemberful:EIMEAMember2024-12-012025-03-01 0000039368ful:EIMEAMember2024-12-012025-03-01 0000039368us-gaap:OperatingSegmentsMemberful:HygieneHealthAndConsumableAdhesivesMembersrt:AsiaPacificMember2024-12-012025-03-01 0000039368us-gaap:OperatingSegmentsMemberful:EngineeringAdhesivesMembersrt:AsiaPacificMember2024-12-012025-03-01 0000039368us-gaap:OperatingSegmentsMemberful:ConstructionAdhesivesMembersrt:AsiaPacificMember2024-12-012025-03-01 0000039368srt:AsiaPacificMember2024-12-012025-03-01 0000039368us-gaap:OperatingSegmentsMemberful:ConstructionAdhesivesMember2024-12-012025-03-01

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

(Mark One)

☒	QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended ~~August~~February 3028, ~~2025~~2026

☐	TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from to .

Commission file number: 001-09225

H.B. FULLER COMPANY

(Exact name of registrant as specified in its charter)

Minnesota	41-0268370
(State or other jurisdiction of	(I.R.S. Employer
incorporation or organization)	Identification No.)

1200 Willow Lake Boulevard, St. Paul, Minnesota	55110-5101
(Address of principal executive offices)	(Zip Code)

Registrant’s telephone number, including area code: (651) 236-5900

Not Applicable

(Former name, former address and former fiscal year, if changed since last report)

Securities registered pursuant to section 12(b) of the Act:

Title of each class	Trading Symbol	Name of each exchange on which registered
Common Stock, par value $1.00 per share	FUL	New York Stock Exchange

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See definitions of “large accelerated filer”, “accelerated filer”, “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act. (Check one):

Large accelerated filer ☒	Accelerated filer ☐
Non-accelerated filer ☐	Smaller reporting company ☐
	Emerging growth company ☐

Table of Contents

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12(b) of the Exchange Act. Yes ☐ No ☒

APPLICABLE ONLY TO ISSUERS INVOLVED IN BANKRUPTCY PROCEEDINGS DURING THE PROCEEDING FIVE YEARS:

Indicate by check mark whether the registrant has filed all documents and reports required to be filed by section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court. Yes ☐ No ☐

APPLICABLE ONLY TO CORPORATE ISSUERS

The number of shares outstanding of the Registrant’s Common Stock, par value $1.00 per share, was 54,~~088~~487,~~889~~294 as of ~~September 19~~March 20, ~~2025~~2026.

. 1

Table of Contents

H.B. Fuller Company

Quarterly Report on Form 10-Q

Table of Contents

		Page
PART 1. FINANCIAL INFORMATION
ITEM 1.	FINANCIAL STATEMENTS (Unaudited)	43
	Consolidated Statements of Income for the three and nine months ended August 30, 2025 and August 31, 2024	4
	Consolidated Statements of Income for the three months ended February 28, 2026 and March 1, 2025	3
	Consolidated Statements of Comprehensive Income for the three and nine months ended August 30, 2025 and August 31, 2024	5
	Consolidated Statements of Comprehensive Income for the three months ended February 28, 2026 and March 1, 2025	4
	Consolidated Balance Sheets as of August 30, 2025 and November 30, 2024	6
	Consolidated Balance Sheets as of February 28, 2026 and November 29, 2025	5
	Consolidated Statements of Total Equity for the three and nine months ended August 30, 2025 and August 31, 2024	7
	Consolidated Statements of Total Equity for the three months ended February 28, 2026 and March 1, 2025	6
	Consolidated Statements of Cash Flows for the nine months ended August 30, 2025 and August 31, 2024	8
	Consolidated Statements of Cash Flows for the three months ended February 28, 2026 and March 1, 2025	7
	Notes to Consolidated Financial Statements	98
ITEM 2.	MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS	2518
ITEM 3.	QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK	3927
ITEM 4.	CONTROLS AND PROCEDURES	3927
PART II. OTHER INFORMATION		4028
ITEM 1.	LEGAL PROCEEDINGS	4028
ITEM 1A.	RISK FACTORS	4028
ITEM 2.	UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS	4128
ITEM 6.	EXHIBITS	4129
SIGNATURES		4230

Table of Contents

PART I. FINANCIAL INFORMATION

Item 1. Financial Statements

H.B. FULLER COMPANY AND SUBSIDIARIES

Consolidated Statements of Income

(In thousands, except per share amounts)

(Unaudited)

Three Months Ended

~~Nine Months Ended~~

August 30,

August 31,

August 30,

August 31,

February 28,

March 1,

2025

2024

2025

2024

2026

2025

Net revenue

~~892~~770,~~043~~844

~~917~~788,~~927~~663

~~2,578,801~~

~~2,645,452~~

Cost of sales

(~~606~~534,~~929~~796

)

(~~642~~561,~~198~~588

)

~~(1,780,228~~

)

~~(1,848,435~~

)

Gross profit

~~285~~236,~~114~~048

~~275~~227,~~729~~075

~~798,573~~

~~797,017~~

Selling, general and administrative expenses

(~~174~~184,~~974~~450

)

(~~171~~180,~~388~~628

)

~~(541,942~~

)

~~(525,204~~

)

Other income, net

56,~~308~~749

23,~~148~~207

~~15,655~~

~~7,282~~

Interest expense

(3332,~~630~~871

)

(3532,~~288~~042

)

~~(100,536~~

)

~~(99,504~~

)

Interest income

12,~~110~~073

1,~~092~~100

~~3,064~~

~~3,597~~

Income before income taxes and income from equity method investments

8227,~~928~~549

7218,~~293~~712

~~174,814~~

~~183,188~~

Income taxes

(167,~~527~~422

)

(185,~~264~~945

)

~~(55,198~~

)

~~(48,496~~

)

Income from equity method investments

~~832~~918

~~1,310~~497

~~2,726~~

~~2,955~~

Net income including non-controlling interest

6721,~~233~~045

5513,~~339~~264

~~122,342~~

~~137,647~~

Net (income) loss attributable to non-controlling interest

(73

)

(106

)

(32

)

Net income attributable to non-controlling interest

(16

)

Net income attributable to H.B. Fuller

6721,~~160~~045

5513,~~361~~248

~~122,236~~

~~137,615~~

Earnings per share attributable to H.B. Fuller common stockholders:

Basic

10.2338

10.0124

~~2.24~~

~~2.51~~

Diluted

10.2238

0.9824

~~2.21~~

~~2.43~~

Weighted-average common shares outstanding:

Basic

54,~~428~~731

54,~~975~~998

~~54,623~~

~~54,874~~

Diluted

55,~~162~~513

56,~~650~~029

~~55,381~~

~~56,620~~

See accompanying Notes to Unaudited Consolidated Financial Statements.

Table of Contents

H.B. FULLER COMPANY AND SUBSIDIARIES

Consolidated Statements of Comprehensive Income (Loss)

(In thousands)

(Unaudited)

	Three Months Ended						~~Nine Months Ended~~
	August 30,			August 31,			August 30,			August 31,
	February 28,			March 1,
	2025			2024			2025			2024
	2026			2025
Net income including non-controlling interest	$	6721,~~233~~045		$	5513,~~339~~264		$	~~122,342~~		$	~~137,647~~
Other comprehensive income (loss)
Foreign currency translation		3652,~~962~~205			33(20,~~355~~986	)		~~139,626~~			~~(12,932~~	)
Defined benefit pension plans adjustment, net of tax		~~158~~18			~~1,270~~130			~~429~~			~~3,808~~
Interest rate swaps, net of tax		~~(3,347~~46	)		(251,~~744~~147	)		~~(6,920~~	)		~~(18,013~~	)
Net investment hedges, net of tax		(149,~~998~~705	)		(86,~~231~~994	)		~~(53,453~~	)		~~(4,318~~	)
Other comprehensive income (loss)		1842,~~775~~564			~~650~~(15,009	)		~~79,682~~			~~(31,455~~	)
Comprehensive income		86,008			55,989			202,024			106,192
Comprehensive income (loss)		63,609			(1,745	)
Less: Comprehensive income attributable to non-controlling interest		4224			933			~~140~~			22
Comprehensive income attributable to H.B. Fuller	$	85,966		$	55,980		$	201,884		$	106,170
Comprehensive income (loss) attributable to H.B. Fuller	$	63,585		$	(1,778	)

See accompanying Notes to Unaudited Consolidated Financial Statements.

Table of Contents

H.B. FULLER COMPANY AND SUBSIDIARIES

Consolidated Balance Sheets

(In thousands, except share and per share amounts)

(Unaudited)

	August 30,			November 30,
	February 28,			November 29,
	2025			2024
	2026			2025
Assets
Current assets:
Cash and cash equivalents	$	~~122~~107,~~458~~877		$	~~169~~107,~~352~~213
Trade receivables (net of allowances of $11,661 and $11,621, as of August 30, 2025 and November 30, 2024, respectively)		563,579			558,336
Trade receivables (net of allowances of $13,172 and $11,922, as of February 28, 2026 and November 29, 2025, respectively)		532,180			564,339
Inventories		~~502~~506,~~956~~776			~~467~~471,~~498~~963
Other current assets		~~111~~128,~~752~~502			~~104~~119,~~019~~750
Total current assets		1,~~300~~275,~~745~~335			1,~~299~~263,~~205~~265
Property, plant and equipment		12,~~913~~009,~~345~~591			1,~~864~~956,~~558~~209
Accumulated depreciation		(1,~~023~~052,~~758~~979	)		(~~982~~1,~~631~~020,948	)
Property, plant and equipment, net		~~889~~956,~~587~~612			~~881~~935,~~927~~261
Goodwill		1,~~681~~697,~~887~~468			1,~~532~~680,~~221~~059
Other intangibles, net		~~829~~791,~~430~~098			~~770~~805,~~226~~867
Other assets		~~464~~499,~~453~~784			~~449~~498,~~665~~254
Total assets	$	5,~~166~~220,~~102~~297		$	45,~~933~~182,~~244~~706
Liabilities, non-controlling interest and total equity
Current liabilities
Notes payable	$	-		$	587
Trade payables	$	453,035		$	470,132
Trade payables		459,409			491,435
Accrued compensation		69,254			114,302
Accrued compensation		90,283			106,005
Income taxes payable		20,313			25,018
Income taxes payable		18,774			24,225
Other accrued expenses		123,306			133,907
Other accrued expenses		105,766			97,038
Total current liabilities		665,908			743,359
Total current liabilities		674,232			719,290
Long-term debt		2,076,062			2,016,937
Long-term debt		2,080,470			2,010,052
Accrued pension liabilities		52,124			51,317
Accrued pension liabilities		56,188			51,755
Other liabilities		360,898			367,899
Other liabilities		396,240			322,299
Total liabilities	$	3,154,992		$	3,179,512
Total liabilities	$	3,207,130		$	3,103,396
Commitments and contingencies (Note 13)
Equity
H.B. Fuller stockholders' equity:
Preferred stock (no shares outstanding) shares authorized – 10,045,900		-			-
Common stock, par value $1.00 per share, shares authorized – 160,000,000, shares outstanding – 54,043,300 and 54,657,103 as of August 30, 2025 and November 30, 2024, respectively	$	54,043		$	54,657
Common stock, par value $1.00 per share, shares authorized – 160,000,000, shares issued and outstanding – 54,476,112 and 54,174,963 as of February 28, 2026 and November 29, 2025, respectively	$	54,476		$	54,175
Additional paid-in capital		~~288~~309,~~195~~114			~~322~~298,~~636~~017
Retained earnings		2,~~009~~034,~~152~~220			12,~~924~~026,~~761~~071
Accumulated other comprehensive loss		(~~393~~332,~~747~~505	)		(~~473~~375,~~395~~045	)
Total H.B. Fuller stockholders' equity		12,~~957~~065,~~643~~305			12,~~828~~003,~~659~~218
Non-controlling interest		~~1,329~~-			~~1,189~~(24	)
Total equity		12,~~958~~065,~~972~~305			12,~~829~~003,~~848~~194
Total liabilities, non-controlling interest and total equity	$	5,~~166~~220,~~102~~297		$	45,~~933~~182,~~244~~706

See accompanying Notes to Unaudited Consolidated Financial Statements.

Table of Contents

H.B. FULLER COMPANY AND SUBSIDIARIES

Consolidated Statements of Total Equity

(In thousands)

(Unaudited)

	H.B. Fuller Company Shareholders
	H.B. Fuller Company Stockholders
										Accumulated
				Additional						Other
	Common			Paid-in			Retained			Comprehensive			Non-Controlling
	Stock			Capital			Earnings			Income (Loss)			Interest			Total
Balance at November 30, 2024	$	54,657		$	322,636		$	1,924,761		$	(473,395	)	$	1,189		$	1,829,848
Balance at November 29, 2025	$	54,175		$	298,017		$	2,026,071		$	(375,045	)	$	(24	)	$	2,003,194
Comprehensive income (loss)		-			-			13,248			(15,026	)		33			(1,745	)
Comprehensive income		-			-			21,045			42,540			24			63,609
Dividends		-			-			(12,~~285~~896	)		-			-			(12,~~285~~896	)
Stock option exercises		33183			17,~~351~~615			-			-			-			17,~~384~~798
Share-based compensation plans and other, net		~~229~~166			56,~~307~~356			-			-			-			56,~~536~~522
Repurchases of common stock		(~~729~~48	)		(432,~~648~~874	)		-			-			-			(442,~~377~~922	)
Balance at March 1, 2025	$	54,190		$	285,646		$	1,925,724		$	(488,421	)	$	1,222		$	1,778,361
Balance at February 28, 2026	$	54,476		$	309,114		$	2,034,220		$	(332,505	)	$	-		$	2,065,305
Comprehensive income		-			-			41,828			75,868			65			117,761
Dividends		-			-			(12,767	)		-			-			(12,767	)
Stock option exercises		32			1,060			-			-			-			1,092
Share-based compensation plans and other, net		33			7,793			-			-			-			7,826
Repurchases of common stock		(302	)		(15,986	)		-			-			-			(16,288	)
Balance at May 31, 2025	$	53,953		$	278,513		$	1,954,785		$	(412,553	)	$	1,287		$	1,875,985
Comprehensive income		-			-			67,160			18,806			42			86,008
Dividends		-			-			(12,793	)		-			-			(12,793	)
Stock option exercises		87			2,957			-			-			-			3,044
Share-based compensation plans and other, net		4			6,787			-			-			-			6,791
Repurchases of common stock		(1	)		(62	)		-			-			-			(63	)
Balance at August 30, 2025	$	54,043		$	288,195		$	2,009,152		$	(393,747	)	$	1,329		$	1,958,972

	H.B. Fuller Company Shareholders
	H.B. Fuller Company Stockholders
										Accumulated
				Additional						Other
	Common			Paid-in			Retained			Comprehensive			Non-Controlling
	Stock			Capital			Earnings			Income (Loss)			Interest		Total
Balance at December 2, 2023	$	54,093		$	301,485		$	1,842,507		$	(442,880	)	$	708	$	1,755,913
Balance at November 30, 2024	$	54,657		$	322,636		$	1,924,761		$	(473,395	)	$	1,189	$	1,829,848
Comprehensive income (loss)		-			-			3013,~~991~~248			(15,~~909~~026	)		1233		15(1,~~094~~745	)
Dividends		-			-			(1112,~~246~~285	)		-			-		(1112,~~246~~285	)
Stock option exercises		~~200~~33			81,~~777~~351			-			-			-		81,~~977~~384
Share-based compensation plans and other, net		~~225~~229			5,~~490~~307			-			-			-		5,~~715~~536
Repurchases of common stock		(80729	)		(643,~~128~~648	)		-			-			-		(644,~~208~~377	)
Balance at March 2, 2024	$	54,438		$	309,624		$	1,862,252		$	(458,789	)	$	720	$	1,768,245
Balance at March 1, 2025	$	54,190		$	285,646		$	1,925,724		$	(488,421	)	$	1,222	$	1,778,361
Comprehensive income (loss)		-			-			51,264			(16,156	)		1		35,109
Dividends		-			-			(12,144	)		-			-		(12,144	)
Stock option exercises		189			9,123			-			-			-		9,312
Share-based compensation plans and other, net		81			7,111			-			-			-		7,192
Repurchases of common stock		(200	)		(15,400	)		-			-			-		(15,600	)
Balance at June 1, 2024	$	54,508		$	310,458		$	1,901,372		$	(474,945	)	$	721	$	1,792,114
Comprehensive income		-			-			55,361			619			9		55,989
Dividends		-			-			(12,353	)		-			-		(12,353	)
Stock option exercises		328			15,553			-			-			-		15,881
Share-based compensation plans and other, net		2			7,650			-			-			-		7,652
Repurchases of common stock		(225	)		(17,337	)		-			-			-		(17,562	)
Balance at August 31, 2024	$	54,613		$	316,324		$	1,944,380		$	(474,326	)	$	730	$	1,841,721

See accompanying Notes to Unaudited Consolidated Financial Statements.

Table of Contents

H.B. FULLER COMPANY AND SUBSIDIARIES

Consolidated Statements of Cash Flows

(In thousands)

(Unaudited)

	Nine Months Ended
	Three Months Ended
	August 30, 2025			August 31, 2024
	February 28, 2026			March 1, 2025
Cash flows from operating activities:
Net income including non-controlling interest	$	~~122~~21,~~342~~045		$	~~137~~13,~~647~~264
Adjustments to reconcile net income including non-controlling interest to net cash provided by operating activities:
Depreciation		6824,~~314~~354			6621,~~990~~717
Amortization		6422,~~525~~011			6120,~~723~~880
Deferred income taxes		(392,~~227~~422	)		~~(45~~5,~~998~~837	)
Income from equity method investments, net of dividends received		~~1,045~~(918	)		~~622~~(497	)
Gain on insurance claims		-			(7,264	)
Loss (gain) on sale or disposal of assets		1,029			(46	)
Loss on equity investment		-			1,966
Share-based compensation		5,348			4,708
Loss on the sale of a business		1,515			-
Pension and other post-retirement benefit plan activity		(1,862	)		(1,988	)
Loss on impairment of intangible asset		478			-
Loss on the sale of a business		-			1,515
Gain on sale or disposal of assets		(178	)		(501	)
Share-based compensation		18,170			17,662
Pension and other post-retirement benefit plan activity		(7,047	)		(6,671	)
Change in assets and liabilities, net of effects of acquisitions:
Trade receivables, net		(339,~~336~~563	)		2613,~~373~~900
Inventories		(4228,~~095~~861	)		(6227,~~206~~122	)
Other assets		(73,~~530~~224	)		(~~39,025~~295	)
Trade payables		~~(25~~3,~~764~~048	)		49(14,~~705~~272	)
Accrued compensation		(1946,~~230~~425	)		(1137,~~566~~913	)
Other accrued expenses		6(12,~~856~~537	)		(511,~~244~~959	)
Income taxes payable		(12,~~993~~699	)		(1721,~~873~~854	)
Other liabilities		28(9,~~622~~854	)		~~856~~(311	)
Foreign currency remeasurement		2(1,~~289~~570	)		49(18,~~591~~471	)
Net cash provided by operating activities		156,756			216,787
Net cash used in operating activities		(3,974	)		(52,907	)
Cash flows from investing activities:
Purchased property, plant and equipment		(9457,~~593~~701	)		(~~112~~32,~~799~~984	)
Purchased businesses, net of cash acquired		~~(162,095~~-	)		(~~274~~162,~~067~~032	)
Purchase of cost method investment		(2,549	)		-
Proceeds from sale of property, plant and equipment		321			477
Proceeds from sale of property, plant and equipment		843			1,048
Purchase of cost method investment		-			(2,549	)
Proceeds from the sale of a business		~~75,727~~-			-75,727
Net cash used in investing activities		(~~182~~57,~~667~~380	)		(~~385~~121,~~818~~361	)
Cash flows from financing activities:
Proceeds from issuance of long-term debt		1288,~~114,300~~100			1526,~~732,900~~300
Repayment of long-term debt		(1231,~~053,593~~441	)		(1359,~~556,135~~535	)
Payment of debt issuance costs		(1,047	)		(3,493	)
Net payment of notes payable		-			(164	)
Net payment of notes payable		(585	)		(1,014	)
Dividends paid		(12,798	)		(12,193	)
Dividends paid		(37,559	)		(35,440	)
Proceeds from stock options exercised		7,798			1,384
Proceeds from stock options exercised		5,519			34,161
Repurchases of common stock		(2,922	)		(44,377	)
Repurchases of common stock		(60,728	)		(39,371	)
Net cash provided by financing activities		48,737			111,415
Net cash (used in) provided by financing activities		(33,693	)		131,608
Effect of exchange rate changes on cash and cash equivalents		13,281			(756	)
Effect of exchange rate changes on cash and cash equivalents		12,710			(10,618	)
Net change in cash and cash equivalents		664			(63,609	)
Net change in cash and cash equivalents		(46,894	)		(48,041	)
Cash and cash equivalents at beginning of period		107,213			169,352
Cash and cash equivalents at beginning of period		169,352			179,453
Cash and cash equivalents at end of period	$	107,877		$	105,743
Cash and cash equivalents at end of period	$	122,458		$	131,412

See accompanying Notes to Unaudited Consolidated Financial Statements.

Table of Contents

H.B. FULLER COMPANY AND SUBSIDIARIES

Notes to Consolidated Financial Statements

(Amounts in thousands, except per share amounts)

(Unaudited)

Note 1: Basis of Presentation

Overview

The accompanying unaudited interim Consolidated Financial Statements of H.B. Fuller Company and Subsidiaries have been prepared in accordance with U.S. generally accepted accounting principles for interim financial information and the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information necessary for a fair presentation of results of operations, comprehensive income, financial position and cash flows in conformity with U.S. generally accepted accounting principles. In our opinion, the unaudited interim Consolidated Financial Statements reflect all adjustments of a normal recurring nature considered necessary for the fair presentation of the results for the periods presented. Operating results for interim periods are not necessarily indicative of results that may be expected for the fiscal year as a whole.

The preparation of financial statements in conformity with U.S. generally accepted accounting principles requires us to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues, expenses and related disclosures at the date of the financial statements and during the reporting period. Actual results could differ from these estimates. These unaudited interim Consolidated Financial Statements should be read in conjunction with the Consolidated Financial Statements and Notes thereto included in our Annual Report on Form 10-K for the year ended November 3029, ~~2024~~2025 as filed with the Securities and Exchange Commission.

New Accounting Pronouncements

In November 2024, the ~~Financial Accounting Standards Board (“~~FASB”) issued Accounting Standards Update ("ASU") No. 2024-03, Income Statement - Reporting Comprehensive Income - Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses, which requires additional disclosure of the nature of expenses included in our Consolidated Financial Statements. Our effective date of this ASU is our fiscal year ending December 2, 2028. We are currently evaluating the ~~effect~~impact of adopting this guidance ~~will have~~ on ~~our~~the ~~Consolidated~~related ~~Finance~~financial ~~Statements~~statement disclosures.

In December 2023, the FASB issued ASU No. 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures. This ASU requires entities to provide additional information in the rate reconciliation and additional disclosures about income taxes paid. This guidance requires public entities to disclose in their rate reconciliation table additional categories of information about federal, state, and foreign income taxes and to provide more details about the reconciling items in some categories if the items meet a quantitative threshold. Our effective date of this ASU is our fiscal year ending November 28, 2026. We are currently evaluating the ~~effect this guidance~~impact ~~will~~of ~~have~~adopting this guidance on ~~our~~the ~~Consolidated~~related ~~Financial~~financial ~~Statements~~statement disclosures.

In November 2023, the FASB issued ASU No. 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures. This ASU requires enhanced disclosures regarding significant segment expenses and other segment items. The guidance requires public entities to provide in interim periods all disclosures about a reportable segment's profit or loss and assets that are currently required annually. Our effective date of this ASU is our fiscal year ending November 29, 2025. We are evaluating the effect this guidance will have on our Consolidated Financial Statements.

Recently issued accounting standards or pronouncements not disclosed above have been excluded as they are not relevant to the company.

Supplier Finance Program

We have agreements with third parties to provide supplier finance programs which facilitate participating suppliers' ability to finance payment obligations of the Company with designated third-party financial institutions. Participating suppliers may, at their sole discretion, elect to finance one or more payment obligations of the Company prior to their scheduled due dates at a discounted price to participating financial institutions. The Company has no economic interest in the sale of these suppliers’ receivables and no direct financial relationship with the financial institutions concerning these services. The Company’s obligations to its suppliers, including amounts due and scheduled payment dates, are not impacted by suppliers’ decisions to finance amounts under these arrangements. The outstanding payment obligations that were confirmed as valid and remained outstanding as of ~~August~~February 3028, ~~2025~~2026, and November 3029, ~~2024~~2025, were approximately $8,~~122~~633 and $57,~~233~~379, respectively. These obligations under the Company’s supplier finance programs are included in ~~Accounts~~accounts payable in the Consolidated Balance Sheets, and the associated payments are reflected in the cash flows from operating activities section of the Consolidated Statements of Cash Flows.

9 Short-term notes classified as long-term debt

~~Table~~As of February ~~Contents~~ 28, 2026, the Company had 10-year unsecured public notes with an aggregate principal balance of $300,000 and a fixed coupon rate of 4.0 percent due February 15, 2027, classified as long term debt on the accompanying Consolidated Balance Sheets based on the Company’s intent and ability to refinance the notes on a long‑term basis. The Company maintains a revolving credit facility with maturity extending beyond twelve months from the balance sheet date and sufficient borrowing capacity to replace the notes with a long-term financing facility.

Note 2: Acquisitions ~~and Divestiture~~

ND Industries Fastening Elements Locking and Sealing Technologies Industry and Trade Inc.

On November 17, 2025, we completed the acquisition of ND Industries Fastening Elements Locking and Sealing Technologies Industry and Trade Inc. ("ND Industries Turkey") for a purchase price of 334,106 Turkish lira, or approximately $7,902 which was funded through existing cash. This includes a holdback amount of 105,699 Turkish lira that will be paid in two payments on the 18-month and 36-month anniversaries of the closing date. Headquartered in Istanbul, Turkey, ND Industries Turkey is a leading provider of specialty adhesives and fastener locking and sealing solutions. The acquisition of ND Industries Turkey is expected to accelerate the realization of our top growth priorities in EIMEA, consistent with our strategy to proactively drive capital allocation to the highest margin, highest growth market segments within the functional coatings, adhesives, sealants and elastomer industry. The acquisition fair value measurement was preliminary as of February 28, 2026 and includes goodwill of $3,960, other intangible assets of $3,300 and other net assets of $642. Goodwill represents expected synergies from combining ND Industries Turkey with our existing business. Goodwill is not deductible for tax purposes. ND Industries Turkey is included in our Engineering Adhesives operating segment.

ND Industries Asia, Inc.

On February 15, 2025, we acquired the assets of ND Industries Asia, Inc. ("ND Industries Taiwan") for a purchase price of 271,860 Taiwan ~~dollar~~dollars, or approximately $8,310 which was funded through existing cash. Headquartered in Kaohsiung, Taiwan, ND Industries Taiwan is a leading provider of specialty adhesives and fastener locking and sealing solutions. The acquisition of ND Industries Taiwan is expected to accelerate the realization of our top growth priorities in Greater Asia, consistent with our strategy to proactively drive capital allocation to the highest margin, highest growth market segments within the functional coatings, adhesives, sealants and elastomer industry. The acquisition fair value measurement was ~~preliminary~~final as of ~~August~~ November 3029, 2025 and includes goodwill of $2,~~422~~801, other intangible assets of $2,400 and other net assets of $3,~~488~~109. Goodwill represents expected synergies from combining ND Industries Taiwan with our existing business. Goodwill is not deductible for tax purposes. ND Industries Taiwan is included in our Engineering Adhesives operating segment.

~~GEM S.r.l. and Medifill Limited~~ 8

On January 15, 2025, we completed the acquisition of GEM S.r.l. (“GEM”) and on December 2, 2024, we completed the acquisition of Medifill Limited (Medifill") for a total purchase price of 191,868 Euros, or approximately $196,990 which was funded through borrowings on our credit facility and existing cash. Included in the purchase price is a holdback to be paid in three annual tranches beginning one year after the date of acquisition. The fair value of the holdback was 28,170 Euros or approximately $28,922 at the date of acquisition. See Note 12 for more information on the fair value of the holdback.

Although they were independent transactions, the acquisitions of GEM and Medifill were accounted for as a single business combination under ASC 805, as they were negotiated concurrently and are economically interdependent. Headquartered in Viareggio, Italy, GEM develops, produces and sells medical adhesives for wound closure in both surgical and topical applications. Headquartered in Dublin, Ireland, Medifill produces medical-grade cyanoacrylate adhesives tailored to the wound closure market for GEM. The acquisitions of GEM and Medifill establish a European headquarters for our Medical Adhesives Technologies business and European production capabilities for our medical adhesive offerings, further shifting our portfolio toward highly profitable, higher growth markets. The acquisition fair value measurement was preliminary as of August 30, 2025 and includes goodwill of $90,198, other intangible assets of $104,723 and other net liabilities of $2,069. Goodwill represents expected synergies from combining GEM and Medifill with our existing business. Goodwill is not deductible for tax purposes. GEM and Medifill are included in our Hygiene, Health and Consumable Adhesives operating segment.

HS Butyl Limited

On August 5, 2024, we acquired HS Butyl Limited (“HS Butyl”) for a purchase price of 18,342 British pounds, or approximately $23,428 which was funded through existing cash. This includes a holdback amount of 2,700 British pound sterling that will be paid on the 18-month anniversary of the closing date. HS Butyl, headquartered in Lymington, England, is the United Kingdom's largest manufacturer and distributor of high-quality butyl tapes, which provide strong, permanent, watertight seals for a wide variety of applications within the construction, infrastructure, automotive and renewable energy industries. The acquisition of HS Butyl establishes our presence in the European waterproofing tape market, expanding our position as a solution provider to existing customers. It also expands our relevance to more markets and creates opportunities to deliver new, in-demand solutions for our customers, given the technology's relevance to multiple high-value applications. The acquisition fair value measurement was final as of August 30, 2025 and includes other intangible assets of $6,974, goodwill of $3,805 and other net assets of $12,649. Goodwill represents expected synergies from combining HS Butyl with our existing business. Goodwill is not deductible for tax purposes. HS Butyl is included in our Building Adhesive Solutions operating segment.

Table of Contents

NDGEM ~~Industries, Inc~~S. r.l. and Medifill Limited

On ~~May~~January 2015, ~~2024~~2025, we ~~acquired~~completed the ~~assets~~acquisition of NDGEM ~~Industries, Inc~~S. r.l. (“~~ND Industries~~GEM”) and on December 2, 2024, we completed the acquisition of Medifill Limited (Medifill) for a ~~base~~total purchase price of ~~$254~~191,~~037~~868 Euros, or approximately $196,990 which was funded through borrowings on our credit facility and existing cash. ~~ND Industries,~~The ~~headquartered~~transaction inincludes ~~Clawson,~~a ~~Michigan~~30,000 isEuro holdback to abe ~~leading~~paid ~~provider~~in ofthree ~~specialty~~annual ~~adhesives~~tranches ~~and~~beginning ~~fastener~~one ~~locking~~year ~~and~~after ~~sealing~~the ~~solutions~~date ~~serving~~of ~~customers~~acquisition inwith the ~~automotive,~~first ~~electronics,~~payment ~~aerospace~~made ~~and~~during ~~other~~the ~~industries.~~first quarter 2026. The fair ~~acquisition~~value of ~~ND Industries is expected to accelerate~~ the ~~realization~~holdback ofwas ~~our top growth priorities~~22,617 ~~consistent~~Euros ~~with~~and ~~our~~is ~~strategy~~included toin ~~proactively~~the ~~drive~~total ~~capital~~purchase ~~allocation~~price. toSee ~~the~~Note ~~highest~~11 for ~~margin,~~more ~~highest~~information ~~growth~~on ~~market segments within~~ the ~~functional coatings, adhesives, sealants and elastomer industry. The acquisition~~ fair value ~~measurement was final as~~ of ~~March~~ ~~1, 2025. ND Industries~~the ~~is included in our Engineering Adhesives operating segment~~holdback.

~~The~~Although ~~following~~they ~~table~~were ~~summarizes~~independent transactions, the acquisitions of GEM and Medifill were accounted for as a single business combination under ASC 805, as they were negotiated concurrently and are economically interdependent. Headquartered in Viareggio, Italy, GEM develops, produces and sells medical adhesives for wound closure in both surgical and topical applications. Headquartered in Dublin, Ireland, Medifill produces medical-grade cyanoacrylate adhesives tailored to the wound closure market for GEM. The acquisitions of GEM and Medifill establish a European headquarters for our Medical Adhesives Technologies business and European production capabilities for our medical adhesive offerings, further shifting our portfolio toward highly profitable, higher growth markets. The acquisition fair value measurement was final as of February ~~the~~28, 2026 and includes goodwill of $91,430, other intangible assets ~~acquired~~of $104,723 and ~~liabilities~~other ~~assumed~~net asassets of ~~the~~$837. ~~date~~Goodwill ofrepresents ~~acquisition:~~expected synergies from combining GEM and Medifill with our existing business. Goodwill is not deductible for tax purposes. GEM and Medifill are included in our Hygiene, Health and Consumable Adhesives operating segment.

	Amounts
Current assets	$	17,085
Property, plant and equipment		26,044
Goodwill		81,268
Other intangibles
Customer relationships		110,100
Trademarks/trade names		8,700
Technology		13,600
Other assets		13
Current liabilities		(2,773	)
Total	$	254,037

The expected useful lives of the acquired intangible assets are 15 years for technology, 13 years for customer relationships and ten years for trademarks and tradenames. Based on the fair value measurement of the assets acquired and liabilities assumed, we allocated $81,268 to goodwill for the expected synergies from combining ND Industries with our existing business. Such goodwill is deductible for tax purposes. The goodwill was assigned to our Engineering Adhesives operating segment.

Table of Contents

All acquisitions, individually and in the aggregate, are not material and therefore pro forma financial information is not provided.

Divestiture

North America Flooring

On December 2, 2024, we completed the sale of certain assets in our North American Flooring business, which was included in our Construction Adhesives segment for $75,727. The net book value of the assets sold was $77,242, which resulted in a $1,515 loss. The loss on sale is recorded in other income net, in the Consolidated Statements of Income for the nine months ended August 30, 2025.

Table of Contents

Note 3: Restructuring Actions

~~During~~Restructuring ~~fiscal year 2023, the Company approved restructuring plans (the "~~Plans") related to organizational changes and other actions to optimize operations and integrate acquired businesses. The Plans were implemented in the second quarter of fiscal year 2023 and are currently expected to be completed during fiscal year 2026. In implementing the Plans, the Company currently expects to incur pre-tax costs of approximately $70,000 to $75,000 for severance and related employee costs globally, other restructuring costs related to the streamlining of processes and the payment of anticipated income taxes in certain jurisdictions related to the Plans.

During fiscal year 2023, the Company approved restructuring plans (the "Plans") related to organizational changes and other actions to optimize operations and integrate acquired businesses. The Plans were implemented in the second quarter of fiscal year 2023 and were completed as of November 29, 2025. Remaining cash payments will continue into fiscal year 2026. In implementing the Plans, the Company currently expects to incur pre-tax costs of approximately $85,000 to $90,000 for severance and related employee costs globally, and other restructuring costs related to the streamlining of processes and the payment of anticipated income taxes in certain jurisdictions related to the Plans.

The following table summarizes the pre-tax distribution of charges under these restructuring plans by income statement classification:

	Three Months Ended				~~Nine Months Ended~~
	August 30, 2025		August 31, 2024		August 30, 2025		August 31, 2024
	February 28, 2026		March 1, 2025
Cost of sales	$	21,~~393~~619	$	2,~~119~~954	$	~~5,328~~	$	~~6,313~~
Selling, general and administrative		~~634~~375		~~2,632~~557		~~3,386~~		~~5,076~~
	$	3,027	$	4,751	$	8,714	$	11,389
Other expense, net		1,196		-
	$	3,190	$	3,511

The restructuring charges are ~~all~~ recorded in Corporate Unallocated for segment reporting purposes.

A summary of the restructuring liability is presented below:

	Employee-Related			Asset-Related			Other			Total
Balance at December 2, 2023	$	11,723		$	-		$	-		$	11,723
Expenses incurred		13,477			4,673			3,936			22,086
Non-cash charges		-			(4,673	)		(3,925	)		(8,598	)
Cash payments		(16,427	)		-			(11	)		(16,438	)
Foreign currency translation		(343	)		-			-			(343	)
Balance at November 30, 2024	$	8,430		$	-		$	-		$	8,430
Expenses incurred		414,~~192~~314			~~1,574~~(547	)		23,~~948~~102			816,~~714~~869
Non-cash charges		-			~~(1,574~~547	)		(~~426~~580	)		(~~2,000~~33	)
Cash payments		(1014,~~462~~143	)		-			(2,522	)		(1216,~~984~~665	)
Foreign currency translation		~~339~~360			-			-			~~339~~360
Balance at August 30, 2025	$	2,499		$	-		$	-		$	2,499
Balance at November 29, 2025	$	8,961		$	-		$	-		$	8,961
Expenses incurred		710			1,065			1,415			3,190
Non-cash charges		-			(1,065	)		(1,302	)		(2,367	)
Cash payments		(3,770	)		-			(113	)		(3,883	)
Foreign currency translation		(15	)		-			-			(15	)
Balance at February 28, 2026	$	5,886		$	-		$	-		$	5,886

Non-cash charges primarily include accelerated depreciation ~~and impairment~~ resulting from the cessation of use of certain long-lived assets, ~~and~~impairments of certain long-lived assets, the recording of an inventory provision related to the discontinuance of certain products, and inventory disposals. Restructuring liabilities have been classified as a component of other accrued expenses on the Consolidated Balance Sheets.

13 Other Restructuring

~~Table~~During the first quarter of ~~Contents~~ 2026, the Company approved other restructuring actions related to global footprint optimization. The other restructuring actions began to be implemented in the first quarter of 2026 and are currently expected to be completed during fiscal year 2028. Restructuring costs are expected to be incurred over the next several fiscal quarters as the measures are implemented with the majority of the charges recognized and cash payments occurring in fiscal 2026 and 2027. In implementing the other restructuring actions, the Company currently expects to incur pre-tax costs of approximately $10,200 to $12,200 for severance and related employee costs globally, and other restructuring costs related to optimizing the Company’s footprint and the payment of anticipated income taxes in certain jurisdictions related to the actions.

The following table summarizes the pre-tax distribution of charges under these restructuring actions by income statement classification:

	*Three Months Ended*
	*February 28, 2026*		*March 1, 2025*
Cost of sales	$	3,920	$	-
Selling, general and administrative		910		-
	$	4,830	$	-

The restructuring charges are recorded in Corporate Unallocated for segment reporting purposes.

A summary of the restructuring liability is presented below:

	Employee-Related			Asset-Related			Total
Expenses incurred		1,731			3,099			4,830
Non-cash charges		-			(3,099	)		(3,099	)
Cash payments		(1,369	)		-			(1,369	)
Foreign currency translation		15			-			15
Balance at February 28, 2026	$	377		$	-		$	377

Non-cash charges primarily include accelerated depreciation resulting from the cessation of use of certain long-lived assets and impairments of certain long-lived assets. Restructuring liabilities have been classified as a component of other accrued expenses on the Consolidated Balance Sheets.

Note 4: Inventories

The composition of inventories is as follows:

	August 30,		November 30,
	February 28,		November 29,
	2025		2024
	2026		2025
Raw materials	$	~~220~~212,~~399~~248	$	~~215~~199,~~936~~031
Finished goods		~~282~~294,~~557~~528		~~251~~272,~~562~~932
Total inventories	$	~~502~~506,~~956~~776	$	~~467~~471,~~498~~963

Table of Contents

Note 5: Goodwill and Other Intangible Assets

The goodwill activity by reportable segment for the ~~nine~~three months ended ~~August~~February 3028, ~~2025~~2026 is presented below:

	Hygiene, Health	~~Hygiene, Health~~				Building	~~Building~~
	and Consumable		Engineering			Adhesive
	Adhesives		Adhesives			Solutions			Total
Balance at November 30, 2024	$	399,513	$	581,344		$	551,364		$	1,532,221
Balance at November 29, 2025	$	517,763	$	610,107		$	552,189		$	1,680,059
Acquisitions		901,~~198~~048		~~2,572~~(756	)		~~(851~~-	)		~~91,919~~292
Foreign currency translation effect		3011,~~716~~430		~~24,427~~(484	)		26,~~604~~171			5717,~~747~~117
Balance at August 30, 2025	$	520,427	$	608,343		$	553,117		$	1,681,887
Balance at February 28, 2026	$	530,241	$	608,867		$	558,360		$	1,697,468

As discussed in Note 14, as of the beginning of fiscal year 2025, we realigned our operating segment structure with the renamed Building Adhesive Solutions segment, which includes all of the former Construction Adhesives goodwill. A portion of the Engineering Adhesives goodwill was reclassified to the Building Adhesive Solutions segment based on the relative fair value approach.

Balances of amortizable identifiable intangible assets, excluding goodwill and other non-amortizable intangible assets, are as follows:

August 30, 2025

February 28, 2026

Purchased

Technology

Customer

Amortizable Intangible Assets

and Patents

Relationships

Trade Names

~~Other~~Total

~~Total~~

Original cost

~~225~~235,~~700~~196

1990,~~000,997~~601

82,~~194~~015

71,~~930~~307,812

~~1,316,821~~

Accumulated amortization

(4862,~~520~~365

)

(~~400~~418,~~390~~027

)

(3336,~~171~~322

)

(5516,~~310~~714

)

~~(487,391~~

)

Net identifiable intangibles

~~177~~172,~~180~~831

~~600~~572,~~607~~574

4945,~~023~~693

2791,~~620~~098

~~829,430~~

November 30, 2024

November 29, 2025

Purchased

Technology

Customer

Amortizable Intangible Assets

and Patents

Relationships

Trade Names

~~Other~~Total

~~Total~~

Original cost

~~145~~232,~~313~~522

1998,~~063,210~~889

6781,~~280~~228

101,~~031~~312,639

~~1,285,834~~

Impairment

~~(343~~-

)

~~(5,616~~-

)

(~~150~~734

)

-(734

)

~~(6,109~~

)

Accumulated amortization

(5557,~~398~~778

)

(~~418~~414,~~805~~706

)

(2833,~~745~~554

)

(7506,~~012~~038

)

~~(509,960~~

)

Net identifiable intangibles

89174,~~572~~744

~~638~~584,~~789~~183

3846,~~385~~940

3805,~~019~~867

~~769,765~~

Amortization expense with respect to amortizable intangible assets was $22,~~082~~011 and $2220,~~149~~880 for the three months ended ~~August~~February 3028, ~~2025~~2026 and ~~August~~March 311, ~~2024, respectively, and was $64,525 and $61,723 for the nine months ended August 30,~~ 2025 ~~and August 31~~, ~~2024,~~ respectively.

Estimated aggregate amortization expense based on the current carrying value of amortizable intangible assets for the next five fiscal years is as follows:

Remainder

Fiscal Year

~~2025~~2026

~~2026~~2027

~~2027~~2028

~~2028~~2029

~~2029~~2030

Thereafter

Amortization expense

2378,~~632~~020

~~105~~106,~~293~~393

~~103~~107,~~909~~953

~~105~~101,~~102~~882

9975,~~473~~346

~~392~~321,~~021~~504

Table of Contents

The above amortization expense forecast is an estimate. Actual amounts may change from such estimated amounts due to fluctuations in foreign currency exchange rates, additional intangible asset acquisitions, potential impairment, accelerated amortization or other events.

~~Non-amortizable~~Note ~~intangible~~6: ~~assets~~Components as of ~~August~~ ~~30,~~Net ~~2025~~Periodic ~~and November~~Benefit ~~30,~~related ~~2024 were $0 and $461, respectively, and relate~~ to ~~trademarks~~Pension and ~~trade~~Other ~~names.~~Postretirement ~~The~~Benefit ~~change in non-amortizable assets as of August 30, 2025 compared to November 30, 2024 was due to impairment.~~Plans

Note 6: Long-Term Debt

	*Three Months Ended February 28, 2026 and March 1, 2025*
													*Other*
	*Pension Benefits*												*Postretirement*
	*U.S. Plans*						*Non-U.S. Plans*						*Benefits*
Net periodic (benefit) cost:	*2026*			*2025*			*2026*			*2025*			*2026*			*2025*
Service cost	$	-		$	-		$	324		$	368		$	-		$	-
Interest cost		3,097			3,242			1,663			1,442			218			249
Expected return on assets		(5,782	)		(5,717	)		(1,838	)		(1,624	)		(3,801	)		(3,484	)
Amortization:
Prior service cost		-			-			30			28			-			-
Actuarial loss (gain)		1,895			1,953			484			475			(2,429	)		(2,277	)
Settlement charge								123
Net periodic (benefit) cost	$	(790	)	$	(522	)	$	786		$	689		$	(6,012	)	$	(5,512	)

On March 6, 2025, we entered into a Refinancing Amendment (the “Refinancing Amendment”), which amended the Second Amended and Restated Credit Agreement dated as of February 15, 2023, as previously amended. Pursuant to the Refinancing Amendment under the Credit Agreement, the outstanding $986,545 principal amount of Term B loans (the “Amended TLB”) were refinanced. Furthermore, the interest rate margins applicable to the Amended TLB were decreased by 25 basis points (0.25 percent per annum) to 175 basis points for SOFR loans and 75 basis points for prime rate loans. Interest on Term Loan B borrowings is payable at SOFR plus an interest rate spread of 175 basis points with a SOFR floor of 50 basis points (6.07 percent at August 30, 2025). The maturity date of February 15, 2030 remains unchanged. The commitment fee rates and interest rates applicable to the revolving credit facility and the Term Loan A facility remain unchanged.

Note 7: Components of Net Periodic Benefit related to Pension and Other Postretirement Benefit Plans

	Three Months Ended August 30, 2025 and August 31, 2024
													Other
	Pension Benefits												Postretirement
	U.S. Plans						Non-U.S. Plans						Benefits
Net periodic (benefit) cost:	2025			2024			2025			2024			2025			2024
Service cost	$	-		$	-		$	408		$	350		$	-		$	-
Interest cost		3,242			3,464			860			1,575			249			291
Expected return on assets		(5,717	)		(6,555	)		(1,094	)		(1,643	)		(3,484	)		(2,727	)
Amortization:
Prior service cost		-			-			14			16			-			-
Actuarial loss (gain)		1,953			1,159			119			516			(2,277	)		-
Net periodic (benefit) cost	$	(522	)	$	(1,932	)	$	307		$	814		$	(5,512	)	$	(2,436	)

	Nine Months Ended August 30, 2025 and August 31, 2024
													Other
	Pension Benefits												Postretirement
	U.S. Plans						Non-U.S. Plans						Benefits
Net periodic (benefit) cost:	2025			2024			2025			2024			2025			2024
Service cost	$	-		$	-		$	1,161		$	1,046		$	-		$	-
Interest cost		9,726			10,391			3,797			4,705			747			875
Expected return on assets		(17,151	)		(19,666	)		(4,403	)		(4,908	)		(10,452	)		(8,182	)
Amortization:
Prior service cost		-			-			70			48			-			-
Actuarial loss (gain)		5,859			3,478			1,084			1,540			(6,831	)		-
Net periodic (benefit) cost	$	(1,566	)	$	(5,797	)	$	1,709		$	2,431		$	(16,536	)	$	(7,307	)

Service cost is included with employee compensation cost in cost of sales and selling, general and administrative expenses in the Consolidated Statements of Income. The components of our net periodic defined benefit pension and postretirement benefit costs other than service cost are presented in other income, net in the Consolidated Statements of Income.

1510

Table of Contents

Note 87: Accumulated Other Comprehensive Income (Loss)

The following table provides details of total comprehensive income (loss):

	Three Months Ended August 30, 2025												Three Months Ended August 31, 2024
	Three Months Ended February 28, 2026												Three Months Ended March 1, 2025
										Non-												Non-
										controlling												controlling
	H.B. Fuller Stockholders									Interest			H.B. Fuller Stockholders									Interest
	Pre-tax			Tax			Net			Net			Pre-tax			Tax			Net			Net
Net income attributable to H.B. Fuller and non-controlling interest							$	6721,~~160~~045		$	73-								$	5513,~~361~~248		$	~~(22~~16	)
Foreign currency translation¹	$	3652,~~993~~181		$	-			3652,~~993~~181			~~(31~~24	)	$	33(21,~~324~~003	)	$	-			33(21,~~324~~003	)		3117
Defined benefit pension plans adjustment²		~~218~~10			~~(60~~8	)		~~158~~18			-			~~1,689~~179			(~~419~~49	)		~~1,270~~130			-
Interest rate swaps³		~~(4,424~~61	)		~~1,077~~(15	)		~~(3,347~~46	)		-			(341,~~068~~516	)		~~8,324~~369			(251,~~744~~147	)		-
Net investment hedges³		(1912,~~822~~826	)		43,~~824~~121			(149,~~998~~705	)		-			~~(10~~9,~~892~~244	)		(2,~~661~~250	)		(86,~~231~~994	)		-
Other comprehensive income (loss)	$	1239,~~965~~426		$	53,~~841~~114		$	1842,~~806~~540		$	~~(31~~24	)	$	(913,~~947~~096	)	$	10(1,~~566~~930	)	$	~~619~~(15,026	)	$	3117
Comprehensive income							$	85,966		$	42								$	55,980		$	9
Comprehensive income (loss)							$	63,585		$	24								$	(1,778	)	$	33

	Nine Months Ended August 30, 2025											Nine Months Ended August 31, 2024
										Non-											Non-
										controlling											controlling
	H.B. Fuller Stockholders									Interest		H.B. Fuller Stockholders									Interest
	Pretax			Tax			Net			Net		Pretax			Tax			Net			Net
Net income attributable to H.B. Fuller and non-controlling interest							$	122,236		$	106							$	137,615		$	32
Foreign currency translation¹	$	139,592		$	-			139,592			34	$	(12,922	)	$	-			(12,922	)		(10	)
Defined benefit pension plans adjustment²		591			(162	)		429			-		5,065			(1,257	)		3,808			-
Interest rate swap³		(9,146	)		2,226			(6,920	)		-		(23,851	)		5,838			(18,013	)		-
Net investment hedges³		(70,646	)		17,193			(53,453	)		-		(5,704	)		1,386			(4,318	)		-
Other comprehensive income (loss)	$	60,391		$	19,257		$	79,648		$	34	$	(37,412	)	$	5,967		$	(31,445	)	$	(10	)
Comprehensive income							$	201,884		$	140							$	106,170		$	22

¹ Income taxes are not provided for foreign currency translation relating to indefinite investments in international subsidiaries.
² Amounts reclassified from accumulated other comprehensive loss into earnings as part of net periodic cost related to pension and other postretirement benefit plans is reported in cost of sales, selling general and administrative expense and other income, net.
³ Amounts reclassified from accumulated other comprehensive loss into earnings is reported in other income, net.

1 Income taxes are not provided for foreign currency translation relating to indefinite investments in international subsidiaries. 2 Amounts reclassified from accumulated other comprehensive loss into earnings as part of net periodic cost related to pension and other postretirement benefit plans is reported in cost of sales and other income, net. 3 Amounts reclassified from accumulated other comprehensive loss into earnings is reported in other income, net.

The components of accumulated other comprehensive loss are as follows:

	August 30, 2025
	February 28, 2026
							Non-
				H.B. Fuller			controlling
	Total			Stockholders			Interest
Foreign currency translation adjustment	$	(~~182~~136,~~626~~973	)	$	(~~182~~137,~~206~~882	)	$	~~(420~~909	)
Defined benefit pension plans adjustment, net of taxes of $54,382		(88,602	)		(88,602	)		-
Defined benefit pension plans adjustment, net of taxes of $47,260		(67,147	)		(67,147	)		-
Interest rate swap, net of taxes of $4,395		(13,664	)		(13,664	)		-
Interest rate swap, net of taxes of $4,444		(13,820	)		(13,820	)		-
Net investment hedges, net of taxes of $29,249		(90,934	)		(90,934	)		-
Net investment hedges, net of taxes of $30,650		(95,315	)		(95,315	)		-
Reclassification of AOCI tax effects		(18,341	)		(18,341	)		-
Accumulated other comprehensive loss	$	(394,167	)	$	(393,747	)	$	(420	)
Accumulated other comprehensive (loss) income	$	(331,596	)	$	(332,505	)	$	909

	November 30, 2024
	November 29, 2025
							Non-
				H.B. Fuller			controlling
	Total			Stockholders			Interest
Foreign currency translation adjustment	$	(~~322~~189,~~184~~131	)	$	(~~321~~190,~~798~~064	)	$	~~(386~~933	)
Defined benefit pension plans adjustment, net of taxes of $54,545		(89,031	)		(89,031	)		-
Defined benefit pension plans adjustment, net of taxes of $47,252		(67,164	)		(67,164	)		-
Interest rate swap, net of taxes of $2,169		(6,744	)		(6,744	)		-
Interest rate swap, net of taxes of $4,459		(13,866	)		(13,866	)		-
Net investment hedges, net of taxes of $12,056		(37,481	)		(37,481	)		-
Net investment hedges, net of taxes of $27,529		(85,610	)		(85,610	)		-
Reclassification of AOCI tax effects		(18,341	)		(18,341	)		-
Accumulated other comprehensive loss	$	(473,781	)	$	(473,395	)	$	(386	)
Accumulated other comprehensive (loss) income	$	(374,112	)	$	(375,045	)	$	933

16 Note 8: Income Taxes

Income tax expense for the three months ended February 28, 2026 includes $98 of discrete tax expense relating to various U.S. and foreign tax matters. Excluding the discrete tax expense, the overall effective tax rate was 26.6 percent for the three months ended February 28, 2026.

Income tax expense for the three months ended March 1, 2025 includes $992 of discrete tax expense relating to various U.S. and foreign tax matters. Excluding the discrete tax expense, the overall effective tax rate was 26.5 percent for the three months ended March 1, 2025.

As of February 28, 2026, we had a liability of $8,969 recorded for gross unrecognized tax benefits (excluding interest) compared to $9,206 as of November 29, 2025. As of February 28, 2026 and November 29, 2025, we had accrued $1,976 and $2,158 of gross interest relating to unrecognized tax benefits, respectively.

Table of Contents

Note 9: ~~Income~~Earnings ~~Taxes~~Per Share

Income tax expense for the three and nine months ended August 30, 2025 includes $3,742 of discrete tax benefit and $11,210 of discrete tax expense, respectively. The discrete tax benefit for the three months ended August 30, 2025 relates to various U.S. and foreign tax matters. The discrete tax expense for the nine months ended August 30, 2025 relates to the impact of withholding tax recorded on earnings that are no longer permanently reinvested, offset by various U.S. and foreign tax matters. Excluding the discrete tax benefit and expense, the overall effective tax rate was 24.4 percent and 25.2 percent for the three and nine months ended August 30, 2025, respectively.

Income tax expense for the three and nine months ended August 31, 2024 includes $2,937 and $4,147 of discrete tax benefit, respectively, relating to an excess tax benefit on U.S. stock compensation, as well as other various U.S. and foreign tax matters. Excluding the discrete tax benefit, the overall effective tax rate was 29.3 percent and 28.7 percent for the three and nine months ended August 31, 2024, respectively.

As of August 30, 2025, we had a liability of $18,012 recorded for gross unrecognized tax benefits (excluding interest) compared to $15,590 as of November 30, 2024. As of August 30, 2025 and November 30, 2024, we had accrued $3,495 and $4,558 of gross interest relating to unrecognized tax benefits, respectively.

Note 10: Earnings Per Share

A reconciliation of the common share components for the basic and diluted earnings per share calculations is as follows:

Three Months Ended

~~Nine Months Ended~~

August 30,

August 31,

August 30,

August 31,

February 28,

March 1,

(Shares in thousands)

~~2025~~2026

~~2024~~2025

~~2025~~

~~2024~~

Weighted-average common shares - basic

54,~~428~~731

54,~~975~~998

~~54,623~~

~~54,874~~

Equivalent shares from share-based compensations plans

~~734~~782

1,~~675~~031

~~758~~

~~1,746~~

Weighted-average common and common equivalent shares diluted

55,~~162~~513

56,~~650~~029

~~55,381~~

~~56,620~~

Basic earnings per share is calculated by dividing net income attributable to H.B. Fuller by the weighted-average number of common shares outstanding during the applicable period. Diluted earnings per share is based upon the weighted-average number of common and common equivalent shares outstanding during the applicable period. The difference between basic and diluted earnings per share is attributable to share-based compensation awards. We use the treasury stock method to calculate the effect of outstanding shares, which computes total employee proceeds as the sum of (a) the amount the employee must pay upon exercise of the award and (b) the amount of unearned share-based compensation costs attributed to future services. Share-based compensation awards for which total employee proceeds exceed the average market price over the applicable period have an antidilutive effect on earnings per share, and accordingly, are excluded from the calculation of diluted earnings per share.

Share-based compensation awards of 12,~~935~~908,~~970~~350 and ~~517~~2,~~442~~140,479 shares for the three months ended ~~August~~February 3028, ~~2025~~2026 and ~~August~~March 311, 2024, respectively, were excluded from diluted earnings per share calculations because they were antidilutive. Share-based compensation awards of 2,132,875 and 957,127 shares for the nine months ended August 30, 2025 ~~and August 31~~, ~~2024,~~ respectively, were excluded from diluted earnings per share calculations because they were antidilutive.

17 Note 10: Financial Instruments

Table of Contents

Note 11: Financial Instruments

Overview

As a result of being a global enterprise, foreign currency exchange rates and fluctuations in those rates may affect the Company's net investment in foreign subsidiaries and our earnings, cash flows and financial position are exposed to foreign currency risk from foreign currency denominated receivables and payables.

We use foreign currency forward contracts, cross-currency swaps, interest rate swaps and net investment hedges to manage risks associated with foreign currency exchange rates and interest rates. We do not hold derivative financial instruments of a speculative nature or for trading purposes. We record derivatives as assets and liabilities on the balance sheet at fair value. Changes in fair value are recognized immediately in earnings unless the derivative qualifies and is designated as a hedge. Cash flows from derivatives are classified in the Consolidated Statement of Cash Flows in the same category as the cash flows from the items subject to designated hedge or undesignated (economic) hedge relationships. We evaluate hedge effectiveness at inception and on an ongoing basis. If a derivative is no longer expected to be effective, hedge accounting is discontinued. Hedge ineffectiveness, if any, is recorded in earnings.

We are exposed to credit risk in the event of nonperformance of counterparties for foreign currency forward exchange contracts and interest rate swap agreements. We select investment-grade multinational banks and financial institutions as counterparties for derivative transactions and monitor the credit quality of each of these banks on a periodic basis as warranted. We do not anticipate nonperformance by any of these counterparties, and valuation allowances, if any, are de minimis.

Cash Flow Hedges

On January 12, 2023, we entered into an interest rate swap agreement to convert $400,000 of our variable rate 1-month LIBOR debt to a fixed rate of 3.6895 percent that matures on January 12, 2028. On February 28, 2023, after refinancing our debt, we amended the interest rate swap agreement to our 1-month SOFR rate debt to a fixed rate of 3.7260 in accordance with the practical expedients included in ASC 848, Reference Rate Reform. The combined fair value of the interest rate swap was a liability of $3,~~756~~882 at ~~August~~February 3028, ~~2025~~2026 and was included in other liabilities in the Consolidated Balance Sheets. The swap was designated for hedge accounting treatment as a cash flow hedge. We are applying the hypothetical derivative method to assess hedge effectiveness for this interest rate swap. Changes in the fair value of a hypothetically perfect swap with terms that match the critical terms of our variable rate debt are compared with the change in the fair value of the swap.

On March 16, 2023, we entered into an interest rate swap agreement to convert $300,000 of our 1-month SOFR debt to a fixed rate of 3.7210 percent that matures on February 15, 2028. The combined fair value of the interest rate swap was a liability of $3,~~067~~183 at ~~August~~February 3028, ~~2025~~2026 and was included in other liabilities in the Consolidated Balance Sheets. The swap was designated for hedge accounting treatment as a cash flow hedge. We are applying the hypothetical derivative method to assess hedge effectiveness for this interest rate swap. Changes in the fair value of a hypothetically perfect swap with terms that match the critical terms of our variable rate debt are compared with the change in the fair value of the swaps.

On March 16, 2023, we entered into an interest rate swap agreement to convert $100,000 of our 1-month SOFR debt to a fixed rate of 3.8990 percent that matures on February 15, 2028. The combined fair value of the interest rate swap was a liability of $1,~~407~~370 at ~~August~~February 3028, ~~2025~~2026 and was included in other liabilities in the Consolidated Balance Sheets. The swap was designated for hedge accounting treatment as a cash flow hedge. We are applying the hypothetical derivative method to assess hedge effectiveness for these interest rate swaps. Changes in the fair value of a hypothetically perfect swap with terms that match the critical terms of our variable rate debt are compared with the change in the fair value of the swaps.

The amounts of pretax ~~losses~~income (loss) recognized in Comprehensive Income related to derivative instruments designated as cash flow hedges are as follows:

Three Months Ended

~~Nine Months Ended~~

August 30, 2025

August 31, 2024

August 30, 2025

August 31, 2024

February 28, 2026

March 1, 2025

Interest rate swap contracts

~~(4,424~~61

)

(341,~~068~~516

)

~~(9,146~~

)

~~(23,851~~

)

1812

Table of Contents

Fair Value Hedges

On February 12, 2021, we entered into interest rate swap agreements to convert our $300,000 Public Notes that were issued on October 20, 2020 to a variable interest rate of 1-month LIBOR plus 3.28 percent. On June 30, 2023, 1-month LIBOR rates ceased to exist and the IBOR Fallbacks Protocol published by the International Swaps and Derivatives Association ("ISDA") took effect as outlined in the interest rate swap agreement. As a result, the interest rate swap agreement was converted to Overnight SOFR plus 3.28 percent. We applied the practical expedients included in ASC 848, Reference Rate Reform. These interest rate swap agreements mature on October 15, 2028. The combined fair value of the interest rate swaps was a liability of $2218,~~571~~230 at ~~August~~February 3028, ~~2025~~2026, and was included in other liabilities in the Consolidated Balance Sheets. The swaps were designated for hedge accounting treatment as fair value hedges. We apply the short cut method and assume hedge effectiveness. Changes in the fair value of a hypothetically perfect swap with terms that match the critical terms of our $300,000 fixed rate Public Notes are compared with the change in the fair value of the swaps.

Net Investment Hedges

On October 17, 2022, we entered into a float-to-float cross-currency interest rate swap agreement with a notional amount of €307,173 maturing in October 2028. On October 20, 2022, we entered into fixed-to-fixed cross-currency interest rate swap agreements for a total notional amount of €300,000 with tranches maturing in August 2025, August 2026 and February 2027. On July 18, 2025, we amended the agreement for the two tranches of the fixed-to-fixed cross-currency interest rate swap, of €50,000 each, that matured in August 2025 to a maturity date of February 2027. On June 30, 2023, 1-month LIBOR rates ceased to exist and the IBOR Fallbacks Protocol published by the International Swaps and Derivatives Association (ISDA) took effect as outlined in the interest rate swap agreement. As a result, the 1-month LIBOR leg of the float-to-float agreement was converted to Overnight SOFR plus 3.28 percent. On July 17, 2023, we amended the 1-month EURIBOR leg of the float-to-float agreement to Overnight ESTR plus 3.2195 percent. We applied the practical expedients included in ASC 848, Reference Rate Reform. As of ~~August~~February 3028, ~~2025~~2026, the combined fair value of the swaps was a liability of $~~120~~125,~~188~~854 and was included in other liabilities in the Consolidated Balance Sheets. The cross-currency interest rate swaps hedge a portion of the Company’s investment in Euro denominated foreign subsidiaries.

The swaps are designated as net investment hedges for accounting treatment. The net gains or losses attributable to changes in spot exchange rates are recorded in the cumulative translation adjustment within other comprehensive income. The gains or losses are reclassified into earnings upon a liquidation event or deconsolidation of the foreign subsidiary. Any ineffective portions of net investment hedges are reclassified from accumulated other comprehensive income (loss) into earnings during the period of change. The amount in accumulated other comprehensive income (loss) related to net investment hedge cross-currency swaps was a loss of $9095,~~934~~315 as of ~~August~~February 3028, ~~2025~~2026. The amounts of pretax loss recognized in comprehensive income related to the net investment hedge was $1912,~~822~~826 for the three months ended ~~August~~February 3028, ~~2025~~2026. As of ~~August~~February 3028, ~~2025~~2026, we reclassified $~~174~~89 of losses into earnings from net investment hedges and we expect to reclassify $~~353~~357 of losses into earnings within the next twelve months. This is related to the portion excluded from the assessment of hedge effectiveness for the net investment hedges in the amount of $706.

Derivatives Not Designated as Hedging Instruments

We use foreign currency forward contracts to offset our exposure to the change in value of certain foreign currency denominated assets and liabilities held at foreign subsidiaries that are remeasured at the end of each period. Although the contracts are effective economic hedges, they are not designated as accounting hedges. Foreign currency forward contracts are recorded as assets and liabilities on the balance sheet at fair value. Changes in the value of these derivatives are recognized immediately in earnings, thereby offsetting the current earnings effect of the related foreign currency denominated assets and liabilities. See Note 1211 for the fair value amounts of these derivative instruments.

As of ~~August~~February 3028, ~~2025~~2026, we had forward foreign currency contracts maturing between ~~September~~March 2, ~~2025~~2026 and ~~February~~July 48, 2026. The mark-to-market effect associated with these contracts was largely offset by the underlying transaction gains and losses resulting from the foreign currency exposures for which these contracts relate.

The amounts of pretax gains recognized in other income, net related to derivative instruments not designated as hedging instruments for the ~~nine~~three months ended ~~August~~February 3028, ~~2025~~2026 and ~~August~~March 311, ~~2024~~2025 were $2,~~989~~ 920 and 1$40,~~524,~~ respectively.

Concentrations of credit risk with respect to trade accounts receivable are limited due to the large number of entities in the customer base and their dispersion across many different industries and countries. As of ~~August~~February 3028, ~~2025~~2026, there were no significant concentrations of credit risk.

19 Note 11: Fair Value Measurements

Table of Contents

Note 12: Fair Value Measurements

Overview

Estimates of fair value for financial assets and liabilities are based on the framework established in the accounting guidance for fair value measurements. The framework defines fair value, provides guidance for measuring fair value and requires certain disclosures. The framework discusses valuation techniques, such as the market approach (comparable market prices), the income approach (present value of future income or cash flow) and the cost approach (cost to replace the service capacity of an asset or replacement cost). The framework utilizes a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value into three broad levels. The following is a brief description of those three levels:

	●	Level 1: Observable inputs such as quoted prices (unadjusted) in active markets for identical assets or liabilities.
	●	Level 2: Inputs other than quoted prices that are observable for the asset or liability, either directly or indirectly. These include quoted prices for similar assets or liabilities in active markets and quoted prices for identical or similar assets or liabilities in markets that are not active.
	●	Level 3: Unobservable inputs that reflect management’s assumptions, and include situations where there is little, if any, market activity for the asset or liability.

~~Balances Measured at Fair Value on a Recurring Basis~~ 13

The following table presents information about our financial assets and liabilities that are measured at fair value on a recurring basis as of August 30, 2025 and November 30, 2024, and indicates the fair value hierarchy of the valuation techniques utilized to determine such fair value.

	August 30,		Fair Value Measurements Using:
Description	2025		Level 1		Level 2		Level 3
Assets:
Marketable securities	$	4,199	$	4,199	$	-	$	-
Foreign exchange contract assets		3,810		-		3,810		-
Liabilities:
Foreign exchange contract liabilities	$	821	$	-	$	821	$	-
Interest rate swaps, cash flow hedge liabilities		8,230				8,230		-
Interest rate swaps, fair value hedge liabilities		22,571		-		22,571		-
Net investment hedge liabilities		120,188		-		120,188		-
Holdback liability		33,570		-		-		33,570

	November 30,		Fair Value Measurements Using:
Description	2024		Level 1		Level 2		Level 3
Assets:
Marketable securities	$	8,584	$	8,584	$	-	$	-
Foreign exchange contract assets		2,147		-		2,147		-
Interest rate swaps, cash flow hedge assets		1,781		-		1,781		-
Liabilities:
Foreign exchange contract liabilities	$	7,074	$	-	$	7,074	$	-
Interest rate swaps, cash flow hedge liabilities		265		-		265		-
Interest rate swaps, fair value hedge liabilities		32,775		-		32,775		-
Net investment hedge liabilities		51,871		-		51,871		-

Table of Contents

~~The~~Balances ~~fair~~Measured ~~value~~at ofFair ~~the~~Value ~~holdback liability related to the acquisition of GEM and Medifill, based~~ on a ~~discounted~~Recurring cash flow model, was $33,570 as of August 30, 2025. Adjustments to the fair value of the holdback are recorded to interest expense in the Statement of Income. See Note 2 for further discussion regarding our acquisitions. The following table provides details of this Level 3 liability.Basis

	Amounts
Balance at November 30, 2024	$	-
Initial valuation of holdback liability		28,922
Interest		641
Foreign currency translation adjustment		4,007
Balance at August 30, 2025	$	33,570

The following table presents information about our financial assets and liabilities that are measured at fair value on a recurring basis as of February 28, 2026 and November 29, 2025, and indicates the fair value hierarchy of the valuation techniques utilized to determine such fair value.

February 28,

Fair Value Measurements Using:

Description

2026

Level 1

Level 2

Level 3

Assets:

Marketable securities

7,495

Foreign exchange contract assets

4,419

Liabilities:

Foreign exchange contract liabilities

1,498

Interest rate swaps, cash flow hedge liabilities

8,435

Interest rate swaps, fair value hedge liabilities

18,230

Net investment hedge liabilities

125,854

Holdback liability

22,617

	*November 29,*		*Fair Value Measurements Using:*
Description	*2025*		*Level 1*		*Level 2*		*Level 3*
Assets:
Marketable securities	$	4,352	$	4,352	$	-	$	-
Foreign exchange contract assets		4,841		-		4,841		-
Interest rate swaps, cash flow hedge assets		-		-		-		-

Liabilities:
Foreign exchange contract liabilities	$	635	$	-	$	635	$	-
Interest rate swaps, cash flow hedge liabilities		8,498		-		8,498		-
Interest rate swaps, fair value hedge liabilities		20,481		-		20,481		-
Net investment hedge liabilities		113,144		-		113,144		-
Holdback liability		33,578		-		-		33,578

The fair value of the holdback liability related to the acquisition of GEM and Medifill, based on a discounted cash flow model, was $22,617 as of February 28, 2026. Adjustments to the fair value of the holdback are recorded to interest expense in the Statement of Income. See Note 2 for further discussion regarding our acquisitions. The following table provides details of this Level 3 liability.

	*Amounts*
Balance at November 29, 2025	$	33,578
Payment of holdback liability		(11,596	)
Interest		221
Foreign currency translation adjustment		414
Balance at February 28, 2026	$	22,617

Balances Measured at Fair Value on a Nonrecurring Basis

We measure certain assets and liabilities at fair value on a nonrecurring basis. These assets include intangible assets acquired in an acquisition. The identified intangible assets of customer relationships, technology and tradenames acquired in connection with our acquisitions were measured using unobservable (Level 3) inputs. The fair value of the intangible assets was calculated using either the income or cost approach. Significant inputs include estimated revenue growth rates, gross margins, operating expenses, attrition rate, royalty rate and discount rate.

See Note 2 for further discussion regarding our acquisitions.

Balances Disclosed at Fair Value

Long-term debt had an estimated fair value of $2,~~082~~115,~~934~~526 and $2,~~015~~041,~~468~~062 as of ~~August~~February 3028, ~~2025~~2026 and November 3029, ~~2024~~2025, respectively. The fair value of long-term debt is based on quoted market prices for the same or similar issues or on the current rates offered for debt of similar maturities. The estimated fair value of these long-term obligations is not necessarily indicative of the amount that would be realized in a current market exchange.

~~Note 13: Commitments and Contingencies~~ 14

Table of Contents

Note 12: Commitments and Contingencies

Environmental Matters

We are involved in environmental investigations, clean-up activities and administrative proceedings related to environmental compliance matters at former and current operating facilities. We have also been identified as a potentially responsible party (“PRP”) under the Comprehensive Environmental Response, Compensation and Liability Act (“CERCLA”) and/or similar state laws that impose liability for costs relating to the clean-up of contamination resulting from past spills, disposal or other release of hazardous substances associated with landfills and/or hazardous waste sites. As a PRP, we may be required to pay a share of the costs of investigation and clean-up of these sites. We are subject to similar laws in some of the countries where current and former facilities are located. Our environmental, health and safety department monitors compliance with applicable laws on a global basis. To the extent we can reasonably estimate the amount of our probable liabilities for environmental matters, we establish an undiscounted financial provision. We recorded liabilities of $2,~~818~~666 and $32,~~445~~625 as of ~~August~~February 3028, ~~2025~~2026 and November 3029, ~~2024~~2025, respectively, for probable and reasonably estimable environmental remediation costs. Of the amount reserved, $508 and $1,055 as of August 30, 2025 and November 30, 2024, respectively, is attributable to a facility we own in Simpsonville, South Carolina that is a designated site under CERCLA.

While uncertainties exist with respect to the amounts and timing of the ultimate environmental liabilities, based on currently available information, we have concluded that these matters, individually or in the aggregate, will not have a material adverse effect on our results of operations, financial condition or cash flow.

Table of Contents

Other Legal Proceedings

From time to time and in the ordinary course of business, we are a party to, or a target of, lawsuits, claims, investigations and proceedings, including product liability, personal injury, contract, patent and intellectual property, environmental, health and safety, tax and employment matters. While we are unable to predict the outcome of these matters, we have concluded, based upon currently available information, that the ultimate resolution of any pending matter, individually or in the aggregate, including the asbestos litigation described in the following paragraphs, will not have a material adverse effect on our results of operations, financial condition or cash flow.

We have been named as a defendant in lawsuits in which plaintiffs have alleged injury due to products containing asbestos manufactured more than 35 years ago. The plaintiffs generally bring these lawsuits against multiple defendants and seek damages (both actual and punitive) in very large amounts. In many cases, plaintiffs are unable to demonstrate that they have suffered any compensable injuries or that the injuries suffered were the result of exposure to products manufactured by us. We are typically dismissed as a defendant in such cases without payment. If the plaintiff presents evidence indicating that compensable injury occurred as a result of exposure to our products, the case is generally settled for an amount that reflects the seriousness of the injury, the length, intensity and character of exposure to products containing asbestos, the number and solvency of other defendants in the case, and the jurisdiction in which the case has been brought.

A significant portion of the defense costs and settlements in asbestos-related litigation is paid by third parties, including indemnification pursuant to the provisions of a 1976 agreement under which we acquired a business from a third party. Currently, this third party is defending and paying settlement amounts, under a reservation of rights, in most of the asbestos cases tendered to the third party.

In addition to the indemnification arrangements with third parties, we have insurance policies that generally provide coverage for asbestos liabilities, including defense costs. Historically, insurers have paid a significant portion of our defense costs and settlements in asbestos-related litigation. However, certain of our insurers are insolvent. We have entered into cost-sharing agreements with our insurers that provide for the allocation of defense costs and settlements and judgments in asbestos-related lawsuits. These agreements require, among other things, that we fund a share of settlements and judgments allocable to years in which the responsible insurer is insolvent.

A summary of the number of and settlement amounts for asbestos-related lawsuits and claims is as follows:

Nine Months Ended

3 Years Ended

Three Months Ended

3 Years Ended

August 30, 2025

August 31, 2024

November 30, 2024

February 28, 2026

March 1, 2025

November 29, 2025

Lawsuits and claims settled

2528

Settlement amounts

~~369~~258

~~1,208~~4

5,~~704~~882

Insurance payments received or expected to be received

~~252~~192

~~844~~2

3,~~418~~547

We do not believe that it would be meaningful to disclose the aggregate number of asbestos-related lawsuits filed against us because relatively few of these lawsuits are known to involve exposure to asbestos-containing products that we manufactured. Rather, we believe it is more meaningful to disclose the number of lawsuits that are settled and result in a payment to the plaintiff. To the extent we can reasonably estimate the amount of our probable liabilities for pending asbestos-related claims, we establish a financial provision and a corresponding receivable for insurance recoveries.

In February 2024, the named plaintiffs in Rouse et al. v. H.B. Fuller Company et al. filed a third amended complaint in their lawsuit against the Company and one of its subsidiaries, which was initiated in September 2022. The suit is pending in the federal District of Minnesota and seeks damages arising from property damage attributed to alleged defects in grout sold by the Company’s ordivested ~~its~~North ~~affiliates~~America Flooring business. ~~The~~As ~~named~~previously ~~plaintiffs~~disclosed, ~~seek~~the toCompany ~~represent~~and athe ~~class~~plaintiffs ~~but~~agreed ~~have~~in ~~not~~principle ~~yet~~to ~~moved~~settle this matter for ~~class~~up ~~certification~~to $75.0 ~~The~~million. ~~court~~Under ~~has~~the ~~ordered~~proposed settlement, in lieu of funding the ~~parties~~maximum ~~and~~settlement ~~their~~amount, ~~insurers~~the Company’s payment obligations will be limited to ~~attend~~validly asubmitted ~~meditation~~claims, ~~session~~settlement onadministration orcosts, ~~around October~~service 21awards, and ~~22,~~plaintiffs’ ~~2025~~attorneys’ fees and expenses. The ~~Company~~terms ~~intends~~of a definitive settlement agreement will be subject to ~~vigorously~~court ~~defend~~approval. ~~itself~~In ~~against~~light of these developments, the ~~claims~~Company ~~outlined~~concluded that a loss is probable and reasonably estimable and recorded an accrual in ~~this~~anticipation ~~lawsuit~~of the settlement of $34.8 Asmillion ($26.3 million after tax) based on a range of possible outcomes. This accrual is included in other accrued expenses in the Consolidated Balance Sheets as of ~~August~~February 3028, ~~2025~~2026 and November 29, we2025. ~~are~~The ~~unable~~Company believes that it is entitled to ~~estimate~~reimbursement ~~any~~from ~~possible~~its ~~loss~~insurers orfor ~~range~~a substantial portion of ~~possible~~the ~~losses~~potential settlement amount as well as legal fees already incurred and ~~have~~paid ~~not~~and ~~recorded~~is aactively ~~loss~~pursuing ~~contingency~~reimbursement ~~for~~from ~~this~~its ~~matter~~insurers.

Based on currently available information, we have concluded that the resolution of any pending matter, including asbestos-related litigation, individually or in the aggregate, will not have a material adverse effect on our results of operations, financial condition or cash flow.

2215

Table of Contents

Note 1413: Share Repurchase Program

On April 22, 2022, the Board of Directors authorized a share repurchase program of up to $300,000 of our outstanding common shares for a period of up to five years. Under the program, we are authorized to repurchase shares for cash on the open market, from time to time, in privately negotiated transactions or block transactions, or through an accelerated repurchase agreement. The timing of such repurchases is dependent on price, market conditions and applicable regulatory requirements. Upon repurchasing shares, we reduce our common stock for the par value of the shares with the excess being applied against additional paid-in capital.

During the ~~third~~first quarter of ~~2025~~2026, ~~there~~we ~~were~~did nonot repurchase shares ~~repurchased~~ under this program. During the ~~nine~~first ~~months~~quarter ~~ended August~~of ~~30,~~ 2025, we repurchased shares under this program with an aggregate value of $5641,~~930~~153. Of this amount, $~~978~~678 reduced common stock and $5540,~~953~~475 reduced additional paid-in capital.

~~During~~Note ~~the third~~14: quarter of 2024, we repurchased shares under this program with an aggregate value of $17,549. Of this amount, $225 reduced common stock and $17,324 reduced additional paid-in capital. During the nine months ended August 31, 2024, we repurchased shares under this program with an aggregate value of $31,811. Of this amount, $407 reduced common stock and $31,404 reduced additional paid-in capital.Segments

~~Note~~Our ~~15:~~three ~~Segments~~reportable operating segments consist of Hygiene, Health and Consumable Adhesives, Engineering Adhesives and Building Adhesive Solutions. We are required to report segment information in the same way that we internally organize our business for assessing performance and making decisions regarding allocation of resources. Revenue and Adjusted EBITDA of each of our segments are regularly reviewed by our chief executive officer, who acts as our chief operating decision maker, to make decisions about resources to be allocated to the segments and assess their performance. Adjusted EBITDA is defined as net income before interest, income taxes, depreciation and amortization and foreign currency gain/loss, adjusted for other items within a relevant period which are not reflective of the segment’s operating performance in the period. Corporate expenses, other than those included in Corporate Unallocated, are allocated to each operating segment. Consistent with our internal management reporting, Corporate Unallocated includes and Adjusted EBITDA excludes amounts related to business acquisition and integration costs, organizational restructuring charges and project costs associated with our implementation of a global Enterprise Resource Planning ("ERP") system that we refer to as Project ONE. Corporate assets are not allocated to the operating segments. Inter-segment revenues are recorded at cost plus a markup for administrative costs. See below for a reconciliation of Adjusted EBITDA to net income attributable H.B. Fuller as reflected in the audited consolidated statement of income.

WeThe ~~are required to report segment information in the same way that we internally organize our~~ business ~~for~~components ~~assessing~~within ~~performance~~each ~~and~~operating ~~making~~segment ~~decisions~~are ~~regarding~~managed ~~allocation~~to ofmaximize ~~resources.~~the ~~Revenue~~results ~~and operating income~~ of ~~each~~the ofoverall ~~our segments are regularly reviewed by our chief~~ operating ~~decision~~segment ~~maker~~rather tothan ~~make~~the ~~decisions~~results ~~about~~of ~~resources~~any toindividual bebusiness ~~allocated~~component toof the ~~segments and assess their performance. Segment~~ operating ~~income is identified as gross profit less SG&A expenses~~segment. ~~Corporate~~Results ~~expenses,~~of ~~other~~individual ~~than~~components ~~those~~of ~~included~~each inoperating ~~Corporate~~segment ~~Unallocated,~~ are ~~allocated~~subject to ~~each~~numerous ~~operating~~allocations of segment.-wide ~~Consistent~~costs ~~with~~that may ~~our~~or may ~~internal~~not ~~management~~have ~~reporting,~~been ~~Corporate~~focused ~~Unallocated~~on ~~amounts~~that ~~include~~particular ~~business~~component ~~acquisition~~for ~~and~~a ~~integration~~particular ~~costs,~~reporting ~~organizational~~period. ~~restructuring~~The ~~charges and project~~ costs ~~associated~~for ~~with~~these ~~implementing~~allocated aresources ~~global~~are ~~Enterprise~~not ~~Resource~~tracked ~~Planning~~on (a “~~ERP~~where-used”) ~~system~~basis ~~that we refer to~~ as ~~Project~~financial ~~ONE. Corporate~~performance ~~assets~~is ~~are~~assessed ~~not~~at ~~allocated to~~ the total operating ~~segments. Inter-~~segment ~~revenues are recorded at cost plus a markup for administrative costs~~level.

AsReportable ~~of November 30, 2024, our three~~ operating segments consisted of Hygiene, Health and Consumable Adhesives, Engineering Adhesives and Construction Adhesives. As of the beginning of fiscal 2025, we reorganized our operating segments by selling our North American Flooring business (“NA Flooring”), previously part of the Construction Adhesives operating segment, and combining our Insulated Glass, Woodworking and Composite businesses, previously part of the Engineering Adhesives operating segment, with Construction Adhesives Roofing and Building Envelope and Infrastructure businesses to form the newly named Building Adhesive Solutions operating segment. All financial ~~results related to NA Flooring have been moved to our Corporate Unallocated segment. Prior period segment~~ information ~~has~~is ~~been~~as ~~recast retrospectively to reflect the realignment.~~follows: ~~Operating results of each of these segments are regularly reviewed by our chief operating decision maker to make decisions about resources to be allocated to the segments and assess their performance.~~

The table below provides certain information regarding net revenue and operating income (loss) for each of our operating segments.

	*Hygiene, Health*				*Building*
Three Months Ended:	*and Consumable*		*Engineering*		*Adhesive*				*Corporate*			*H.B. Fuller*
February 28, 2026	*Adhesives*		*Adhesives*		*Solutions*		*Total*		*Unallocated*			*Consolidated*
Net revenue	$	346,527	$	242,448	$	181,869	$	770,844	$	-		$	770,844
Segment expenses and other items ¹		298,490		194,289		160,260		653,039		(899	)		652,140
Adjusted EBITDA	$	48,037	$	48,159	$	21,609	$	117,805	$	899		$	118,704
Depreciation and amortization	$	16,553	$	15,922	$	13,548	$	46,023	$	342		$	46,365
Capital Expenditures		9,905		6,608		8,233		24,746		32,955			57,701

	Three Months Ended
	Hygiene, Health					Building
	August 30, 2025					August 31, 2024
Three Months Ended:	and Consumable		Engineering			Adhesive					Corporate			H.B. Fuller
	Net		Operating			Net		Operating
March 1, 2025	Adhesives		Adhesives			Solutions		Total			Unallocated			Consolidated
	Revenue		Income (Loss)			Revenue		Income (Loss)
Net revenue	$	368,225	$	236,758		$	183,680	$	788,663		$	-		$	788,663
Hygiene, Health and Consumable Adhesives	$	386,068	$	46,491		$	389,980	$	48,677
Segment expenses and other items 1		321,334		192,570			161,877		675,781			(1,474	)		674,307
Engineering Adhesives		272,297		46,852			260,038		40,087
Adjusted EBITDA	$	46,891	$	44,188		$	21,803	$	112,882		$	1,474		$	114,356
Building Adhesive Solutions		233,678		25,859			228,408		25,976
Depreciation and amortization	$	14,731	$	15,165		$	12,671	$	42,567		$	30		$	42,597
Total segment	$	892,043	$	119,202		$	878,426	$	114,740
Capital Expenditures		2,286		6,999			6,438		15,723			17,261			32,984
Corporate Unallocated		-		(9,062	)		39,501		(10,399	)
Total	$	892,043	$	110,140		$	917,927	$	104,341

	Nine Months Ended
	August 30, 2025					August 31, 2024
	Net		Operating			Net		Operating
	Revenue		Income (Loss)			Revenue		Income (Loss)
Hygiene, Health and Consumable Adhesives	$	1,151,768	$	119,840		$	1,151,371	$	145,910
Engineering Adhesives		785,474		121,880			743,726		104,894
Building Adhesive Solutions		641,559		54,550			630,558		55,102
Total segment	$	2,578,801	$	296,270		$	2,525,655	$	305,906
Corporate Unallocated		-		(39,639	)		119,797		(34,093	)
Total	$	2,578,801	$	256,631		$	2,645,452	$	271,813

¹ Segment expenses and other items for all segments primarily include raw material costs, compensation and benefits, delivery expense, rent and lease expense, professional services, travel and entertainment, repairs and maintenance and other manufacturing overhead.

~~The table below provides a reconciliation of operating income to income before income taxes and income from equity method investments:~~ 16

	Three Months Ended						Nine Months Ended
	August 30,			August 31,			August 30,			August 31,
	2025			2024			2025			2024
Operating income	$	110,140		$	104,341		$	256,631		$	271,813
Other income, net		5,308			2,148			15,655			7,282
Interest expense		(33,630	)		(35,288	)		(100,536	)		(99,504	)
Interest income		1,110			1,092			3,064			3,597
Income before income taxes and income from equity method investments	$	82,928		$	72,293		$	174,814		$	183,188

The table below provides total assets as of November 30, 2024, restated for our new operating segments:

	November 30,
	2024
Hygiene, Health and Consumable Adhesives	$	1,610,902
Engineering Adhesives		1,533,675
Building Adhesive Solutions		1,239,527
Corporate		549,140
Total	$	4,933,244

Table of Contents

Reconciliation of Net income attributable to H.B. Fuller to Adjusted EBITDA:

	*Three Months Ended*
	*February 28,*			*March 1,*
	*2026*			*2025*
Net income attributable to H.B. Fuller	$	21,045		$	13,248

Adjustments:
Acquisition project costs		931			9,828
Organizational realignment		10,022			8,774
Project One		3,053			3,064
Other		(95	)		-
Discrete tax items		98			992
Income tax effect on adjustments		(3,539	)		(5,909	)
Adjusted net income attributable to H.B. Fuller		31,515			29,997

Add:
Interest expense¹		32,373			32,030
Interest income		(2,069	)		(1,100	)
Adjusted Income taxes		10,862			10,862
Depreciation and Amortization expense²		46,023			42,567
Adjusted EBITDA		118,704			114,356

¹ Interest expense added back for EBITDA is adjusted for amounts already included in adjusted net income attributable to H.B. Fuller.

² Depreciation and amortization expense added back for EBITDA is adjusted for amounts already included in adjusted net income attributable to H.B. Fuller.

We view the following disaggregation of net revenue by geographic region as useful to understanding the composition of revenue recognized during the respective reporting periods:

Three Months Ended August 30, 2025

Three Months Ended February 28, 2026

Hygiene, Health

Building

and Consumable

Engineering

Adhesive

~~Corporate~~

Adhesives

Solutions

~~Unallocated~~Total

~~Total~~

Americas

~~215~~189,~~634~~143

~~117~~105,~~894~~159

~~130~~93,~~236~~698

-388,000

~~463,764~~

EIMEA

~~122~~104,~~251~~354

5954,~~778~~392

8774,~~934~~193

-232,939

~~269,963~~

Asia Pacific

4853,~~183~~030

9482,~~625~~897

1513,~~508~~978

-149,905

~~158,316~~

Total

~~386~~346,~~068~~527

~~272~~242,~~297~~448

~~233~~181,~~678~~869

-770,844

~~892,043~~

Three Months Ended August 31, 2024

Three Months Ended March 1, 2025

Hygiene, Health

Building

and Consumable

Engineering

Adhesive

~~Corporate~~

Adhesives

Solutions

~~Unallocated~~Total

~~Total~~

Americas

~~223~~207,~~016~~354

~~110~~97,~~163~~209

~~128~~95,~~834~~700

39400,~~501~~263

~~501,514~~

EIMEA

~~115~~110,~~740~~767

5750,~~142~~262

8275,~~759~~163

-236,192

~~255,641~~

Asia Pacific

5150,~~224~~104

9289,~~733~~287

1612,~~815~~817

-152,208

~~160,772~~

Total

~~389~~368,~~980~~225

~~260~~236,~~038~~758

~~228~~183,~~408~~680

39788,~~501~~663

~~917,927~~

	Nine Months Ended August 30, 2025
	Hygiene, Health				Building
	and Consumable		Engineering		Adhesive		Corporate
	Adhesives		Adhesives		Solutions		Unallocated		Total
Americas	$	651,007	$	334,265	$	352,396	$	-	$	1,337,668
EIMEA		351,256		171,594		245,170		-		768,020
Asia Pacific		149,505		279,615		43,993		-		473,113
Total	$	1,151,768	$	785,474	$	641,559	$	-	$	2,578,801

	Nine Months Ended August 31, 2024
	Hygiene, Health				Building
	and Consumable		Engineering		Adhesive		Corporate
	Adhesives		Adhesives		Solutions		Unallocated		Total
Americas	$	668,073	$	304,809	$	338,048	$	119,797	$	1,430,727
EIMEA		331,307		172,029		245,696		-		749,032
Asia Pacific		151,991		266,888		46,814		-		465,693
Total	$	1,151,371	$	743,726	$	630,558	$	119,797	$	2,645,452

Table of Contents

Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations

Overview

The Management’s Discussion and Analysis of Financial Condition and Results of Operations (“MD&A”) should be read in conjunction with the MD&A included in our Annual Report on Form 10-K for the year ended November 3029, ~~2024~~2025, for important background information related to our business.

Net revenue in the ~~third~~first quarter of ~~2025~~2026 decreased 2.83 percent from the ~~third~~first quarter of ~~2024~~2025. The decrease was due to a ~~2.9 percent decrease in acquisitions/divestitures, and~~ a 17.92 percent decrease due to sales volume, partially offset by a 13.06 percent increase due to positive currency effects, ~~compared to the~~a ~~third~~0.7 percent ~~quarter~~increase ofdue ~~2024~~to acquisitions and a 1.0.6 percent increase due to pricing compared to the first quarter of 2025. The positive currency effect was primarily driven by a stronger Euro, Chinese renminbi, British pound, Brazilian real, Mexican peso and ~~Egyptian~~Australian ~~pound,~~dollar partially offset by a weaker Turkish lira compared to the U.S. dollar. Gross profit margin increased ~~200~~180 basis points primarily due to ~~the~~ higher product pricing, lower ~~distribution~~raw material costs, ~~and~~ the impact of acquisitions~~/divestitures~~ and restructuring actions.

Net ~~revenue~~income inattributable ~~the~~to ~~first nine months of 2025 decreased 2~~H.~~5 percent~~B. ~~from~~Fuller in the first ~~nine~~quarter ~~months~~ of ~~2024.~~ ~~The~~2026 ~~decrease~~ was ~~due to a 1~~$21.80 ~~percent~~million ~~decrease~~compared into ~~acquisitions/divestitures, a 1~~$13.12 ~~percent~~million ~~decrease~~in ~~due to negative currency effects compared to~~ the first ~~nine~~quarter ~~months~~ of ~~2024 and a 0~~2025.~~2 percent~~ ~~decrease~~Diluted ~~due~~earnings toper ~~sales~~share ~~volume,~~for ~~partially~~the ~~offset~~first byquarter ~~a 0.6~~of ~~increase~~2026 ~~due~~was ~~to pricing~~$0.38 ~~The~~per ~~negative~~share ~~currency effect was primarily driven by a weaker Brazilian real, Egyptian pound, Mexican peso and Turkish lira, partially offset by a stronger Euro~~ compared to ~~the U~~$0.~~S. dollar. Gross profit margin increased 90~~24 ~~basis~~per ~~points due~~share tofor ~~higher pricing and~~ the ~~impact~~first quarter of ~~acquisitions/divestitures~~2025.

~~Net~~Adjusted ~~income~~EBITDA ~~attributable to H.B. Fuller~~ in the ~~third~~first three months ~~quarter~~ of ~~2025~~2026 ~~was $67.2~~increased ~~million compared to $55~~3.~~4 million~~8 inpercent from the first ~~third~~three ~~quarter~~months of ~~2024. Diluted earnings per share for the third quarter of~~ 2025, ~~was~~primarily ~~$1.22 per~~driven ~~share~~by ~~compared~~higher tonet ~~$0.98 per~~income ~~share~~and ~~for~~depreciation ~~the~~and ~~third~~amortization ~~quarter of 2024~~expense.

Net income attributable to H.B. Fuller in the first nine months of 2025 was $122.2 million compared to $137.6 million in the first nine months of 2024. Diluted earnings per share for the first nine months of 2025 was $2.21 per share compared to $2.43 per share for the first nine months of 2024.

Restructuring Plans

During ~~the~~fiscal ~~second~~year ~~and third quarters of~~ 2023, the Company approved restructuring plans (the “Plans”) related to organizational changes and other actions to optimize operations and integrate acquired businesses. In implementing the Plans, the Company currently expects to incur costs of approximately $7085.0 million to $7590.0 million ($4758.80 million to $5161.24 million after- tax), which include (i) cash expenditures of approximately $4151.0 million to $4252.0 million ($2834.08 million to $2835.75 million after tax) for severance and related employee costs globally and (ii) other restructuring costs related to the streamlining of processes and the payment of anticipated income taxes in certain jurisdictions related to the Plans. We have incurred costs of $6983.7 2 million under the Plans as of ~~August~~February 3028, ~~2025~~2026. ~~The~~Remaining ~~Plans~~cash ~~were~~payments ~~implemented in~~will ~~the~~continue ~~second~~into ~~quarter of~~ fiscal year ~~2023 and are currently expected to be completed during fiscal year~~ 2026. ~~The remaining restructuring costs will be spread across the next several fiscal quarters as the measures are implemented.~~

25 During the first quarter of 2026, the Company approved other restructuring actions related to global footprint optimization. In implementing the other restructuring actions, the Company currently expects to incur costs of approximately $10.2 million to $12.2 million ($7.5 million to $9.0 million after tax), which include (i) cash expenditures of approximately $5.8 million to $6.8 million ($4.3 million to $5.0 million after tax) for severance and related employee costs globally and (ii) other restructuring costs related to optimizing the Company’s footprint and the payment of anticipated income taxes in certain jurisdictions related to the other restructuring actions. We have incurred costs of $4.8 million under the other restructuring actions as of February 28, 2026. The other restructuring actions began to be implemented in the first quarter of 2026 and are currently expected to be completed during fiscal year 2028. Restructuring costs are expected to be incurred over the next several fiscal quarters as the measures are implemented with the majority of the charges recognized and cash payments occurring in fiscal 2026 and 2027.

Table of Contents

Results of Operations

Net revenue:

Three Months Ended

~~Nine Months Ended~~

August 30,

August 31,

2025 vs

August 30,

August 31,

2025 vs

February 28,

March 1,

2026 vs

($ in millions)

~~2025~~2026

~~2024~~2025

~~2025~~

~~2024~~

Net revenue

~~892~~770.08

~~917~~788.97

(2.83

~~2,578.8~~

~~2,645.5~~

~~(2.5~~

We review variances in net revenue in terms of changes related to sales volume and product pricing (referred to as organic revenue growth), business acquisitions ~~and~~ /divestitures (“M&A”) and changes in foreign currency exchange rates. The following table shows the net revenue variance analysis for the ~~third~~first quarter ~~and first nine months~~ of ~~2025~~2026 compared to the ~~third~~first quarter ~~and first nine months~~ of ~~2024~~2025:

	Three Months Ended			~~Nine Months Ended~~
	August 30, 2025 vs. August 31, 2024			August 30, 2025 vs. August 31, 2024
	February 28, 2026 vs. March 1, 2025
Organic growth		(0.9	)%		0.4	%
Organic revenue growth		(6.6	)%
M&A		(20.97	)%		~~(1.8~~	)%
Currency		13.06	%		~~(1.1~~	)%
Total		(2.8	)%		(2.5	)%
Net revenue growth		(2.3	)%

Organic revenue decreased 06.96 percent in the ~~third~~first quarter of ~~2025~~2026 compared to the ~~third~~first quarter of ~~2024~~2025 and consisted of a 10.1 percent decrease in Hygiene, Health and Consumable Adhesives, a 5.1 percent decrease in Building Adhesive Solutions and a 2.0 percent decrease in Engineering Adhesives. The overall decrease was driven by a 17.92 percent decrease in sales volume, partially offset by a 1.0.6 percent increase in product pricing. The 20.97 percent ~~decrease~~increase from M&A was due to the ~~sale~~acquisition of ~~our~~GEM, Medifill, ~~North~~ND ~~American~~Industries ~~Flooring~~Taiwan ~~business~~and ~~(“NA~~ND ~~Flooring”),~~Industries Turkey, discussed further in Operating Segment Results below~~, net of acquisitions that occurred in the last twelve months~~. The positive 13.06 percent foreign currency impact was primarily driven by a stronger Euro, Chinese renminbi, British pound, Brazilian real, Mexican peso and ~~Egyptian~~Australian ~~pound~~dollar, partially offset by a weaker Turkish lira compared to the U.S. dollar.

Organic revenue increased 0.4 percent in the first nine months of 2025 compared to the first nine months of 2024 driven by a 0.6 percent increase in product pricing, partially offset by a 0.2 percent decrease in sales volume. The 1.8 percent decrease from M&A was due to the sale of NA Flooring, net of acquisitions that occurred in the last twelve months. The negative 1.1 percent foreign currency impact was primarily driven by a weaker Brazilian real, Egyptian pound, Mexican peso and Turkish lira, partially offset by a stronger Euro compared to the U.S. dollar. 18

Table of Contents

Cost of sales:

Three Months Ended

~~Nine Months Ended~~

August 30,

August 31,

2025 vs

August 30,

August 31,

2025 vs

February 28,

March 1,

2026 vs

($ in millions)

~~2025~~2026

~~2024~~2025

~~2025~~

~~2024~~

Cost of sales

~~606~~534.98

~~642~~561.26

(54.58

~~1,780.2~~

~~1,848.5~~

~~(3.7~~

Percent of net revenue

6869.04

7071.02

~~69.0~~

~~69.9~~

Cost of sales as a percentage of net revenue in the ~~third~~first quarter of ~~2025~~2026 compared to the ~~third~~first quarter of ~~2024~~2025 decreased ~~200~~180 basis points. Raw material cost as a percentage of net revenue decreased ~~130~~250 basis points in ~~2025~~2026 compared to ~~2024~~2025 primarily due to higher product pricing, lower raw material costs and the impact of acquisitions~~/divestitures~~. Other manufacturing costs as a percentage of net revenue ~~decreased~~increased 70 basis points in ~~2025~~2026 compared to ~~2024~~2025 due to ~~lower~~higher manufacturing and distribution costs, and the impact of acquisitions~~/divestitures~~.

Cost of sales as a percentage of net revenue in the first nine months of 2025 compared to the first nine months of 2024 decreased 90 basis points. Raw material cost as a percentage of net revenue decreased 50 basis points in 2025 compared to 2024. Other manufacturing costs as a percentage of net revenue decreased 40 basis points in 2025 compared to 2024.

Gross profit:

Three Months Ended

~~Nine Months Ended~~

August 30,

August 31,

2025 vs

August 30,

August 31,

2025 vs

February 28,

March 1,

2026 vs

($ in millions)

~~2025~~2026

~~2024~~2025

~~2025~~

~~2024~~

Gross profit

~~285~~236.10

~~275~~227.71

3.49

~~798.6~~

~~797.0~~

~~0.2~~

Percent of net revenue

3230.06

3028.08

~~31.0~~

~~30.1~~

Gross profit in the ~~third~~first quarter of ~~2025~~2026 increased 3.49 percent and gross profit margin increased ~~200~~180 basis points compared to the ~~third~~first quarter of ~~2024~~2025. The increase in gross profit margin was due to ~~due to~~ higher product pricing, lower raw material costs and the impact of acquisitions~~/divestitures~~.

Gross profit in the first nine months of 2025 increased 0.2 percent and gross profit margin increased 90 basis points compared to the first nine months of 2024. The increase in gross profit margin was due to higher product pricing and the impact of acquisitions/divestitures.

Selling, general and administrative (SG&A) expenses:

Three Months Ended

~~Nine Months Ended~~

August 30,

August 31,

2025 vs

August 30,

August 31,

2025 vs

February 28,

March 1,

2026 vs

($ in millions)

~~2025~~2026

~~2024~~2025

~~2025~~

~~2024~~

SG&A

~~175~~184.05

~~171~~180.46

2.12

~~541.9~~

~~525.2~~

~~3.2~~

Percent of net revenue

1923.69

1822.79

~~21.0~~

~~19.9~~

SG&A expenses for the ~~third~~first quarter of ~~2025~~2026 compared to the ~~third~~first quarter of ~~2024~~2025 increased 90100 basis points as a percentage of net revenue. The increase was due to ~~higher~~lower ~~compensation~~revenue ~~costs~~ and the impact of acquisitions~~/divestitures~~.

SG&A expenses for the first nine months of 2025 compared to the first nine months of 2024 increased 110 basis points as a percentage of net revenue. The increase was due to higher compensation costs and the impact of acquisitions/divestitures.

Table of Contents

Other income, net:

Three Months Ended

~~Nine Months Ended~~

August 30,

August 31,

2025 vs

August 30,

August 31,

2025 vs

February 28,

March 1,

2026 vs

($ in millions)

~~2025~~2026

~~2024~~2025

~~2025~~

~~2024~~

Other income, net

56.37

23.12

~~152~~109.4

~~15.7~~

~~7.3~~

~~115.1~~

Other income, net in the ~~third~~first quarter of ~~2025~~2026 included $56.73 million of net defined benefit pension benefits, ~~and~~ $0.13 million of ~~other~~currency ~~income,~~transaction ~~partially~~gains ~~offset by a~~and $0.51 million of ~~currency~~other ~~transaction losses~~income. Other income, net in the ~~third~~first quarter of ~~2024~~2025 included $45.07 million of net defined benefit pension benefits, and $0.3 6 million of currency transaction gains, partially offset by a $21.0 5 million loss on ~~equity~~the ~~investment and~~sale of our North American Flooring business ("NA Flooring") and $01.2 6 million of other expense.

Other income, net in the first nine months of 2025 included $17.1 million of net defined benefit pension benefits and $1.5 million of currency transaction gains, partially offset by a $1.5 million loss on the sale of our NA Flooring business and $1.4 million of other expense. Other income, net in the first nine months of 2024 included $11.9 million of net defined benefit pension benefits, partially offset by $2.0 million of currency transaction losses, a $2.0 million loss on equity investment and $0.6 million of other expense.

Interest expense:

Three Months Ended

~~Nine Months Ended~~

August 30,

August 31,

2025 vs

August 30,

August 31,

2025 vs

February 28,

March 1,

2026 vs

($ in millions)

~~2025~~2026

~~2024~~2025

~~2025~~

~~2024~~

Interest expense

3332.69

3532.30

(42.8

~~100.5~~

~~99.5~~

~~1.0~~

Interest expense in the ~~third~~first quarter of ~~2025~~2026 was $3332.69 million compared to $3532.30 million in the ~~third~~first quarter of ~~2024~~2025 due to ~~lower interest~~higher ~~rates~~debt levels partially offset by ~~higher~~lower ~~debt~~interest ~~levels~~rates.

Interest expense in the first nine months of 2025 was $100.5 million compared to $99.5 million in the first nine months of 2024 due to higher debt levels.

Table of Contents

Interest income:

Three Months Ended

~~Nine Months Ended~~

August 30,

August 31,

2025 vs

August 30,

August 31,

2025 vs

February 28,

March 1,

2026 vs

($ in millions)

~~2025~~2026

~~2024~~2025

~~2025~~

~~2024~~

Interest income

12.1

1.1

090.09

~~3.1~~

~~3.6~~

~~(13.9~~

Interest income in the ~~third~~first quarter of ~~2025~~2026 and ~~2024~~2025 was $12.1 million and $1.1 million, respectively, consisting primarily of interest on cross-currency swap activity and other miscellaneous interest income.

Interest income in the first nine months of 2025 and 2024 was $3.1 million and $3.6 million, respectively, consisting primarily of interest on cross-currency swap activity and other miscellaneous interest income. 19

Income taxes:

	Three Months Ended									Nine Months Ended
	August 30,			August 31,			2025 vs			August 30,			August 31,			2025 vs
($ in millions)	2025			2024			2024			2025			2024			2024
Income taxes	$	16.5		$	18.3			(9.8	)%	$	55.2		$	48.5			13.8	%
Effective tax rate		19.9	%		25.3	%					31.6	%		26.5	%

Income tax expense of $16.5 million in the third quarter of 2025 includes $3.7 million of discrete tax benefit. Excluding the discrete tax benefit, the overall effective tax rate was 24.4 percent. The discrete tax benefit relates to various U.S. and foreign tax matters. Income tax expense of $18.3 million in the third quarter of 2024 includes $2.9 million of discrete tax benefit. Excluding the discrete tax benefit, the overall effective tax rate was 29.3 percent. The discrete tax benefit related to an excess tax benefit on U.S. stock compensation, as well as other various U.S. and foreign tax matters.

Income tax expense of $55.2 million in the first nine months of 2025 includes $11.2 million of discrete tax expense. Excluding the discrete tax expense, the overall effective tax rate was 25.2 percent. The discrete tax expense relates to the impact of withholding tax recorded on earnings that are no longer permanently reinvested, offset by various U.S. and foreign tax matters. Income tax expense of $48.5 million in the first nine months of 2024 includes $4.1 million of discrete tax benefit. Excluding the discrete tax benefit, the overall effective tax rate was 28.7 percent. The discrete tax benefit related to an excess tax benefit on U.S. stock compensation, as well as other various U.S. and foreign tax matters.

Table of Contents

Income taxes:

	Three Months Ended
	February 28,			March 1,			2026 vs
($ in millions)	2026			2025			2025
Income taxes	$	7.4		$	5.9			25.4	%
Effective tax rate		26.9	%		31.8	%

Income tax expense of $7.4 million in the first quarter of 2026 includes $0.1 million of discrete tax expense. Excluding the discrete tax expense, the overall effective tax rate was 26.6 percent. The discrete tax expense relates to various U.S. and foreign tax matters. Income tax expense of $5.9 million in the first quarter of 2025 includes $0.9 million of discrete tax expense. Excluding the discrete tax expense, the overall effective tax rate was 26.5 percent. The discrete tax expense related to various U.S. and foreign tax matters.

Income from equity method investments:

Three Months Ended

~~Nine Months Ended~~

August 30,

August 31,

2025 vs

August 30,

August 31,

2025 vs

February 28,

March 1,

2026 vs

($ in millions)

~~2025~~2026

~~2024~~2025

~~2025~~

~~2024~~

Income from equity method investments

0.89

10.35

~~(38~~80.50

~~2.7~~

~~3.0~~

~~(10.0~~

The income from equity method investments relates to our 50 percent ownership of the Sekisui-Fuller joint venture in Japan. The ~~lower~~ higher income for the ~~third~~first quarter of ~~2025~~2026 compared to the ~~third~~first quarter of ~~2024~~2025 is due to ~~lower~~ higher net income in our joint venture during the quarter compared to the prior year ~~partially offset by the strengthening of the Japanese yen compared to the U~~.~~S. dollar.~~

The income from equity method investments relates to our 50 percent ownership of the Sekisui-Fuller joint venture in Japan. The lower income for the first nine months of 2025 compared to the first nine months of 2024 is due to lower net income in our joint venture compared to the prior year partially offset by the strengthening of the Japanese yen compared to the U.S. dollar.

Net income attributable to H.B. Fuller:

Three Months Ended

~~Nine Months Ended~~

August 30,

August 31,

2025 vs

August 30,

August 31,

2025 vs

February 28,

March 1,

2026 vs

($ in millions)

~~2025~~2026

~~2024~~2025

~~2025~~

~~2024~~

Net income attributable to H.B. Fuller

6721.20

5513.42

2159.31

~~122.2~~

~~137.6~~

~~(11.2~~

Percent of net revenue

72.57

61.07

~~4.7~~

~~5.2~~

The net income attributable to H.B. Fuller in the ~~third~~first quarter of ~~2025~~2026 was $6721.20 million compared to $5513.42 million in the ~~third~~first quarter of ~~2024~~2025. The diluted earnings per share in the ~~third~~first quarter of ~~2025~~2026 was $10.2238 per share as compared to $0.9824 per share in the ~~third~~first quarter of ~~2024~~2025.

~~The~~Adjusted net income attributable to H.B. Fuller in the first nine months of 2025 was $122.2 million compared to $137.6 million in the first nine months of 2024. The diluted earnings per share in the first nine months of 2025 was $2.21 per share as compared to $2.43 per share in the first nine months of 2024.EBITDA:

	Three Months Ended
	February 28,			March 1,			2026 vs
($ in millions)	2026			2025			2025
Adjusted EBITDA	$	118.7		$	114.4			3.8	%
Percent of net revenue		15.4	%		14.5	%

Adjusted EBITDA for H.B. Fuller in the first quarter of 2026 was $118.7 million compared to $114.4 million in the first quarter of 2025. Adjusted EBITDA as a percentage of net revenue increased 90 basis points in the first quarter of 2026 compared to first quarter of 2025 due to higher net income and depreciation and amortization expense. For a reconciliation of Adjusted EBITDA to net income attributable to H.B. Fuller as reflected in the unaudited consolidated statement of income see "Non-GAAP Measures" below.

Operating Segment Results

AsOur ~~of November 30, 2024, our~~ three reportable operating segments ~~consisted~~consist of Hygiene, Health and Consumable Adhesives, Engineering Adhesives and ~~Construction~~Building ~~Adhesives~~Adhesive Solutions. We Asare ofrequired ~~the~~to ~~beginning~~report ofsegment ~~fiscal~~information ~~2025,~~in the same way that we ~~reorganized~~internally organize our ~~operating~~business ~~segments by~~for ~~selling~~assessing ~~our~~performance NAand ~~Flooring~~making ~~business,~~decisions ~~previously~~regarding ~~part~~allocation of ~~the~~resources. Revenue ~~Construction~~and ~~Adhesives~~Adjusted ~~operating~~EBITDA ~~segment,~~of ~~and~~each ~~combining~~of our ~~Insulated~~segments ~~Glass,~~are ~~Woodworking and~~regularly ~~Composite~~reviewed ~~businesses,~~by ~~previously~~our ~~part~~chief ofexecutive ~~the~~officer, ~~Engineering~~who ~~Adhesives~~acts as our chief operating ~~segment~~decision maker, ~~with~~to ~~Construction~~make ~~Adhesives~~decisions ~~Roofing~~about ~~and~~resources ~~Building~~to ~~Envelope~~be allocated to the segments and ~~Infrastructure~~assess ~~businesses~~their toperformance. ~~form~~Adjusted ~~the~~EBITDA ~~newly~~is ~~named~~defined ~~Building~~as ~~Adhesive~~net ~~Solutions~~income ~~operating~~before ~~segment.~~interest, ~~All~~income ~~financial~~taxes, ~~results~~depreciation ~~related~~and toamortization NAand ~~Flooring~~foreign ~~have~~currency ~~been~~gain/loss, ~~moved~~adjusted tofor ~~our~~other ~~Corporate~~items ~~Unallocated~~within a relevant period which are not reflective of the segment’s operating performance in the period. ~~Prior~~Corporate ~~period~~expenses, ~~segment~~other ~~information~~than ~~has~~those ~~been~~included ~~recast~~in ~~retrospectively~~Corporate Unallocated, are allocated to ~~reflect~~each ~~the~~operating ~~realignment~~segment.

The tables below provide certain information regarding the net revenue, Adjusted EBITDA and ~~operating~~Adjusted ~~income~~EBITDA margin of each of our operating segments. Adjusted EBITDA margin is defined as Adjusted EBITDA divided by net revenue for each operating segment. Corporate Unallocated amounts include business acquisition and integration costs, organizational restructuring charges and project costs associated with implementing a global Enterprise Resource Planning (“ERP”) system that we refer to as Project ONE.

Corporate Unallocated amounts include business acquisition and integration costs, organizational restructuring charges and project costs associated with implementing a global Enterprise Resource Planning (“ERP”) system that we refer to as Project ONE. As a result of the change in operating segments and the sale of our NA Flooring business, we have retrospectively moved the results of our Flooring business to Corporate Unallocated for prior periods. 20

Table of Contents

Net Revenue by Segment:

	Three Months Ended										~~Nine Months Ended~~
	August 30, 2025					August 31, 2024					August 30, 2025					August 31, 2024
	February 28, 2026					March 1, 2025
	Net		% of			Net		% of			~~Net~~		~~% of~~			~~Net~~		~~% of~~
($ in millions)	Revenue		Total			Revenue		Total			~~Revenue~~		~~Total~~			~~Revenue~~		~~Total~~
Hygiene, Health and Consumable Adhesives	$	~~386~~346.05		4345	%	$	~~390~~368.02		4247	%	$	~~1,151.8~~		45	%	$	~~1,151.4~~		44	%
Engineering Adhesives		~~272~~242.34		31	%		~~260~~236.08		2830	%		~~785.5~~		30	%		~~743.7~~		28	%
Building Adhesive Solutions		~~233~~181.79		2624	%		~~228~~183.47		2523	%		~~641.5~~		25	%		~~630.6~~		24	%
Segment total	$	~~892~~770.08		100	%	$	~~878~~788.47		95100	%	$	~~2,578.8~~		~~100~~	%	$	~~2,525.7~~		96	%
Corporate Unallocated		-		-0	%		~~39.5~~-		50	%		-		-			~~119.8~~		4	%
Total	$	~~892~~770.08		100	%	$	~~917~~788.97		100	%	$	~~2,578.8~~		~~100~~	%	$	~~2,645.5~~		~~100~~	%

Segment ~~Operating~~Adjusted ~~Income (Loss):~~EBITDA

	Three Months Ended												~~Nine Months Ended~~
	August 30, 2025						August 31, 2024						August 30, 2025						August 31, 2024
	February 28, 2026						March 1, 2025
	Segment						Segment						Segment						Segment
	Adjusted			% of			Adjusted			% of
	Operating						Operating						Operating						Operating
($ in millions)	EBITDA			Total			EBITDA			Total
	Income			% of			Income			% of			Income			% of			Income			% of
Hygiene, Health and Consumable Adhesives	$	48.0			40	%	$	46.9			41	%
($ in millions)	(Loss)			Total			(Loss)			Total			(Loss)			Total			(Loss)			Total
Engineering Adhesives		48.2			41	%		44.2			39	%
Hygiene, Health and Consumable Adhesives	$	46.5			42	%	$	48.6			47	%	$	119.8			47	%	$	145.9			54	%
Building Adhesive Solutions		21.6			18	%		21.8			19	%
Engineering Adhesives		46.8			42	%		40.1			38	%		121.9			47	%		104.9			39	%
Segment total	$	117.8			99	%	$	112.9			99	%
Building Adhesive Solutions		25.9			24	%		26.0			25	%		54.5			21	%		55.1			20	%
Corporate Unallocated		0.9			1	%		1.5			1	%
Segment total	$	119.2			108	%	$	114.7			110	%	$	296.2			115	%	$	305.9			113	%
Total	$	118.7			100	%	$	114.4			100	%
Corporate Unallocated		(9.1	)		(8	)%		(10.4	)		(10	)%		(39.6	)		(15	)%		(34.1	)		(13	)%
Total	$	110.1			100	%	$	104.3			100	%	$	256.6			100	%	$	271.8			100	%

Hygiene, Health and Consumable Adhesives

	Three Months Ended									~~Nine Months Ended~~
	August 30,			August 31,			2025 vs			August 30,			August 31,			2025 vs
	February 28,			March 1,			2026 vs
($ in millions)	~~2025~~2026			~~2024~~2025			~~2024~~2025			~~2025~~			~~2024~~			~~2024~~
Net revenue	$	~~386~~346.05		$	~~390~~368.02			(15.09	)%	$	~~1,151.8~~		$	~~1,151.4~~			~~0.0~~	%
Segment operating income	$	46.5		$	48.6			(4.3	)%	$	119.8		$	145.9			(17.9	)%
Segment adjusted EBITDA	$	48.0		$	46.9			2.3	%
Segment operating margin		12.0	%		12.5	%					10.4	%		12.7	%
Segment adjusted EBITDA margin		13.9	%		12.7	%

Table of Contents

The following table provides details of the Hygiene, Health and Consumable Adhesives net revenue variances:

	Three Months Ended			~~Nine Months Ended~~
	August 30, 2025 vs. August 31, 2024			August 30, 2025 vs. August 31, 2024
	February 28, 2026 vs. March 1, 2025
Organic growth		(3.1	)%		0.8	%
Organic revenue growth		(10.1	)%
M&A		10.58	%		~~1.3~~	%
Currency		03.64	%		~~(2.1~~	)%
Total		(15.09	)%		~~0.0~~	%

Net revenue decreased 15.09 percent in the ~~third~~first quarter of ~~2025~~2026 compared to the ~~third~~first quarter of ~~2024~~2025. Organic revenue growth decreased due to a decrease in sales volume~~, partially offset by an~~ ~~increase in~~ and product pricing. The 10.58 percent increase in net revenue from M&A was due to the acquisitions of GEM and Medifill in the first quarter of 2025. The positive currency effect was due to a stronger Euro, Brazilian real, Mexican peso and ~~Egyptian~~ ~~pound~~Chinese renminbi, partially offset by a weaker Turkish lira compared to the U.S. dollar. AsSegment aadjusted ~~percentage~~EBITDA ofincreased ~~net revenue, raw material costs decreased~~2.3 ~~90 basis points due to higher product pricing and~~ percent in the ~~impact~~first ofquarter ~~acquisitions. Other manufacturing costs as a percentage~~ of ~~net revenue decreased~~ 602026 ~~basis points~~ compared to the ~~prior~~first ~~year~~quarter ~~due to higher product pricing and the impact~~ of ~~acquisitions~~2025. ~~SG&A~~Segment ~~expenses~~adjusted EBITDA ~~as a percentage of net revenue increased~~margin ~~200~~increased 120 basis points primarily due to ~~higher~~lower ~~compensation~~revenue, ~~costs~~lower ~~and~~raw ~~the~~materials ~~impact of acquisitions.~~cost ~~Segment operating income decreased 4.3 percent~~ and ~~segment operating margin as a percentage of net revenue decreased 50 basis points compared to~~ the ~~third~~impact ~~quarter~~ of ~~2024~~acquisitions.

Net revenue was flat in the first nine months of 2025 compared to the first nine months of 2024. Organic growth increased due to an increase in product pricing, partially offset by a decrease in sales volume. The 1.3 percent increase in net revenue from M&A was due to the acquisitions of GEM and Medifill in the first quarter of 2025. The negative currency effect was due to a weaker Egyptian pound, Brazilian real and Mexican peso compared to the U.S. dollar. As a percentage of net revenue, raw material costs increased 110 basis points due to higher raw material costs partially offset by higher product pricing and the impact of acquisitions. Other manufacturing costs as a percentage of net revenue were flat compared to the prior year. SG&A expenses as a percentage of net revenue increased 120 basis points due to higher compensation costs and the impact of acquisitions. Segment operating income decreased 17.9 percent and segment operating margin as a percentage of net revenue decreased 230 basis points compared to the first nine months of 2024. 21

Table of Contents

Engineering Adhesives

	Three Months Ended									~~Nine Months Ended~~
	August 30,			August 31,			2025 vs			August 30,			August 31,			2025 vs
	February 28,			March 1,			2026 vs
($ in millions)	~~2025~~2026			~~2024~~2025			~~2024~~2025			~~2025~~			~~2024~~			~~2024~~
Net revenue	$	~~272~~242.34		$	~~260~~236.08			42.74	%	$	~~785.5~~		$	~~743.7~~			~~5.6~~	%
Segment operating income	$	46.8		$	40.1			16.7	%	$	121.9		$	104.9			16.2	%
Segment adjusted EBITDA	$	48.2		$	44.2			9.0	%
Segment operating margin		17.2	%		15.4	%					15.5	%		14.1	%
Segment adjusted EBITDA margin		19.9	%		18.7	%

The following tables provide details of the Engineering Adhesives net revenue variances:

	Three Months Ended			~~Nine Months Ended~~
	August 30, 2025 vs. August 31, 2024			August 30, 2025 vs. August 31, 2024
	February 28, 2026 vs. March 1, 2025
Organic growth		2.2	%		0.1	%
Organic revenue growth		(2.0	)%
M&A		1.31	%		~~6.0~~	%
Currency		13.23	%		~~(0.5~~	)%
Total		42.74	%		~~5.6~~	%

Net revenue increased 42.74 percent in the ~~third~~first quarter of ~~2025~~2026 compared to the ~~third~~first quarter of ~~2024~~2025. Organic revenue growth ~~increased~~decreased due to a decrease in sales volume, partially offset by an increase in ~~both~~ product pricing ~~and sales volume~~. The 1.31 percent increase in net revenue from M&A was due to the acquisition of ND Industries Taiwan and ND Industries Turkey. The positive currency effect was due to a stronger Euro and ~~British~~Chinese ~~pound~~ renminbi compared to the U.S. dollar. AsSegment aadjusted ~~percentage~~EBITDA ofincreased ~~net~~9.0 ~~revenue,~~percent in the ~~raw~~first ~~material~~quarter ~~costs decreased~~of ~~140~~2026 ~~basis~~compared ~~points primarily due~~ to ~~higher product pricing and~~ the ~~impact~~first quarter of ~~acquisitions offset by higher raw material costs~~2025. ~~Other~~Segment ~~manufacturing~~adjusted ~~costs~~EBITDA ~~as a percentage of net revenue decreased~~margin 70increased 120 basis points primarily due to ~~the~~higher ~~impact~~product ofpricing, ~~higher~~lower ~~sales~~raw ~~volume~~materials ~~offset~~cost byand the impact of acquisitions~~. SG&A~~, ~~expenses~~partially asoffset aby ~~percentage~~higher ofmanufacturing ~~net revenue increased 30 basis points. Segment operating income increased 16.7 percent~~ and ~~segment~~distribution ~~operating margin increased 180 basis points compared to the third quarter of 2024~~costs.

Net revenue increased 5.6 percent in the first nine months of 2025 compared to the first nine months of 2024. Organic growth increased due to an increase in product pricing, partially offset by a decrease in sales volume. The 6.0 percent increase in net revenue from M&A was due to the acquisition of ND Industries and ND Industries Taiwan. The negative currency effect was due to a weaker Chinese renminbi and Mexican peso, partially offset by a stronger Euro and British pound compared to the U.S. dollar. As a percentage of net revenue, raw material costs decreased 280 basis points due to higher product pricing and the impact of acquisitions. Other manufacturing costs as a percentage of net revenue increased 30 basis points. SG&A expenses as a percentage of net revenue increased 110 basis points primarily due to higher compensation and the impact of acquisitions. Segment operating income increased 16.2 percent and segment operating margin increased 140 basis points compared to the first nine months of 2024.

Building Adhesive Solutions

	Three Months Ended									~~Nine Months Ended~~
	August 30,			August 31,			2025 vs			August 30,			August 31,			2025 vs
	February 28,			March 1,			2026 vs
($ in millions)	~~2025~~2026			~~2024~~2025			~~2024~~2025			~~2025~~			~~2024~~			~~2024~~
Net revenue	$	~~233~~181.79		$	~~228~~183.47			2(1.30	)%	$	~~641.5~~		$	~~630.6~~			~~1.7~~	%
Segment operating income	$	25.9		$	26.0			(0.4	)%	$	54.5		$	55.1			(1.1	)%
Segment adjusted EBITDA	$	21.6		$	21.8			(0.9	)%
Segment operating margin		11.1	%		11.4	%					8.5	%		8.7	%
Segment adjusted EBITDA margin		11.9	%		11.9	%

Table of Contents

The following tables provide details of the Building Adhesive Solutions net revenue variances:

	Three Months Ended			~~Nine Months Ended~~
	August 30, 2025 vs. August 31, 2024			August 30, 2025 vs. August 31, 2024
	February 28, 2026 vs. March 1, 2025
Organic growth		(1.0	)%		0.0	%
Organic revenue growth		(5.1	)%
M&A		10.70	%		~~2.0~~	%
Currency		14.61	%		~~(0.3~~	)%
Total		2(1.30	)%		~~1.7~~	%

Net revenue ~~increased~~decreased 21.30 percent in the ~~third~~first quarter of ~~2025~~2026 compared to the ~~third~~first quarter of ~~2024~~2025. Organic growth decreased due to a decrease in sales volume partially offset by an increase in product pricing. ~~The~~ ~~1.7 percent increase in net revenue from M&A was due to the acquisition of HS Butyl in the third quarter of 2024.~~ The positive currency effect was due to a stronger Euro and British pound compared to the U.S. dollar. Segment Asadjusted aEBITDA ~~percentage~~increased ~~of net revenue, raw material costs decreased 40 basis points~~0.9 ~~Other manufacturing costs as a percentage of net revenue~~percent ~~increased~~in ~~30 basis~~the ~~points. SG&A~~first ~~expenses~~quarter ~~as a percentage~~ of ~~net revenue increased~~ 402026 ~~basis~~compared ~~points.~~to ~~Segment~~the ~~operating~~first ~~income~~quarter ~~decreased~~of 02025.4 ~~percent~~Segment ~~and~~adjusted ~~segment operating~~ EBITDA margin ~~decreased 30~~was ~~basis points compared to the third quarter of 2024~~flat.

Net revenue increased 1.7 percent in the first nine months of 2025 compared to the first nine months of 2024. Organic growth was flat due to a decrease in sales volume offset by an increase in product pricing. The 2.0 percent increase in net revenue from M&A was due to the acquisition of HS Butyl in the third quarter of 2024. The negative currency effect was due to a weaker Turkish lira and Australia dollar, partially offset by the Euro and British pound, compared to the U.S. dollar. As a percentage of net revenue, raw material costs decreased 40 basis points. Other manufacturing costs as a percentage of net revenue increased 10 basis points. SG&A expenses as a percentage of net revenue increased 50 basis points. Segment operating income decreased 1.1 percent and segment operating margin decreased 20 basis points compared to the first nine months of 2024. 22

Table of Contents

Corporate Unallocated

	Three Months Ended									~~Nine Months Ended~~
	August 30,			August 31,			2025 vs			August 30,			August 31,			2025 vs
	February 28,			March 1,			2026 vs
($ in millions)	~~2025~~2026			~~2024~~2025			~~2024~~2025			~~2025~~			~~2024~~			~~2024~~
Net revenue	$	-		$	~~39.5~~-			~~(100~~0.0	)%	$	-		$	~~119.8~~			~~(100.0~~	)%
Segment operating loss	$	(9.1	)	$	(10.4	)		(12.5	)%	$	(39.6	)	$	(34.1	)		16.1	%
Adjusted EBITDA	$	0.9		$	1.5			(40.0	)%
Segment operating margin	NMP				-26.3	%				NMP			-28.5		%

NMP = Non-meaningful percentage

Corporate Unallocated amounts include business acquisition and integration costs, organizational restructuring charges and project costs associated with implementing a global Enterprise Resource Planning (“ERP”) system that we refer to as Project ONE. ~~As a result of the change in operating segments and the sale of our NA Flooring business, we have retrospectively moved the results of our Flooring business to Corporate Unallocated for prior periods.~~

Segment operating loss in the third quarter of 2025 decreased 12.5 percent compared to the third quarter of 2024 due to the inclusion of the NA Flooring business results in 2024.

Segment operating loss in the first nine months of 2025 increased 16.1 percent compared to the first nine months of 2024 due to higher acquisition project in costs and the inclusion of the NA Flooring business results in 2024.

Table of Contents

Financial Condition, Liquidity and Capital Resources

Total cash and cash equivalents as of ~~August~~February 3028, ~~2025~~2026 were $~~122~~107.59 million compared to $~~169~~107.42 million as of November 3029, ~~2024~~2025 and $~~131~~105.47 million as of ~~August~~March 311, ~~2024~~2025. The majority of the $~~122~~107.59 million in cash and cash equivalents as of ~~August~~February 3028, ~~2025~~2026 was held outside the United States. Total long and short-term debt was $2,~~080~~076.51 million as of ~~August~~February 3028, ~~2025~~2026, $2,~~010~~016.69 million as of November 3029, ~~2024~~2025 and $2,~~021~~180.10 million as of ~~August~~March 311, ~~2024~~2025. The total debt to total capital ratio as measured by total debt divided by total debt plus total stockholders’ equity was 5150.51 percent as of ~~August~~February 3028, ~~2025~~2026 as compared to 50.82 percent as of November 3029, ~~2024~~2025 and 5255.31 percent as of ~~August~~March 311, ~~2024~~2025.

We believe that cash flows from operating activities will be adequate to meet our short-term and long-term liquidity and capital expenditure needs. In addition, we believe we have the ability to obtain both short-term and long-term debt to meet our financing needs for the foreseeable future. Cash available in the United States has historically been sufficient and we expect it will continue to be sufficient to fund U.S. operations, U.S. capital spending and U.S. pension and other postretirement benefit contributions in addition to funding U.S. acquisitions, dividend payments, debt service and share repurchases as needed. For those international earnings considered to be reinvested indefinitely, we currently have no intention to, and plans do not indicate a need to, repatriate these funds for U.S. operations.

Our credit agreements include restrictive covenants that, if not met, could lead to a renegotiation of our credit lines and a significant increase in our cost of financing. As of ~~August~~February 3028, ~~2025~~2026, we were in compliance with all covenants of our credit agreement contractual obligations as shown in the following table:

Covenant	Debt Instrument	Measurement	Result as of ~~August~~February 3028, ~~2025~~2026
Secured Total Indebtedness / TTM1 EBITDA	Revolving Facility and Term Loan A Facility	Not greater than 4.~~502~~50	2.43
TTM1 EBITDA / Consolidated Interest Expense	Revolving Facility and Term Loan A Facility	Not less than 2.0	45.80

¹ TTM = Trailing 12 months

EBITDA for covenant purposes is defined as consolidated net income, plus (i) interest expense, (ii) expense for taxes paid or accrued, (iii) depreciation and amortization, (iv) certain non-cash impairment losses, (v) extraordinary non-cash losses incurred other than in the ordinary course of business, (vi) nonrecurring extraordinary non-cash restructuring charges and the non-cash impact of purchase accounting, (vii) any non-cash charge for the excess of rent expense over actual cash rent paid due to the use of straight-line rent, non-cash charge pursuant to any management equity plan, stock option plan or any other management or employee benefit, (viii) any non-cash finance charges in respect of any pension liabilities or other provisions and income (loss) attributable to deferred compensation plans, (ix) any non-recurring or unusual cash restructuring charges and operating improvements, (x) cost savings initiative and cost synergies related to acquisitions within 12 months, (xi) non-capitalized charges relating to the Company’s SAP implementation, (xii) fees, costs, expenses and charges incurred in connection with the financing, (xiii) fees, costs, expenses, make-whole or penalty payments and other similar items arising out of acquisitions, investments and dispositions, the incurrence, issuance, repayment or refinancing of indebtedness and any issuance of equity interests; minus, non-recurring or unusual non-cash gains incurred not in the ordinary course of business. Provided that the aggregate amounts that may be added back for any period pursuant to clauses (ix), (x) and (xi) shall not exceed 15% of EBITDA for such period (calculated prior to giving effect to all addbacks and adjustments). For Secured Total Indebtedness / TTM EBITDA ratio, TTM EBITDA is adjusted for the pro forma results from Material Acquisitions and Material Divestitures, both as defined in the Second Amended and Restated Credit Agreement, as if the acquisition or divestiture occurred at the beginning of the calculation period. The full definition is set forth in the Second Amended and Restated Credit Agreement filed as an exhibit to the Company's 8-K filing dated February 21, 2023.

Consolidated Interest Expense for covenant purposes is defined as the interest expense (including without limitation to the portion of capital lease obligations that constitutes imputed interest in accordance with GAAP) of the Company and its subsidiaries calculated on a consolidated basis for such period with respect to all outstanding indebtedness allocable to such period in accordance with GAAP, including net costs (or benefits) under Interest Rate Swap Agreements and commissions, discounts and other fees and charges with respect to letters of credit and the interest component of all Attributable Receivables Indebtedness.

We believe we have the ability to meet all of our contractual obligations and commitments for the next twelve months.

3523

Table of Contents

Selected Metrics of Liquidity

Key metrics we monitor are net working capital as a percent of annualized net revenue, trade receivable days sales outstanding (“DSO”), inventory days on hand, trade accounts payable outstanding ("DPO") free cash flow ~~after dividends~~ and debt capitalization ratio.

	August 30,			August 31,
	February 28,			March 1,
	2025			2024
	2026			2025
Net working capital as a percentage of annualized net revenue1		1719.0	%		1617.12	%
Accounts receivable DSO (in days)2		5763			5761
Inventory days on hand (in days)3		7890			7579
Trade accounts payable DPO (in days)4		6977			7073
Free cash flow5	$	62(61.27	)	$	~~104~~(85.09	)
Total debt to total capital ratio6		5150.51	%		5255.31	%

1 ~~Current~~Net ~~quarter net~~ working capital (trade receivables, net of allowance for doubtful accounts plus inventory minus trade payables) divided by annualized net revenue (current quarter multiplied by four).

2 Trade receivables net of the allowance for doubtful accounts ~~at the balance sheet date~~ multiplied by 91 (13 weeks) and divided by the net revenue for the quarter.

³Total inventory multiplied by 91 (13 weeks) and divided by cost of sales (excluding delivery costs) for the quarter.

4 Trade accounts payable multiplied by 91 (13 weeks) and divided by ~~the~~ net revenue for the quarter.

5 Year-to-date net cash provided by operating activities, less purchased property, plant and equipment. See "Non GAAP Measures" for reconciliation of net cash provided by operating activities to free cash flow.

⁶ Total debt divided by (total debt plus total stockholders’ equity).

Free cash flow, a non-GAAP financial measure, is defined as net cash provided by operating activities less purchased property, plant and equipment. Free cash flow is an integral financial measure used by the Company to assess its ability to generate cash in excess of its operating needs, therefore, the Company believes this financial measure provides useful information to investors. ~~The~~For ~~following table reflects the manner in which free cash flow is determined and provides~~ a reconciliation of ~~free cash flow to~~ net cash provided by operating activities, ~~the~~to ~~most~~free ~~directly~~cash ~~comparable~~flow ~~financial~~see ~~measure~~“Non-GAAP ~~calculated~~Measures” ~~and reported in accordance with U~~below.~~S. GAAP.~~

Reconciliation of "Net cash provided by operating activities" to free cash flow

	Nine Months Ended
($ in millions)	August 30, 2025		August 31, 2024
Net cash provided by operating activities	$	156.8	$	216.8
Less: Purchased property, plant and equipment		94.6		112.8
Free cash flow	$	62.2	$	104.0

Table of Contents

Summary of Cash Flows

Cash Flows from Operating Activities:

	Nine Months Ended
	Three Months Ended
	August 30,			August 31,
	February 28,			March 1,
($ in millions)	~~2025~~2026			~~2024~~2025
Net cash provided by operating activities	$	~~156~~(4.80	)	$	~~216~~(52.89	)

Net income including non-controlling interest was $~~122~~21.30 million in the first ~~nine~~three months of ~~2025~~2026 compared to $~~137~~13.63 million in the first ~~nine~~three months of ~~2024~~2025. Depreciation and amortization expense totaled $~~132~~46.84 million in the first ~~nine~~three months of ~~2025~~2026 compared to $~~128~~42.76 million in the first ~~nine~~three months of ~~2024~~2025. Deferred income taxes ~~was~~were a use of cash of $~~39.~~2.4 million in the first ~~nine~~three months of ~~2025~~2026 compared to a source of cash of $465.08 million in the first ~~nine~~three months of ~~2024~~2025. Accrued compensation was a use of cash of $1946.24 million in ~~2025~~the first three months of 2026 compared to $1137.69 million in ~~2024~~the first three months of 2025. Other assets ~~was~~were a use of cash of $73.52 million in the first ~~nine~~three months of ~~2025~~2026 compared to $~~39.~~0.3 million in the first ~~nine~~three months of ~~2024~~2025. Other liabilities ~~was~~were a ~~source~~use of cash of $289.69 million in the first ~~nine~~three months of ~~2025~~2026 compared to $0.93 million in the first ~~nine~~three months of ~~2024~~2025.

Changes in net working capital (trade receivables, inventory and trade payables) accounted for a ~~use~~source of cash of $7113.27 million in the first three months of 2026 compared to a ~~source~~use of cash of $1327.95 million ~~last~~in ~~year~~the first three months of 2025. The table below provides the cash flow impact due to changes in the components of net working capital and an assessment of each of the components:

		Nine Months Ended
	Three Months Ended
		August 30,				August 31,
	February 28,			March 1,
($ in millions)	2026	~~2025~~		2025		~~2024~~
Trade receivables, net	$	$39.6	~~(3.3~~	)$	13.9	$	~~26.4~~
Inventory		(28.9	~~(42.1~~)	)	(27.1	)	~~(62.2~~	)
Trade payables		3.0	~~(25.8~~	)	(14.3	)	~~49.7~~
Total cash flow impact	$	$13.7	~~(71.2~~	)$	(27.5	$)	~~13.9~~

● Trade receivables, net – Trade receivables, net was a ~~use~~source of cash of $339.36 million and ~~a source of cash of~~ $2613.49 million in the first ~~nine~~three months of ~~2025~~2026 and ~~2024~~2025, respectively. The ~~use~~higher source of cash in ~~2025~~2026 compared to ~~source~~2025 ~~of cash in 2024~~ was due to ~~less~~more cash collected on trade receivables in the current year compared to the prior year. The DSO were 5763 days at ~~August~~February 3028, ~~2025~~2026 and 5761 days at ~~August~~March 311, ~~2024~~2025.

● Inventory – Inventory was a use of cash of $4228.19 million and $6227.21 million in the first ~~nine~~three months of ~~2025~~2026 and ~~2024~~2025, respectively. The ~~lower~~slightly higher use of cash in ~~2025~~2026 compared to ~~2024~~2025 was due to ~~lower~~higher inventory purchases in ~~2025~~2026 compared to ~~2024~~2025. Inventory days on hand were 7890 days as of ~~August~~February 3028, ~~2025~~2026 and 7579 days as of ~~August~~March 311, ~~2024~~2025.

● Trade payables – Trade payables was a ~~use~~source of cash of $253.80 million and a ~~source~~use of cash of $4914.73 million in the first ~~nine~~three months of ~~2025~~2026 and ~~2024~~2025, respectively. The ~~use~~source of cash in ~~2025~~2026 compared to ~~source~~use of cash in ~~2024~~2025 reflects ~~higher~~lower payments on trade payables in the current year compared to the prior year. Days payable outstanding were 6977 days as of ~~August~~February 3028, ~~2025~~2026 and 7073 days as of ~~August~~March 311, ~~2024~~2025.

3724

Table of Contents

Cash Flows from Investing Activities:

	Nine Months Ended
	Three Months Ended
	August 30,			August 31,
	February 28,			March 1,
($ in millions)	~~2025~~2026			~~2024~~2025
Net cash used in investing activities	$	(~~182~~57.74	)	$	(~~385~~121.84	)

Purchases of property, plant and equipment were $9457.67 million during the first ~~nine~~three months of ~~2025~~2026 compared to $~~112~~33.80 million for the same period of ~~2024~~2025. This difference reflects the timing of capital projects and expenditures related to growth initiatives.

~~During~~We did not pay any cash for business acquisitions during the first ~~nine~~three months of 2026. ~~2025,~~During the first three months of 2025 we paid $162.1 0 million ofin cash for business acquisitions. and ~~Additionally,~~ we received $75.7 million in cash related to the sale of our NA Flooring business. ~~During the first nine months of 2024, we paid $274.1 million of cash for business acquisitions.~~

Cash Flows from Financing Activities:

	Nine Months Ended
	Three Months Ended
	August 30,			August 31,
	February 28,			March 1,
($ in millions)	~~2025~~2026			~~2024~~2025
Net cash provided by financing activities	$	~~(33~~48.7	)	$	~~131~~111.64

In the first ~~nine~~three months of ~~2025~~2026, borrowings on our revolving credit facility were $~~1,114~~288.31 million and repayments on our revolving credit facility and our long-term debt totaled $~~1,053~~231.64 million. These borrowings are for general working capital purposes and permitted acquisitions. Borrowings on our revolving credit facility were $~~1,732~~526.93 million and repayments on our revolving credit facility and our long-term debt totaled $~~1,556~~359.15 million in the first ~~nine~~three months of ~~2024~~2025. ~~Net~~There were no net payments of notes payable ~~were a use of cash of $0.6 million~~ in the first ~~nine~~three months of ~~2025~~2026 compared to $1.0.2 million in the same period of ~~2024~~2025. Cash dividends paid were $3712.68 million in the first ~~nine~~three months of ~~2025~~2026 compared to $3512.42 million in the same period of ~~2024~~2025. Repurchases of common stock were $602.79 million in the first ~~nine~~three months of ~~2025~~2026 compared to $3944.4 million in the same period of ~~2024~~2025.

38 Non-GAAP Measures

We use both GAAP and non-GAAP financial measures for operational and financial decision making, and to assess Company and segment business performance. Our non-GAAP measures include Adjusted EBITDA and Free Cash Flow. Our calculation of these non-GAAP measures may not be comparable to similarly titled measures of other companies due to potential differences between companies in the method of calculation. As a result, the use of these non-GAAP measures has limitations and should not be considered superior to, in isolation from, or as a substitute for, related U.S. GAAP measures.

These non-GAAP measures allow management and investors to view operating trends, perform analytical comparisons and benchmark performance between periods and among geographic regions to understand operating performance without regard to items we do not consider a component of our core operating performance. Furthermore, these non-GAAP measures allow investors the opportunity to measure and monitor our performance against our externally communicated targets and evaluate the investment decisions being made by management to improve Adjusted EBITDA. Management uses these measures in its financial, investment and operational decision-making processes, for internal reporting and as part of its forecasting and budgeting processes. Further, our Board of Directors uses certain of these and other measures as key metrics to determine management performance under our performance-based compensation plans. For these reasons, we believe these non-GAAP measures are useful for our investors.

Adjusted EBITDA is presented net of noncontrolling interests and is used by management and can be used by investors to review our consolidated operating results because it excludes depreciation, amortization, interest income, interest expense and income taxes as well as certain additional adjustments that are not considered part of our core operations. Examples of adjustments to EBITDA include, but are not limited to, costs for acquisition projects, organizational realignment, Project One, business divestitures, discrete taxes, and the income tax effect on these adjustments. For Adjusted EBITDA, once we have made an adjustment in the current period for an item, we will also adjust the related non-GAAP measure in future periods in which there is an impact from the item. The following table reflects the manner in which Adjusted EBITDA is determined and provides a reconciliation of Adjusted EBITDA to Net income attributable to H.B. Fuller, the most directly comparable financial measure calculated and reported in accordance with U.S. GAAP.

Table of Contents

Reconciliation of Net income attributable to H.B. Fuller to Adjusted EBITDA

	Three Months Ended
	February 28,			March 1,
	2026			2025
Net income attributable to H.B. Fuller	$	21,045		$	13,248

Adjustments:
Acquisition project costs		931			9,828
Organizational realignment		10,022			8,774
Project One		3,053			3,064
Other		(95	)		-
Discrete tax items		98			992
Income tax effect on adjustments		(3,539	)		(5,909	)
Adjusted net income attributable to H.B. Fuller		31,515			29,997

Add:
Interest expense¹		32,373			32,030
Interest income		(2,069	)		(1,100	)
Adjusted Income taxes		10,862			10,862
Depreciation and Amortization expense²		46,023			42,567
Adjusted EBITDA		118,704			114,356

¹ Interest expense added back for EBITDA is adjusted for amounts already included in adjusted net income attributable to H.B. Fuller.

² Depreciation and amortization expense added back for EBITDA is adjusted for amounts already included in adjusted net income attributable to H.B. Fuller.

Free cash flow, a non-GAAP financial measure, is defined as net cash provided by operating activities less purchased property, plant and equipment. Free cash flow is an integral financial measure used by the Company to assess its ability to generate cash in excess of its operating needs, therefore, the Company believes this financial measure provides useful information to investors. The following table reflects the manner in which free cash flow is determined and provides a reconciliation of free cash flow to net cash provided by operating activities, the most directly comparable financial measure calculated and reported in accordance with U.S. GAAP.

Reconciliation of Net cash provided by operating activities to Free cash flow

	Three Months Ended
($ in millions)	February 28, 2026			March 1, 2025
Net cash provided by operating activities	$	(4.0	)	$	(52.9	)
Less: Purchased property, plant and equipment		57.7			33.0
Free cash flow	$	(61.7	)	$	(85.9	)

Forward-Looking Statements and Risk Factors

The Private Securities Litigation Reform Act of 1995 provides a safe harbor for forward-looking statements. This Quarterly Report on Form 10-Q contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified by the use of words like "plan," "expect," "aim," "believe," "project," "anticipate," "intend," "estimate," "will," "should," "could" (including the negative or variations thereof) and other expressions that indicate future events and trends. These plans and expectations are based upon certain underlying assumptions, including those mentioned with the specific statements. Such assumptions are in turn based upon internal estimates and analyses of current market conditions and trends, our plans and strategies, economic conditions and other factors. These plans and expectations and the assumptions underlying them are necessarily subject to risks and uncertainties inherent in projecting future conditions and results. Actual results could differ materially from expectations expressed in the forward-looking statements if one or more of the underlying assumptions and expectations proves to be inaccurate or is unrealized. In addition to the factors described in this report, Item 1A. Risk Factors identifies some of the important factors that could cause our actual results to differ materially from those in any such forward-looking statements. In order to comply with the terms of the safe harbor, we have identified these important factors which could affect our financial performance and could cause our actual results for future periods to differ materially from the anticipated results or other expectations expressed in the forward-looking statements. These factors should be considered, together with any similar risk factors or other cautionary language that may be made elsewhere in this Quarterly Report on Form 10-Q.

The list of important factors in Item 1A. Risk Factors does not necessarily present the risk factors in order of importance. This disclosure, including that under Forward-Looking Statements and Risk Factors, and other forward-looking statements and related disclosures made by us in this report and elsewhere from time to time, represents our best judgment as of the date the information is given. We do not undertake responsibility for updating any of such information, whether as a result of new information, future events, or otherwise, except as required by law. Investors are advised, however, to consult any further public company disclosures (such as in filings with the SEC or in our press releases) on related subjects.

Table of Contents

Item 3. Quantitative and Qualitative Disclosures about Market Risk

We are exposed to various market risks, including changes in interest rates, foreign currency rates and prices of raw materials. Market risk is the potential loss arising from adverse changes in market rates and prices, such as interest rates and foreign currency exchange rates. See Part II, Item 7A in our Annual Report on Form 10-K for the year ended November 3029, ~~2024~~2025 for further discussion of these market risks. There have been no material changes in the reported market risk of the Company since November 3029, ~~2024~~2025.

Item 4. Controls and Procedures

Controls and Procedures

We conducted an evaluation, under the supervision and with the participation of our president and chief executive officer and executive vice president, chief financial officer, of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934 (Exchange Act)) as of ~~August~~February 3028, ~~2025~~2026. Based on this evaluation, our president and chief executive officer and executive vice president, chief financial officer concluded that, as of ~~August~~February 3028, ~~2025~~2026, our disclosure controls and procedures were effective.

For purposes of Rule 13a-15(e), the term disclosure controls and procedures means controls and other procedures of an issuer that are designed to ensure that information required to be disclosed by the issuer in the reports that it files or submits under the Exchange Act (15 U.S.C. 78a et seq.) is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by an issuer in the reports that it files or submits under the Exchange Act is accumulated and communicated to the issuer’s management, including its president and chief executive officer and executive vice president, chief financial officer, or persons performing similar functions, as appropriate to allow timely decisions regarding required disclosure.

Changes in Internal Control over Financial Reporting

There were no changes in our internal control over financial reporting during our most recently completed fiscal quarter that have materially affected or are reasonably likely to materially affect our internal control over financial reporting, as defined in Rule 13a-15(f) under the Exchange Act.

3927

Table of Contents

PART II. OTHER INFORMATION

Item 1. Legal Proceedings

Environmental Matters

To the extent we can reasonably estimate the amount of our probable liabilities for environmental matters, we establish a financial provision.

While uncertainties exist with respect to the amounts and timing of the ultimate environmental liabilities, based on currently available information, we have concluded that these matters, individually or in the aggregate, will not have a material adverse effect on our results of operations, financial condition or cash flow.

Other Legal Proceedings

From time to time and in the ordinary course of business, we are a party to, or a target of, lawsuits, claims, investigations and proceedings, including product liability, personal injury, contract, patent and intellectual property, environmental, health and safety, tax and employment matters. While we are unable to predict the outcome of these matters, we have concluded, based upon currently available information, that the ultimate resolution of any pending matter, individually or in the aggregate, including asbestos-related litigation, will not have a material adverse effect on our results of operations, financial condition or cash flow. However, adverse developments and/or periodic settlements could negatively impact the results of operations or cash flows in one or more future periods.

For additional information regarding environmental matters and other legal proceedings, see Note 13 to our Consolidated Financial Statements.

Item 1A. Risk Factors

This Form 10-Q contains forward-looking statements concerning our future programs, products, expenses, revenue, liquidity and cash needs as well as our plans and strategies. These forward-looking statements are based on current expectations and we assume no obligation to update this information. Numerous factors could cause actual results to differ significantly from the results described in these forward-looking statements, including the risk factors identified under Part I, Item 1A. Risk Factors contained in our Annual Report on Form 10-K for the fiscal year ended November 3029, ~~2024~~2025. There have been no material changes in the risk factors disclosed by us under Part I, Item 1A. Risk Factors contained in the Annual Report on Form 10-K for the fiscal year ended November 3029, ~~2024~~2025.

Table of Contents

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

Issuer Purchases of Equity Securities

Information on our purchase of equity securities during the quarter ended ~~August~~February 3028, ~~2025~~2026 is as follows:

							(d)
					(c)		Maximum
					Number of		Approximate Dollar
	(a)				Shares		Value of Shares that
	Total		(b)		Purchased		may yet be
	Number of		Average		as Part of		Purchased Under the
	Shares		Price Paid		Publicly Announced		Plan or Program
Period	Purchased		per Share		Plan or Program		(millions)
June 1, 2025 - July 5, 2025		-	$	-		-	$	211
November 30, 2025 - January 3, 2026		-	$	-		-	$	211
July 6, 2025 - August 2, 2025		-	$	-		-	$	211
January 4, 2026 - January 31, 2026		-	$	-		-	$	211
August 3, 2025 - August 30, 2025		-	$	-		-	$	211
February 1, 2025 - February 28, 2026		-	$	-		-	$	211

On April 7, 2022, the Board of Directors authorized a ~~new~~ share repurchase program of up to $300.0 million of our outstanding common shares for a period of up to five years. Under the program, we are authorized to repurchase shares for cash on the open market, from time to time, in privately negotiated transactions or block transactions, or through an accelerated repurchase agreement. The timing of such repurchases is dependent on price, market conditions and applicable regulatory requirements.

Table of Contents

Item 5. Other Information

Rule 10b5-1 Plan Adoptions and Modifications

None.

Item 6. Exhibits

*	10.1	Form of Non-Qualified Stock Option Agreement under the Third Amended and Restated H.B. Fuller Company 2020 Master Incentive Plan for awards made on or after April 15, 2025
*	10.2	Form of Restricted Stock Unit Award Agreement under the Third Amended and Restated H.B. Fuller Company 2020 Master Incentive Plan for awards made on or after April 15, 2025
*	10.3	Form of Performance Share Award Agreement under the Third Amended and Restated H.B. Fuller Company 2020 Master Incentive Plan for awards made on or after April 15, 2025
*	10.4	Form of Restricted Stock Unit Award Agreement for Non-Employee Directors under the Third Amended and Restated H.B. Fuller Company 2020 Master Incentive Plan for awards made on or after April 15, 2025
	31.1	Form of 302 Certification – Celeste B. Mastin
	31.2	Form of 302 Certification – John J. Corkrean
	32.1	Form of 906 Certification – Celeste B. Mastin
	32.2	Form of 906 Certification – John J. Corkrean
	101	The following materials from the H.B. Fuller Company Quarterly Report on Form 10-Q for the quarter ended ~~August~~February 3028, ~~2025~~2026 formatted in Inline Extensible Business Reporting Language (Inline XBRL): (i) the Consolidated Statements of Income, (ii) the Consolidated Statements of Comprehensive Income, (iii) the Consolidated Balance Sheets, (iv) the Consolidated Statements of Total Equity, (v) the Consolidated Statements of Cash Flows and (vi) the Notes to Consolidated Financial Statements.
	104	Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101).

* Asterisked items are management contracts or compensatory plans or arrangements required to be filed.

~~(1) Incorporated by reference to Appendix B to the H.B. Fuller Company Proxy Statement on Schedule 14A filed with the Securities and Exchange Commission on March 4, 2025~~ 29

Table of Contents

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

	H.B. Fuller Company
Dated: September 25, 2025		/s/ John J. Corkrean
Dated: March 26, 2026		/s/ John J. Corkrean
		John J. Corkrean
		Executive Vice President,
		Chief Financial Officer

Exhibit Index

Exhibits

*	10.1	Form of Non-Qualified Stock Option Agreement under the Third Amended and Restated H.B. Fuller Company 2020 Master Incentive Plan for awards made on or after April 15, 2025
*	10.2	Form of Restricted Stock Unit Award Agreement under the Third Amended and Restated H.B. Fuller Company 2020 Master Incentive Plan for awards made on or after April 15, 2025
*	10.3	Form of Performance Share Award Agreement under the Third Amended and Restated H.B. Fuller Company 2020 Master Incentive Plan for awards made on or after April 15, 2025
*	10.4	Form of Restricted Stock Unit Award Agreement for Non-Employee Directors under the Third Amended and Restated H.B. Fuller Company 2020 Master Incentive Plan for awards made on or after April 15, 2025
	31.1	Form of 302 Certification – Celeste B. Mastin
	31.2	Form of 302 Certification – John J. Corkrean
	32.1	Form of 906 Certification – Celeste B. Mastin
	32.2	Form of 906 Certification – John J. Corkrean
	101	The following materials from the H.B. Fuller Company Quarterly Report on Form 10-Q for the quarter ended ~~August~~February 3028, ~~2025~~2026 formatted in Inline Extensible Business Reporting Language (Inline XBRL): (i) the Consolidated Statements of Income, (ii) the Consolidated Statements of Comprehensive Income, (iii) the Consolidated Balance Sheets, (iv) the Consolidated Statements of Total Equity, (v) the Consolidated Statements of Cash Flows and (vi) the Notes to Consolidated Financial Statements.
	104	Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101).

* Asterisked items are management contracts or compensatory plans or arrangements required to be filed.

~~(1) Incorporated by reference to Appendix B to the H.B. Fuller Company Proxy Statement on Schedule 14A filed with the Securities and Exchange Commission on March 4, 2025~~ 30

Filing Compare · FULLER H B CO